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F
or the past 30 years, many communities and
countries in sub-Saharan Africa have suffered from
the ravages of the HIV epidemic. During this time
the mortality rates in HIV-infected people have been 10
20 times higher than in HIV-uninfected people (1). Since
the advent of anti-retroviral therapy (ART), mortality
and morbidity have decreased considerably (2). However,
it has been difficult to get reliable estimates of the impact
of ART in population-based studies. The measurement
of the impact of ART on mortality requires long-term
follow-up in communities where regular HIV testing
allows the estimation of mortality by HIV status, such as
the population cohorts in the network for Analysing Lon-
gitudinal Population-based HIV data in Africa (ALPHA)
(3). An alternative estimation from verbal autopsy (VA)
requires reliable tools and consistent interpretation of
causes of death, which have been taken forward by
recent standards from the World Health Organization
(WHO) and the development of the corresponding
InterVA-4 model for cause of death assignment (4, 5).
This supplement puts together evidence from different
sources in order to estimate the impact of ART on adult
HIVmortality.Thepapersinthis supplementusedifferent
measures to estimate the effect of ART, and the stories
from the different papers provide a consistent picture of
the reduction in HIV-related mortality with the advent of
ART in sub-Saharan Africa. However, in developed
countries the mortality in HIV-positive people on ART
is similar to the mortality in the general population (6),
but based on the evidence from the population studies
reported in this supplement, it is not the case in sub-
Saharan Africa, even if it may be achieved in the future.
The AIDS impact module within the Spectrum soft-
ware is a modeling tool for estimating many facets of the
HIV epidemic in the population, usually using HIV
prevalence and program data available at the national
level (7). We can evaluate the mortality estimate from the
Spectrum model against the empirical data from long-
itudinal studies if we can accurately create a Spectrum
model for the small area where the longitudinal study is
located. This comparison allows us to validate the
assumptions used in Spectrum that lead to the mortality
estimates from the model.
The paper by Kanjala et al. documents the changes in
age-specific mortality rates (ASMR) from 1994 to 2010 in
a cohort in Tanzania (8). This study showed an overall
reduction in mortality in those aged 1559 from 12.3 per
1,000 person years (95% CI 11.513.1) in the 5 years
before ART was introduced to 8.0 per 1,000 person years
(95% CI 7.28.8) after ART was introduced. In that
period, the greatest reduction was seen in HIV positives
aged 3045 years, with a 44% reduction in male
mortality, and a 71% reduction in female mortality in
this group. For both sexes, the HIV-attributable mortality
among the population showed a reduction from more
than 50% in 2000, to around 35% in 2010, which can be
related to the availability of ART since around 2005. The
pooled analysis of adults aged 1554 in five sites in East
and Southern Africa showed an overall halving of the
excess mortality in HIV positives, with the decline evident
across all sites and for both sexes (9).
Four papers in this supplement reported the use of
InterVA-4 to interpret the cause of death from VA data.
Byass et al. validated the InterVA-4 model against pre-
mortem serological data from six ALPHA sites (5). This
showed 90% specificity in identifying HIV-related deaths
among those with confirmed HIV sero-status, which
was consistent across the six sites, and across time,
making InterVA-4 an effective tool in assessing HIV-
related mortality. Glynn et al. compared the use of
InterVA-4 with the interpretation of deaths by clinician
review in Malawi from 2002 to 2012 (10). The results
confirm the specificity of InterVA-4, as 88% of the deaths
identified as unrelated to HIV by the physicians were
correctly identified by InterVA-4. For HIV-related deaths
defined by the physician review, InterVA-4 identified 59%
due to HIV/AIDS, and a further 20% where TB was the
cause of death. Byass et al. identified these two causes
(HIV/AIDS and TB) plus acute respiratory infections as
highly associated with HIV positivity, indicating that
these are likely causes of death in people living with HIV
(5). Both Glynn and Kanjala reported that InterVA-4
may underestimate the number of deaths due to HIV,
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causes (8, 10). This raises questions about the ICD-10
coding rules whereby almost all deaths among HIV
positives are expected to be coded as HIV related (11).
This is likely to become a bigger issue as more HIV-
positive individuals experience ART for longer periods of
time, before going on to die from a potentially wider
range of causes.
Two papers used Spectrum model estimates and
showed good agreement with empirical data in Kenya
and Tanzania (12, 13). Oti et al. compared the Spectrum
model outputs for the Nairobi area against the health and
demographic surveillance site (HDSS) observed mortality
using InterVA-4 to interpret cause of death. The Spec-
trum model estimated that in 2003, 63% of adult
mortality was HIV-related, decreasing to 40% in 2010,
while for InterVA-4, including deaths from both HIV/
AIDS and TB showed that 59% were HIV-related in
2003, and 46% in 2010. In Tanzania, using adult
mortality between the ages of 15 and 49 years, Michael
et al. found the Spectrum model estimated that HIV-
related mortality had fallen from 43% in 1994 to 37% in
2009, compared to the results from the demographic and
serological data which showed a reduction from 39 to
22% over the same period. They concluded that Spectrum
predicts a greater proportion of adult deaths being due to
HIV than observed in the cohort, and speculate that this
may have been influenced by the low reported uptake of
ART services in the cohort. Further work is needed to
refine the Spectrum models created using small area data
(as opposed to national data which is usually used for
Spectrum estimates), but this seems a useful challenge to
bring together the Spectrum model with existing HDSS
data, and to identify the limitations of such comparisons.
Most countries have now adopted the 2010 WHO
guidelines to initiate ART for those with HIV infection
and CD4 counts under 350 cells per mm
3, but new
guidelines in 2013 recommend initiation of ART in all
those with CD4 counts less than 500 cells per mm
3 (14).
Masiira et al. used standardized mortality rates (SMR)
for HIV-positive, ART-naive Ugandan adults, and com-
pared the mortality of those with CD4 counts between
350 and 499 cells per mm
3, to those with CD4 counts
greater than 500 cells per mm
3, and with the Ugandan
general population (15). Mortality rates were 1.6 times
higher in those with lower CD4 counts (between 350 and
499 cells per mm
3), and 2.5 times higher than the general
population. The excess HIV mortality in those with CD4
counts between 350 and 499 cells per mm
3 would be
prevented with the implementation of the WHO guide-
lines for people living with HIV in developing countries.
The final paper in the supplement, by Levira et al.,
looks at a different impact that ART may have on
mortality (16). Many people migrate back from the cities
to their rural home villages when severely sick and
expecting to die (17). With the advent of ART, the
mortality among urbanrural migrants in Tanzania has
reduced by 39% compared to a reduction of 27% among
non-migrants.
The message from the papers in this supplement across
the first decade of ART roll-out in sub-Saharan Africa
shows a consistent reduction of overall mortality rates in
the population of around 30%, with the proportion of
deaths attributable to HIV falling by 3050%. In this
period, excess mortality among HIV-positive adults has
halved, but the mortality rates in HIV positives are still
up to 10 times higher than among HIV negatives (9). In
the coming decade, there is a lot more to be done in terms
of increasing access to, and availability of, ART. This
should lead to further reductions in mortality rates, but
will also bring new challenges to measuring HIV-related
mortality, particularly among those who have received
long-term treatment.
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Background: Reliable population-based data on HIV infection and AIDS mortality in sub-Saharan Africa are
scanty, even though that is the region where most of the world’s AIDS deaths occur. There is therefore a great
need for reliable and valid public health tools for assessing AIDS mortality.
Objective: The aim of this article is to validate the InterVA-4 verbal autopsy (VA) interpretative model within
African populations where HIV sero-status is recorded on a prospective basis, and examine the distribution of
cause-specific mortality among HIV-positive and HIV-negative people.
Design: Data from six sites of the Alpha Network, including HIV sero-status and VA interviews, were pooled.
VA data according to the 2012 WHO format were extracted, and processed using the InterVA-4 model into
likely causes of death. The model was blinded to the sero-status data. Cases with known pre-mortem HIV
infection status were used to determine the specificity with which InterVA-4 could attribute HIV/AIDS as a
cause of death. Cause-specific mortality fractions by HIV infection status were calculated, and a person-time
model was built to analyse adjusted cause-specific mortality rate ratios.
Results: The InterVA-4 model identified HIV/AIDS-related deaths with a specificity of 90.1% (95% CI
88.7 91.4%). Overall sensitivity could not be calculated, because HIV-positive people die from a range of
causes. In a person-time model including 1,739 deaths in 1,161,688 HIV-negative person-years observed and
2,890 deaths in 75,110 HIV-positive person-years observed, the mortality ratio HIV-positive:negative was
29.0 (95% CI 27.1 31.0), after adjustment for age, sex, and study site. Cause-specific HIV-positive:negative
mortality ratios for acute respiratory infections, HIV/AIDS-related deaths, meningitis, tuberculosis, and
malnutrition were higher than the all-cause ratio; all causes had HIV-positive:negative mortality ratios
significantly higher than unity.
Conclusions: These results were generally consistent with relatively small post-mortem and hospital-based
diagnosis studies in the literature. The high specificity in cause of death attribution achieved in relation to HIV
status, andlargedifferencesbetweenspecific causesbyHIVstatus,showthatInterVA-4isaneffectiveandvalid
tool for assessing HIV-related mortality.
Keywords: HIV/AIDS; mortality; Africa; verbal autopsy; InterVA; Alpha Network
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A
s the HIV/AIDS pandemic has evolved, reliable
assignment of cause of death for people who have
lived with the infection has been a persistent
difficulty. Although there is no doubt about increased
mortality risks associated with HIV infection (1), in
settings where people frequently die outside the scope
$Peter Byass, Editor, did not participate in the review and decision process for this paper.
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tinues to carry some stigma, there may be inadequate
information or unwillingness to document HIV/AIDS as
a cause of death (2). The situation is further complicated
by the interactions between HIV infection and other
diseases, whereby clear manifestations of AIDS may not
be major features of final illnesses among HIV-positive
people, particularly among those receiving treatment (3).
As a result of these difficulties, reliable community-
based data on HIV/AIDS-related mortality, particularly
in highly HIV-infected areas in Africa, have been very
scanty. Modelled estimates of AIDS mortality at national
and global levels have therefore fluctuated widely as the
pandemic has progressed, and despite improving estima-
tion methods, details remain uncertain (4). It is widely
recognised that where deaths are not routinely certified as
to their cause, verbal autopsy (VA) is the interim method
of choice for documenting cause-specific mortality pat-
terns (5). Although VA has been variously implemented
in areas of high HIV infection and AIDS mortality,
VA procedures have generally not been validated at the
individual level against measurable outcomes such as
HIV sero-status, leading to suppositions that VA is an
unreliable approach for identifying HIV/AIDS deaths (6).
Some sero-validation studies have been implemented in
the context of HIV treatment centres (7), but not on a
population basis, where there is normally no informa-
tion on pre-mortem infection status. Other studies have
compared VA results on AIDS mortality from different
sources, such as between InterVA and physician inter-
pretation, but in the absence of any absolute standard for
comparison (8).
In a collaboration between the Health Metrics Net-
work (9), the Alpha Network (10), and the INDEPTH
Network (11), one aim was to validate measurement of
AIDS mortality in documented population surveillance
sites in which HIV infection status was gathered pro-
spectively. This initiative coincided with the development
of the InterVA-4 model for interpreting VA interview
material, the latest model in the InterVA series (12) which
corresponds to the 2012 WHO VA tool (13) and is freely
available at www.interva.net.
The aim of this article is to analyse InterVA-4 inter-
pretations of routinely gathered VA material from six
population surveillance sites in Africa, as shown in Fig. 1,
against known HIV sero-status. This will permit an
assessment of the specificity of the InterVA-4 model
for the assignment of HIV/AIDS-related deaths, as well
as investigating differences in cause of death patterns
according to HIV infection as a risk factor for mortality
in African populations.
Methods
The basic modes of operation of the six population
surveillance sites involved, of which all are members of
the Alpha Network and some are members of the
INDEPTH Network, have been described previously
(14 19). These sites are located on a north south transect
of some 3,500 km through eastern and southern Africa.
Briefly, all the sites followed a particular geographically
defined adult population longitudinally, capturing vital
events as well as the results of HIV sero-testing. Exact
procedures for following up deaths and carrying out VA
interviews (interviews with relatives or other witnesses
of a death about the circumstances and symptoms of
the final illness) varied to some extent between sites, and
have developed over time. Intervals between deaths and
VA follow-up vary across sites, ranging up to 2 years in
Manicaland. For the purposes of this study, no special
procedures were implemented, and it was important to
make use of all available archived VA interview material,
most of which was collected before current standards for
undertaking VAs were established. Nevertheless, for the
purposes of standard comparison over time and between
sites, all the archived VA data were converted into the
WHO 2012 standard VA format, which corresponds
exactly to the input parameters needed for the InterVA-
4 interpretative model (13). In some cases, desirable data
items were not available in the VA archives, in which case
they remained absent from the InterVA-4 input. However,
the InterVA-4 model was deliberately designed to deter-
mine cause of death on the basis of available data items,
and does not make any distinction between negative and
missing values for individual parameters.
The data used for this validation study relate to 17,560
adult deaths (15 years and over) occurring between 1990
and 2011, all of which were successfully documented in
VA interviews, from the six population sites shown in
Fig. 1. Overall 5,029 (28.6%) of these cases had one or
more documented HIV sero-test results sometime before
death. Any recorded positive test was taken as evidence
of HIV infection, and person-time from the test date
onwards categorised as HIV positive. Recorded negative
tests were only considered in relation to cause of death if
documented within 5 years of death, and the time period
between testing and death was recorded individually.
HIV-negative person-time was calculated starting from
any negative test result, and running until the first of: a
positive test result, death, or the fifth anniversary of the
negative test. In the majority of the VA interviews con-
ducted, a specific question was included as to whether,
to the knowledge of the respondent, the deceased had any
history of HIV/AIDS diagnosis or treatment. If such a
declaration was made in the VA interview for someone
who had only documented a negative test, then those
cases were put into a separate positive category, on the
grounds that they had most likely sero-converted since
testing. Similarly, a further positive category was defined
for those who had not been sero-tested within 5 years of
death, but were declared in VA interviews to have had a
Validating verbal autopsy for HIV/AIDS in Africa
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diagnoses were not included in the VA instruments used
in the Manicaland and Masaka sites. Those cases which
had no sero-test recorded or whose most recent negative
test result was recorded more than 5 years before death,
and for which no diagnosis of HIVor AIDS was declared
at VA, remained in an unknown status group. For the
data input to the InterVA-4 model, if a diagnosis of
HIV or AIDS was reported in the VA interview, then the
corresponding input indicator was flagged, as would
normally happen in the absence of serological data. In
this study, the InterVA-4 model was not provided with
any information on sero-test results, so that the cause of
death assignment was blinded to those additional data.
Input indicators for the InterVA-4 model, as defined in
the WHO 2012 VA tool, were retrospectively extracted
from VA archives in each participating site. These were
accumulated into a pooled dataset which was split into
low malaria (South Africa) and high malaria (other sites)
for InterVA-4 processing. This is in line with recommen-
dations in the InterVA-4 documentation of high malaria
corresponding to populations where approximately 1%
or more of all deaths are due to malaria. Cause of death
assignments (up to three per case) was made with asso-
ciated likelihoods. Where input data are scanty, lower
likelihood outputs typically result. As previously recom-
mended with InterVA outputs, these data were analysed
by taking the likelihoods of the assigned causes for each
case and attributing any residual proportion of the death
as indeterminate (12). InterVA-4 outputs were read into
Stata 12 to process cause of death likelihoods. Conse-
quently fractional causes of death arose, which have
been aggregated in the following analyses. Cause of death
categories assigned by InterVA-4 corresponds to the
WHO 2012 VA standard cause of death groupings, one
of which is ‘HIV/AIDS-related death’ (5). Specific causes
Fig. 1. Participating Alpha Network sites, showing numbers of deaths with verbal autopsies, by HIV status.
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HIV-negative test before death, at: HIV-positive on the basis of:
0 11 months 12 23 months 24 59 months Overall
Positive test
and positive VA
Positive test,
not VA
No test,
positive VA
Prev. negative
test, positive VA Overall
HIV status
unknown
Overall
Deaths 860 516 530 1,906 1,010 1,983 2,204 130 5,327 10,327
% HIV/AIDS 8.4 9.4 12.8 9.9 45.8 36.7 43.4 43.0 41.4 15.4
15 49 years
Deaths 314 266 282 862 719 1,627 1,465 67 3,878 5,414
% HIV/AIDS 16.1 13.9 20.1 16.7 51.2 39.3 49.0 55.1 45.4 23.8
50 64 years
Deaths 186 86 95 367 89 235 204 18 546 1,570
% HIV/AIDS 6.8 7.5 8.2 7.3 37.4 32.6 45.4 48.1 38.7 12.8
65  years
Deaths 360 164 153 677 202 121 535 45 903 3,343
% HIV/AIDS 2.6 3.2 2.0 2.6 30.4 10.7 27.1 22.8 25.4 3.0
Male
Deaths 439 288 286 1,013 416 831 1,020 71 2,338 4,935
% HIV/AIDS 5.1 7.3 6.4 6.1 39.9 27.9 38.0 39.9 34.8 12.4
Female
Deaths 421 228 244 893 594 1,152 1,184 59 2,989 5,392
% HIV/AIDS 12.0 12.1 20.3 14.3 50.0 43.1 48.0 46.6 46.5 18.2
Pre-2002
Deaths 110 78 45 233 49 374 326 8 757 1,953
% HIV/AIDS 24.6 18.1 26.5 22.8 70.1 58.8 53.0 85.1 57.3 20.6
2002 07
Deaths 299 200 253 752 545 1,173 1,199 59 2,976 6,338
% HIV/AIDS 10.9 12.4 15.7 12.9 51.6 36.1 47.4 55.0 43.9 15.7
2008 on
Deaths 451 238 232 921 416 436 679 63 1,594 2,036
% HIV/AIDS 2.9 4.1 6.9 4.2 35.5 19.5 31.7 26.3 29.1 9.3
Karonga
Deaths 96 27 17 140 43 14 199 2 258 932
% HIV/AIDS 4.2 3.3 0 3.5 27.5 0 67.9 0 57.0 15.5
Kisesa
Deaths 97 127 141 365 68 224 90 11 393 914
% HIV/AIDS 17.1 11.9 11.5 13.1 91.1 40.3 84.2 72.7 60.1 20.4
Manicaland
Deaths 60 60 84 204   639    639 186
% HIV/AIDS 31.6 29.6 38.4 33.8   58.1    58.1 57.8
Masaka
Deaths 129 22 24 175   101    101 134
% HIV/AIDS 27.0 21.0 7.8 23.6   57.5    57.5 34.6
Rakai
Deaths 78 77 67 222 507 230 921 76 1,734 1,424
% HIV/AIDS 3.1 5.4 7.6 5.3 49.0 18.8 41.3 45.6 40.8 6.8
uMkhanyakude
Deaths 400 203 197 800 392 775 994 41 2,202 6,737
% HIV/AIDS 1.7 2.9 6.2 3.1 35.8 21.3 36.7 32.2 31.0 15.0
The InterVA-4 model was ‘blinded’ to the HIV sero-status data, only taking into account a history or diagnosis of HIV/AIDS if reported in the VA interview.
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7which occurred very rarely were subsumed into the
relevant residual categories.
Using data for individual residence episodes observed
in the six participating sites, a Poisson regression model
was constructed in Stata 12, using the sero-test results
and cause of death findings to facilitate analysing cause-
specific mortality fractions and rates by HIV infection
status, allowing adjustment by age group, sex, and site.
Results
Table 1 shows the total number of deaths, split by age
group, sex, time period, and site, according to HIV
infection status. Individuals who had reported negative
tests are divided according to time period between testing
and death, and positive individuals categorised according
to the source of information, including recorded positive
tests and diagnoses reported in VA interviews. Each cell
shows the total number of deaths and the percentage
of those assigned by InterVA-4 to ‘HIV/AIDS-related
death’. It is not inevitable that all causes of death among
HIV-positive people are HIV/AIDS related. Here, the
overall proportion of deaths among the HIV positive
attributed as HIV/AIDS-related was 41.4%. Deaths
under the HIV-negative categories should, in principle,
have no HIV/AIDS-related deaths assigned, and so
those that are recorded must arise from sero-conversion
after testing, false-positive assignments by the model, or
errors in test records. These cases amounted to 9.9%
of the HIV-negative deaths. The overall specificity with
which InterVA-4 identified HIV/AIDS-related deaths was
90.1%. Table 2 shows the specificities by age group, sex,
time period, and site.
For cases where HIV sero-status was known before
death, it is possible to calculate cause-specific mortality
fractions and rates according to HIV-negative and HIV-
positive person-years observed. Table 3 shows results
of this approach applied to 1,739 deaths in 1,161,688
HIV-negative person-years observed and 2,890 deaths in
75,110 HIV-positive person-years observed. The crude
mortality ratio was thus 25.7, and on this basis 96% of
the mortality in the HIV-positive group was excess over
what would be expected in the absence of HIV. HIV-
positive deaths attributed to HIV/AIDS, pneumonia,
and tuberculosis accounted for most of this excess. For
all causes, mortality rates were higher among the HIV-
positive group, and for many the rate ratios were con-
siderably greater than unity. A Poisson regression model
was used to estimate cause-specific mortality ratios adjus-
ted for age group, sex, and site. The all-cause adjusted
mortality ratio was 29.0 (95% CI 27.1 31.0). Cause-
specific adjusted mortality ratios, with 95% confidence
intervals, are shown in Fig. 2. For all causes, HIV-positive
people had significantly higher mortality than HIV-
negative people (lower limits of 95% CIs for mortality
ratios1), but with considerable variation in ratios
between causes, as shown on the horizontal logarithmic
scale of Fig. 2.
Discussion
Overall, these results show that the InterVA-4 detects
typical AIDS deaths in adults with high specificity,
without the model having access to sero-status data.
Exactly what constitutes a typical AIDS death is not easy
to define, even though it is clear that the clinical expertise
encapsulated within the InterVA model is, to a large
extent, successfully identifying symptom patterns that are
strongly associated with final illnesses in HIV-infected
people, which might reasonably fall into the category
of ‘HIV/AIDS-related death’. Nevertheless, HIV infec-
tion also clearly affects many other cause-specific mor-
tality rates. Therefore, it is not possible to calculate a
single parameter for sensitivity, because there is no single
cause of death that inevitably follows HIV infection, and
it is also evident that patterns of cause of death do vary
considerably between the HIV-negative and HIV-positive
groups, again without the model having access to those
data.
Achieving 90% specificity overall in identifying typical
HIV/AIDS-related deaths with the InterVA-4 model,
although blinding the model to sero-status, is an impor-
tant achievement. Interestingly, the number of false posi-
tives recorded only slightly exceeded the number of cases
with a negative test during the previous 5 years where a
diagnosis of HIV was subsequently declared in the VA
interview. Because it is clear that HIV positivity is by no
means universally disclosed in VA interviews (here not
disclosed in 37.2% of the HIV-positive cases), it is likely
Table 2. Speciﬁcities for InterVA-4 assignment of
HIV/AIDS-related deaths, based on people with a negative
HIV test result in the 5-year period before death
Specificity
95% confidence
interval
Overall 90.1 88.7 91.4
15 49 years 83.3 80.6 85.6
Age group 50 64 years 92.7 89.5 94.9
65  years 97.4 95.9 98.4
Sex
Male 94.0 92.3 95.3
Female 85.7 83.3 87.9
1990 2002 77.2 71.4 82.1
Period 2002 2007 87.1 84.5 89.3
2008 2011 95.8 94.3 96.9
Study site
Karonga 96.5 92.0 98.5
Kisesa 86.9 83.0 90.0
Manicaland 66.2 59.5 72.3
Masaka 87.0 81.2 91.2
Rakai 94.8 91.0 97.0
uMkhanyakude 95.9 94.3 97.1
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here were in fact true positives by the time of death. The
generally lower proportions of false positives who tested
negative closer to their time of death also support this
possibility. The recall period from death to VA interview
varied by site, and this may have influenced specificity in
some sites.
Although HIV infection represents a substantial risk
factor for mortality from many causes, as shown in Fig.
2, it was also the case numerically, as shown in Table 3,
that the overwhelming majority of deaths (73.9%) among
HIV-infected people were assigned to acute respira-
tory infections, AIDS, or pulmonary TB. However, it is
equally clear that not all of the 25-fold overall mortality
risk among the HIV infected is accounted for by these
main causes. As anti-retroviral therapy (ART) coverage
increases in scope and effectiveness, the overall mortality
risk associated with HIV infection is likely to decrease,
but at the same time there is likely to be increasing
diversity in cause of death among the HIV infected.
Monitoring these changes in cause-specific mortality at
the community level, using a standardised tool such as
InterVA-4, will be an important strategy for understand-
ing the future trajectory of the HIV pandemic.
Cause of death patterns for HIV-positive people in
African populations are generally not well documented.
Table 3. InterVA-4 causes of death, cause-speciﬁc mortality fractions, and adjusted mortality ratios by known HIV status for
1,739 deaths in 1,161,688 HIV-negative person-years observed and 2,890 deaths in 75,110 HIV-positive person-years observed
Cause-specific mortality
fraction (%)
Mortality rate per
1,000 per year
WHO VA cause of death by InterVA-4 HIV negative HIV positive HIV negative HIV positive Mortality rate ratio
01.02 Acute respiratory infections, including pneumonia 4.16 6.33 0.06 2.44 39.1
01.03 HIV/AIDS-related death 10.60 38.89 0.16 14.96 94.3
01.04 Diarrhoeal diseases 1.07 0.36 0.02 0.14 8.6
01.05 Malaria 3.17 1.95 0.05 0.75 15.8
01.07 Meningitis and encephalitis 1.12 1.33 0.02 0.51 30.5
01.09 Pulmonary tuberculosis 11.54 28.71 0.17 11.05 63.9
01.99 Other and unspecified infectious disease 1.68 1.54 0.03 0.59 23.5
02.01 Oral neoplasms 0.49 0.37 0.01 0.14 19.2
02.02 Digestive neoplasms 3.92 1.98 0.06 0.76 13.0
02.03 Respiratory neoplasms 2.58 0.60 0.04 0.23 6.0
02.04 Breast neoplasms female 0.51 0.19 0.01 0.07 9.6
02.06 Reproductive neoplasms female 1.61 0.90 0.02 0.34 14.3
02.99 Other and unspecified neoplasms 1.85 0.56 0.03 0.21 7.7
03.01 Severe anaemia 0.80 0.11 0.01 0.04 3.7
03.02 Severe malnutrition 0.35 0.41 0.01 0.16 29.7
03.03 Diabetes mellitus 3.75 0.73 0.06 0.28 5.0
04.01 Acute cardiac disease 1.62 0.40 0.02 0.15 6.4
04.02 Stroke 4.73 0.40 0.07 0.15 2.2
04.99 Other and unspecified cardiac disease 5.31 0.69 0.08 0.27 3.4
05.01 Chronic obstructive pulmonary disease 2.82 0.17 0.04 0.07 1.6
05.02 Asthma 1.59 0.49 0.02 0.19 8.0
06.01 Acute abdomen 6.38 2.79 0.10 1.07 11.2
98 Other and unspecified non-communicable disease 2.45 0.44 0.04 0.17 4.6
12.01 Road traffic accident 2.71 0.47 0.04 0.18 4.4
12.08 Intentional self-harm 0.99 0.14 0.01 0.05 3.6
12.09 Assault 6.18 1.29 0.09 0.50 5.4
12.99 Other and unspecified external cause of death 1.57 0.23 0.02 0.09 3.8
09.03 Pregnancy-induced hypertension 0.38 0.14 0.01 0.05 9.1
09.04 Obstetric haemorrhage 1.09 0.15 0.02 0.06 3.6
09.06 Pregnancy-related sepsis 0.28 0.17 0.00 0.07 15.7
09.99 Other and unspecified maternal cause of death 0.37 0.33 0.01 0.13 22.9
99 Indeterminate 12.31 6.74 0.18 2.59 14.1
All causes 100 100 1.50 38.48 25.7
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three ranked causes of death among HIV-positive people
were TB, pneumonia, and meningitis (20) and the same
pattern was observed in a smaller series in Uganda (21).
A review of autopsy studies in Africa showed that TB,
pneumonia, and meningitis were major causes of death
among HIV-positive people, though there were major
discrepancies between hospital causes of death and
pathology findings (22). Similar causes of death patterns
have been observed in hospital patient series in Thailand
(23) and South Africa (24). Comparisons betweenvarious
studies are sometimes difficult to make because of a
variety of understandings of what ‘AIDS deaths’ consti-
tute against a background of specific causes of death such
as pneumonia and meningitis among the HIV positive.
The very different nature of HIV epidemiology in other
settings, such as Taiwan (25) and Korea (26), also make
comparison with African populations difficult. However,
the VA findings from this study are broadly consistent
with these other cause of death findings among HIV-
positive people.
Lopman et al. proposed a number of key symptoms
that were associated with HIV infection (27), many of
which are directly reflected in the causes of death with
high rate ratios associated with HIV positivity here. The
largest numbers of relevant symptoms involved relate to
pulmonary TB and acute respiratory infections, although
there are very high rate ratios for symptoms associated
with some rarer causes as well. An indirect comparison
can also be made with excess risks among transplant
patients who are artificially immunosuppressed to counter-
rejection. A population-based study in Sweden showed
very high incidence rates for some specific cancers among
immunosuppressed transplant patients: lip [standardised
incidence ratio (SIR) 53]; mediastinum (SIR 43); vulva
and vagina (SIR 21); and non-melanoma skin cancer
(SIR 56) (28). Although VA does not readily enable
highly detailed site-specific identification of neoplasms,
the very high mortality rate ratios for oral and female
reproductive neoplasms in Table 3 are not inconsistent
with these findings from Sweden.
As might be expected in a multi-site study, there were
some differences observed between sites, and these are
likely to be due to a combination of procedural and
methodological differences, as well epidemiological and
geographical variation. In many ways recovering VA data
retrospectively from a variety of instruments is a worst-
case scenario, even if a realistic one; at least it is very
unlikely to have enhanced the performance of cause of
death assignment. We would expect that VA interviews
conducted directly under the WHO 2012 standard pro-
tocol would yield higher quality data. A further impor-
tant factor that will have changed over time, but is not
documented here, is the uptake of ART. As yet it remains
an open question as to what the cause of death patterns
may turn out to be among HIV-positive people who have
1 10 100
mortality rate ratio HIV+ve : HIV-ve 
01.02 Acute resp infect, incl pneumonia  
01.03 HIV/AIDS related death
01.04 Diarrhoeal diseases
01.05 Malaria
01.07 Meningitis and encephalitis
01.09 Pulmonary tuberculosis
01.99 Other and unspecified infect dis
02.01 Oral neoplasms
02.02 Digestive neoplasms
02.03 Respiratory neoplasms
02.04 Breast neoplasms, female 
02.05 Reproductive neoplasms, female
02.99 Other and unspecified neoplasms
03.01 Severe anaemia
03.02 Severe malnutrition
03.03 Diabetes mellitus
04.01 Acute cardiac disease
04.02 Stroke
04.99 Other and unspecified cardiac dis
05.01 Chronic obstructive pulmonary dis
05.02 Asthma
06.01 Acute abdomen
98 Other and unspecified NCD
12.01 Road traffic accident
12.08 Intentional self-harm
12.09 Assault
12.99 Other and unspecified external CoD 
09.03 Pregnancy-induced hypertension
09.04 Obstetric haemorrhage
09.06 Pregnancy-related sepsis
09.99 Other and unspecified maternal CoD 
99 Indeterminate
ALL CAUSES
Fig. 2. Cause-speciﬁc mortality rate ratios for HIV-positive: HIV-negative deaths, based on Poisson multivariate modelling of
mortality rates, adjusted for age group, sex, and study site, showing 95% conﬁdence intervals (CIs). The all-cause adjusted
mortality rate ratio was 29.0 (95% CI 27.1 31.0), represented by the vertical axis.
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appears here that there was a lower proportion of typical
AIDS deaths among all categories of HIV positivity in
the later periods, and this may well be due, at least in
part, to treatment effects. The WHO 2012 VA standard
(and hence InterVA-4) does not include any specific item
on ART, though this may be something that needs to be
incorporated in a future version.
Despite the difficulties in making precise comparisons
of causes of death, the major differences between cause-
specific adjusted mortality rate ratios by HIV status
generated by InterVA-4 are important, given the blinding
of the model to HIV sero-status. Unlike the relatively
small post-mortem series that have been reported, this
study of nearly 5,000 VAs on deaths of known HIV status
allows examination of relatively rare causes of death in
relation to HIV, as well as confirming the major causes of
death related to the risk of HIV infection. Although VA
as an overall approach, and the InterVA-4 model as a
specific tool for determining cause of death, cannot be
regarded as equivalent to undertaking post-mortems, this
study shows that VA can realistically be applied in large-
scale community-based settings and yield cause of death
results that are consistent with other approaches, success-
fully differentiating by HIV status. In addition, the use of
a standardised model such as InterVA-4 for interpreting
VA material obviates the possibility of local differences in
interpretation. We conclude that InterVA-4 is an effective
and valid public health tool for assessing mortality in
relation to HIV infection and deaths due to AIDS.
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Using HIV-attributable mortality to assess the impact of
antiretroviral therapy on adult mortality in rural Tanzania
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Background: The Tanzanian national HIV care and treatment programme has provided free antiretroviral
therapy (ART) to HIV-positive persons since 2004. ART has been available to participants of the Kisesa open
cohort study since 2005, but data to 2007 showed a slow uptake of ART and a modest impact on mortality.
Additional data from the 2010 HIV serological survey provide an opportunity to update the estimated impact
of ART in this setting.
Methods: The Kisesa Health and Demographic Surveillance Site (HDSS) has collected HIV serological data
and demographic data, including verbal autopsy (VA) interviews since 1994. Serological data to the end of
2010 were used to make two estimates of HIV-attributable mortality, the first among HIV positives using the
difference in mortality between HIV positives and HIV negatives, and the second in the population using
the difference between the observed mortality rate in the whole population and the mortality rate among the
HIV negatives. Four time periods (19941999, 20002004, 20052007, and 20082010) were used and HIV-
attributable mortality estimates were analysed in detail for trends over time. A computer algorithm, InterVA-4,
was applied to VA data to estimate the HIV-attributable mortality for the population, and this was compared
to the estimates from the serological survey data.
Results: Among HIV-positive adults aged 4559 years, high mortality rates were observed across all time
periods in both males and females. In HIV-positive men, the HIV-attributable mortality was 91.6% (95%
confidence interval (CI): 84.6%95.3%) in 20002004 and 86.3% (95% CI: 71.1%93.3%) in 20082010, while
among women, the HIV-attributable mortality was 87.8% (95% CI: 71.1%94.3%) in 20002004 and 85.8%
(95% CI: 59.6%94.4%) in 20082010. In the whole population, using the serological data, the HIV-attributable
mortality among men aged 3044 years decreased from 57.2% (95% CI: 46.9%65.3%) in 20002004 to 36.5%
(95% CI: 18.8%50.1%) in 20082010, while among women the corresponding decrease was from 57.3% (95%
CI: 49.7%63.6%) to 38.7% (95% CI: 27.4%48.2%). The HIV-attributable mortality in the population using
estimates from the InterVA model was lower than that from HIV sero-status data in the period prior to ART,
but slightly higher once ART became available.
Discussion: In the Kisesa HDSS, ART availability corresponds with a decline in adult overall mortality,
although not as large as expected. Using InterVA to estimate HIV-attributable mortality showed smaller
changes in HIV-related mortality following ART availability than the serological results.
Keywords: HIV-attributable mortality; ART; HDSS; InterVA model; serological survey; verbal autopsy
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S
ince the first AIDS case was identified in the 1980s,
HIV/AIDS has been a major public health chal-
lenge, particularly in sub-Saharan Africa, where the
burden of the disease is greatest. Prior to the introduction
of free antiretroviral therapy (ART) treatment, the age-
standardised mortality rates among HIV-positive adults
were high, being of the order of 925 times those of the
uninfected (1). In some populations, the probability of
dying between 15 and 60 years of age reached 60% among
men (2). Results from modelling vital registration data
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40% of deaths in South African adults aged 1549 years
were HIV related (3).
The positive effect of ART use on mortality (46),
and support from donor organisations, encouraged the
introduction of free national ART programmes in many
sub-Saharan African countries from 2004. Data from
longitudinal demographic surveillance in several coun-
tries have confirmed the impact of ART on HIV mor-
tality in poor-resource settings. In rural, northern Malawi
there was a 19% decline in AIDS-related mortality amongst
adults aged 1559 within 8 months of ART becoming
available (7), and a 68% decline over the 5 years from
20042009 (8). In northern KwaZulu-Natal, South Africa,
HIV-related mortality in adults aged 2549 years was
reduced by 22% in women and 29% in men between
20022003 and 20042006 following the introduction of
ART in 2004 (9). In South-west Uganda, there was a 19%
decline in the HIV population-attributable fraction of
mortality among adults aged 1559 in the 5-year period
after ART introduction in 2004 (10).
This study aims to assess the long-term impact of
ARTon HIV/AIDS mortality in Kisesa, Tanzania. In this
observational study, care and treatment services were
provided by local health facilities in line with national
policies. While residents of Kisesa had initial access to
ART in 2005, it was only available at a referral hospital
20 km away. Referrals from the local voluntary counselling
and testing (VCT) to the regional hospitals in Mwanza
were not well organised. In addition, travel and other
logistics were difficult for the Kisesa residents. By 2007,
only 3% of adults in need of treatment were receiving
ART (11) but even at this low level of coverage there was
evidence to suggest ART was having an impact on adult
mortality (12). To improve the situation, the Kisesa study
group (TAZAMA study) facilitated referrals to the
hospital to improve uptake of ART in the study area
during this ART introduction period. However from
2008, ART became available at a local clinic in Kisesa
which allowed easier access and improved uptake of
ART, with a corresponding increase in the proportion of
adults in need receiving treatment (unpublished data). In
this study, data from the serological surveys and demo-
graphic follow-up until 2010 are used to examine trends
in HIV-attributable mortality, both among HIV-positive
adults and in the whole population, over time.
Methods
The Kisesa open cohort study consists of six villages in
Mwanza region in Tanzania. In 2010, the total popula-
tion was approximately 30,000. In the period 19941998,
life expectancy was 4344 years, and approximately
50% of the population were younger than age 15 (13).
Biannual health demographic surveillance system (HDSS)
rounds since 1994 have measured births, deaths, and migra-
tion in the resident population, with mortality among
adults aged 1559 years estimated at 39% in 1994, and
22% in 2009 (14). Annual adult external migration (out of
the Kisesa cohort) has been shown to be 10% in males
and 12% in females in 19941998 (15), and around
8% among both male and female adults in 2012 (16)
(unpublished thesis). Verbal autopsies (VAs) have been
conducted to track the leading causes of death (13), in
which the main care giver or the most reliable informant
available is interviewed to capture the signs and symp-
toms that the deceased had in the time leading to their
death (17). The current VA questionnaire is taken from
the recommended WHO tool (18), although previous
versions were very similar, and included the same ques-
tions on signs and symptoms required for the ascertain-
ment of cause of death.
Since 1994, six serological surveys have been carried
out to measure HIV prevalence and incidence in the
cohort population; the first was restricted to adults aged
between 15 and 50 years of age while subsequent sero-
logical surveys were conducted amongst all adults aged
15 years and above (19, 20). The serological surveys were
done at 2- to 3-year intervals and the first four were done
in 1994/1995, 1996/1997, 1999/2000, and 2003/2004 (20).
The other two were done in 2006/2007 and in 2010. They
included questionnaire-based interviews and thereafter,
consenting adults provided a finger prick blood sample,
which was tested for HIV at the National Institute for
Medical Research laboratory in Mwanza (12). Almost all
of the respondents aged 15 who got interviewed also
got tested for HIV. In the first four serological surveys, of
the 28,591 interviews done, 28,523 interviewees got tested
(20). Attendance rates were between 61 and 86% across
the sexes and surveys. Non-attendance is mainly due to
absence from home during the survey and not rejecting to
get tested for HIV (20).
HIV prevalence in Kisesa HDSS increased steadily
from about 6% in 19941995 until its peak at about 8.3%
in 20002001 (20). It then went down to 7.6% in 2004
and then 7.1% in 2007 (21). By 2011, the prevalence was
6% (22).
Statistical methods
For this analysis, adult person-years of residence were
assessed from entry into the HDSS either at age 15 years,
through in-migration, or since the start of the HDSS in
1994, until their exit due to out-migration, death or cen-
soring at the time of the latest HDSS survey. Returning
migrants (the individuals re-entering the study following
out-migration) contribute person-years only for the time
they were actually resident in the study site. Person-years
were stratified by sex and further by age group, and years
related to ART rollout. Age was stratified into three age
groups (1529, 3044 and 4559 years, respectively).
Person-years of exposure were also stratified into different
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HIV status unknown. HIV-negative person-years were
obtained by summing the time between successive HIV-
negative tests, up to 5 years following the last recorded
HIV-negative test, and the half the period between a
negative test and a subsequent positive test in which the
sero-conversion interval is less than 5 years. HIV-positive
person-years were obtained from the time following an
HIV-positive test. HIV unknown person-years were ob-
tained from summing the time observed for those never
tested or not yet tested (i.e. before first test, whether or
not that first test was positive or negative) and the period
more than 5 years following the last negative test.
Mortality rates were obtained by dividing the number
of deaths by the person-years at risk, and 95% confidence
intervals (95% CI) obtained from the normal approxima-
tion to the log rate (23).
Analysis was carried out separately based on the avail-
ability of ART, with four time periods identified as fol-
lows: 1) More than 5 years before ART (i.e. no treatment
available) from 1994 to 2000; 2) 5 years leading to the
introduction of ART (20002004); 3) a 3-year roll-out
phase immediately following the introduction of ART
when ART was assumed to be only partially available
(20052007); and 4) a phase when ART was widely and
locally available (20082010).
Mortality rates, Mx, were calculated by dividing the
deaths, Dx, by the person-years of residence, Lx, for each
age and sex group (designated as x in the equation),
Mx ¼
Dx
Lx and are expressed as mortality per 1,000 person-
years (1,000 pyrs).
HIV-attributable fraction among HIV-positive adults
Within each period, mortality rates were calculated
separately among the HIV positives (MHIVþ
x ) and HIV
negatives (MHIV 
x ). The HIV-attributable mortality among
the positives was calculated as the excess mortality
among the HIV positives after subtracting the expected
non-AIDS mortality among the HIV positives, as given
by:
M
HIVþattrib
x ¼
DHIVþattrib
x
LHIVþ
x
¼ M
HIVþ
x   M
HIV 
x ;
where MHIVþattrib
x is the age-specific mortality due to HIV
among the HIV positive, DHIVþattrib
x are the deaths due to
HIV among the HIV positive, LHIVþ
x are the person-years
lived by the HIV positives, MHIVþ
x is the overall mortality
among the HIV positives and MHIV 
x is the mortality
among the HIV negatives. HIV-attributable fractions
among the HIV positives were then calculated by dividing
MHIVþattrib
x by MHIVþ
x .
HIV-attributable fraction among the whole
population
The HIV-attributable mortality in the population was
calculated as:
M
PopAttrib
x ¼ M
TotalPop
x   M
HIV 
x ;
where MPopAttrib
x is the age-specific mortality rate due to
HIV in the population and MTotalPop
x is the mortality rate
in the total population. Similarly, HIV-attributable mor-
tality fractions in the entire population were calculated by
dividing MPopAttrib
x by MTotalPop
x .
The InterVA4 algorithm
The InterVA4 algorithm is a probability-based model for
assigning causes of death on the basis of verbal autopsy
(VA) interview reports from the main caregivers of the
deceased (24). In this study, it was used to assign the
cause of deaths occurring in the study population for
the period 1994 to 2010. The InterVA4 model takes res-
ponses from a VA interview and uses these inputs to
determine probabilistic causes of deaths.
InterVA4 is not intended to diagnose the cause of death
for an individual case, but the probabilities of any cause of
death can be added up across the population to give the
expected total number of deaths for that cause. In this
study, the InterVA algorithm was applied to all deaths
where a VA had been performed in the Kisesa cohort in
order to estimate the probability of HIV being the cause
of the death. These probabilities were added up over all
deaths to obtain the number of HIV-related deaths and
the HIV-attributable mortality in the population. The
population HIV-attributable mortality fraction from the
InterVA4 model was compared to the HIV-attributable
mortality fraction from the serological data in Kisesa.
Table 1. Number of subjects, person-years and deaths by ART phase in adults aged 15 years and above in the HDSS population
ART phase Number of subjects Person-years Deaths Mortality rate per 1,000 pyrs 95% CI
5 years before ART (19942000) 23,316 60,057 783 13.0 12.014.0
05 years before ART (20002004) 26,031 63,248 780 12.3 11.513.1
During ART introduction (20052007) 22,253 48,309 523 10.8 9.811.8
After ART became available (20082010) 22,387 46,274 370 8.0 7.28.8
ARTantiretroviral therapy; CIconfidence interval; HDSSHealth and Demographic Surveillance Site; pyrs=person-years.
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Characteristics of data
Table1showsthecrudemortality ratesamong adultsaged
15 years and over by time period. Overall crude mortality
in the adult population has gone down from 13 deaths per
1,000 person-years in the period at least 5 years before
ART, to 12 deaths per 1,000 person-years in the 5-year
period leading to the introduction of ART, to eight deaths
per 1,000 person-years during the period of widespread
availability of ART. There was strong evidence for a
declineinmortalityratesbetweentheperiod5yearsbefore
ART introduction and the period when ART became
widely available (HR: 0.61, 95% CI: 0.540.69, pB0.000).
Age-specific mortality rates by HIV status and ART
availability
Tables 2 and 3, show person-years, deaths and mortality
rates stratified by age, HIV status and ART availability
for males and females, respectively. Mortality among
the HIV negatives was generally lower than among HIV
positives for both sexes and all age groups across the four
time periods considered. The levels of mortality for those
with unknown HIV status were generally in between
those of the HIV negatives and those of the HIV posi-
tives. The mortality rates among the HIV positives
declined over time following the introduction of ART,
while the HIV-negative mortality rates of both males and
females fluctuated over time without a clearly defined
trend. In each time period and HIV status group, mor-
tality increased by age, except in the period 5 or more
years before introduction of ART during which it was
highest in the 3044 years age group for HIV-positive
males and in the period of wide ART availability where
for females it was highest in the 1529 age group. The
decline in mortality is clearer and more consistent in the
HIV-positive women compared to men. However, the CI
are overlapping and wide indicating high uncertainty
surrounding the magnitude of the decline in the mortality
reported.
HIV-attributable mortality in the Kisesa HDSS
HIV-attributable mortality estimates are presented in
Tables 4 and 5 for males and females, respectively. In
HIV-positive people of both sexes, and across all of the
periods, around 90% of the deaths among those aged
1559 years of age are due to HIV. There was little change
in this proportion in the periods after the introduction
of ART, suggesting that mortality attributable to HIV
among HIV-positive people is still very high. The HIV-
attributable mortality in the entire population appears to
decline over time. In the periods before ART, more than
40% of the deaths in both males and females aged 1544
years of age were attributable to HIV. After the introduc-
tion of ART, the proportion of mortality attributable to
HIV in the 1544 year age groups reduced to less than
40% among the males, although among females the
pattern was less clear.
Table 2. Age-speciﬁc person-years, deaths and mortality rates per 1000 person-years by HIV status and ART availability
observed in Kisesa open cohort among male adults aged 1559 in the period 19942010
HIV negative HIV positive HIV status unknown
Age interval
Person-
years Deaths
Mortality rate
(95% CI)
Person-
years Deaths
Mortality rate
(95% CI)
Person-
years Deaths
Mortality rate
(95% CI)
5 years before ART (19941999)
1529 7618.5 21 2.8 (1.84.2) 170.5 7 41.1 (19.686.1) 7081.8 38 5.4 (3.97.4)
3044 4015.3 26 6.5 (4.49.5) 260.3 34 130.6 (93.3182.8) 3848.8 57 14.8 (11.419.2)
4559 530.3 8 15.1 (7.530.2) 44.6 5 112.0 (46.6269.1) 3495.6 69 19.7 (15.625.0)
05 years before ART (20002004)
1529 7382.8 9 1.2 (0.62.3) 252.9 8 31.6 (15.863.3) 7816.7 44 5.6 (4.27.6)
3044 4335.5 24 5.5 (3.78.3) 354.7 28 78.9 (54.5114.3) 4084.3 61 14.9 (11.619.2)
4559 2115.0 29 13.7 (9.519.7) 133.1 22 165.2 (108.8251.0) 1843.5 27 14.6 (10.021.4)
ART introduction (20052007)
1529 5723.7 16 2.8 (1.84.6) 145.1 6 41.3 (18.692.0) 5681.6 20 3.5 (2.35.5)
3044 3061.3 27 8.8 (6.012.9) 277.5 21 75.7 (49.3116.1) 3417.5 29 8.5 (5.912.2)
4559 1789.3 27 15.1 (10.322) 112.0 10 89.3 (48.0166.0) 1457.0 23 15.8 (10.523.8)
ART available (20082010)
1529 4558.6 15 3.3 (2.05.5) 85.0 3 35.3 (11.4109.5) 6182.4 24 3.9 (2.65.8)
3044 2075.4 4 1.9 (0.75.1) 181.3 8 44.1 (22.188.3) 4303.0 23 5.3 (3.68.0)
4559 1420.1 8 5.6 (2.811.3) 141.7 9 63.5 (33.1122.1) 1679.6 24 14.3 (9.621.3)
ARTantiretroviral therapy; CIconfidence interval.
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observed in Kisesa open cohort among female adults aged 1559 in the period 19942010
HIV negative HIV positive HIV status unknown
Age interval
Person-
years Deaths
Mortality rate
(95% CI)
Person-
years Deaths
Mortality rate
(95% CI)
Person-
years Deaths
Mortality rate
(95% CI)
5 years before ART (19941999)
1529 6671.8 15 2.3 (1.43.7) 408.5 21 51.4 (33.578.8) 7787.0 46 5.9 (4.47.9)
3044 5153.5 19 3.7 (2.45.8) 305.7 31 101.4 (71.3144.2) 3081.6 45 14.6 (10.919.6)
4559 632.6 3 4.7 (1.514.7) 18.5 3 161.9 (52.2501.9) 3503.2 51 14.6 (11.119.2)
05 years before ART (20002004)
1529 6536.0 19 2.9 (1.94.6) 407.9 17 41.7 (25.967.0) 8418.8 43 5.1 (3.86.9)
3044 6166.7 34 5.5 (3.97.7) 482.6 39 80.8 (59.0110.6) 2766.0 42 15.2 (11.220.5)
4559 3139.6 35 11.1 (8.015.5) 106.1 10 94.3 (50.7175.2) 1251.6 17 13.6 (8.421.8)
ART introduction (20052007)
1529 4958.0 12 2.4 (1.44.3) 217.8 11 50.5 (28.091.2) 6034.2 22 3.6 (2.45.5)
3044 4699.5 19 4.0 (2.66.3) 429.9 18 41.9 (26.466.5) 2212.6 19 8.6 (5.513.5)
4559 2619.0 20 7.6 (4.911.8) 116.7 10 85.7 (46.1159.3) 948.4 10 10.5 (5.719.6)
ART available (20082010)
1529 4091.1 6 1.5 (0.73.3) 155.0 5 32.3 (13.477.5) 6946.9 17 2.4 (1.53.9)
3044 3422.1 9 2.6 (1.45.1) 441.5 10 22.6 (12.242.1) 2977.2 19 6.4 (4.110.0)
4559 2261.4 7 3.1 (1.56.5) 144.7 3 20.7 (6.764.3) 1216.7 16 13.1 (8.121.5)
ARTantiretroviral therapy; CIconfidence interval.
Table 4. HIV-attributable mortality for males aged 1559 in Kisesa open cohort from serological data and InterVA model,
19942010
Using sero-status data Using InterVA4
Age interval *Deaths
HIV-attributable mortality
fractions among the HIV-
positive deaths (95% CI)
HIV-attributable mortality
fractions in the entire
population (95% CI) **Deaths
HIV-deaths
assigned by
InterVA4
% deaths
attributable to HIV
using InterVA4
5 years before ART (19941999)
1529 66 94.1 (83.597.6) 41.1 (28.151.6) 64 19 29.7
3044 117 95.3 (91.997.3) 56.2 (46.264.3) 109 39 35.8
4559 82 85.0 (30.296.2) 27.6 (19.755.5) 71 12 16.9
05 years before ART (20002004)
1529 61 96.1 (88.598.7) 68.5 (53.578.4) 36 8 22.2
3044 113 93.0 (87.596.1) 57.2 (46.965.3) 52 11 21.2
4559 78 91.6 (84.695.3) 26.2 (15.435.6) 44 7 15.9
ART introduction (20052007)
1529 42 91.5 (50.498.0) 11.8 (12.530.2) 34 6 17.6
3044 77 79.8 (41.592.3) 12.7 (4.927.1) 64 14 21.9
4559 60 87.9 (61.195.7) 13.5 (3.027.0) 56 11 19.6
ART available (20082010)
1529 42 91.4 (74.696.6) 14.2 (1.225.4) 27 8 29.6
3044 35 93.2 (86.596.6) 36.5 (18.850.1) 29 16 55.2
4559 41 86.3 (71.193.3) 35.8 (22.746.5) 29 5 17.2
Of the *814 male deaths among adults aged 1559. **615 (76%) had VAs thus the difference in the number of deaths with a sero-status
and those with a corresponding VA. ARTantiretroviral therapy; CIconfidence interval; VAsverbal autopsies.
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Table 4 (males) and 5 (females) show the population
HIV-attributable mortality from the InterVA4 model
compared to the population HIV-attributable mortality
from the serological data.
The InterVA-4 model gave higher HIV-attributable
mortality among the females compared to the males. The
exception is the period of ART introduction in which
the proportions of deaths attributable to HIV are higher
among the males than the females in all age groups.
Comparison of the InterVA-4 estimates to those obtained
from serological data show that for the pre-ART period,
InterVA-4 provides lower estimates of mortality attribu-
table to HIV in the population. However, in the period of
ART introduction and the subsequent period of ART
availability, the InterVA model tended to overestimate
the population-level HIV-attributable mortality in both
males and females.
Discussion
This paper uses age-specific mortality rates and HIV-
attributable mortality fractions to assess the impact of
ART availability on adult mortality in the Kisesa HDSS.
The results show that the availability of ART to HIV-
positive participants has so far yielded a slow decline in
adult mortality, six years after it was introduced in 2005.
However, the coverage of ART in Kisesa was very low,
estimated at 3% for the first 3 years after it was introduced
(11, 12). The availability of ART has improved over time,
but the impact on population-level mortality may still
take some time to observe. Although the methods used in
this paper (population attributable fractions among the
HIV positives and in the entire population) are different
from the exponential regression and hazard rate ratios
used previously in this setting (12), the results from these
two studies broadly agree in showing that the impact of
ART is modest, even with the additional data from the
most recently completed serological survey in 2010.
This decline in mortality in Kisesa is less than that
reported in other sub-Saharan countries where ART
has been introduced, including sites collecting similar
community-level serological and demographic data in
Uganda (10), South Africa (9) and Malawi (8, 25). Results
from the Karonga Prevention Study (KPS), which is a
similar mixture of semi-urban and rural settings as the
Kisesa open cohort, showed a mortality decline of 21%
(95% CI: 236%) after ART introduction (between 2004
05 and 200809), especially when ART became available
within the KPS area (8). These differences are likely to
be partially explained by different levels of uptake of
HIV testing services. For example, in Kisesa, VCTuptake
among HIV-positive people during the serological surveys
Table 5. HIV-attributable mortality for females aged 1559 in Kisesa open cohort from serological data and InterVA model,
19942010
Using sero-status data Using InterVA4
Age interval *Deaths
HIV-attributable mortality
fractions among the HIV-
positive deaths (95% CI)
HIV-attributable mortality
fractions in the entire
population (95% CI) **Deaths
HIV deaths
assigned by
InterVA4
% deaths
attributable to HIV
using InterVA4
5 year before ART (19941999)
1529 82 95.4 (90.597.8) 58.2 (44.668.3) 78 39 50.0
3044 95 96.2 (93.098.0) 65.3 (55.972.7) 83 43 51.8
4559 57 97.0 (77.499.6) 61.8 (14.382.0) 57 10 17.5
05 year before ART (20002004)
1529 79 93.2 (86.396.6) 44.9 (30.756.1) 51 16 31.4
3044 115 93.5 (89.396.1) 57.3 (49.763.6) 61 30 49.2
4559 62 87.8 (71.194.3) 19.1 (12.025.5) 35 4 11.4
ART introduction (20052007)
1529 45 92.0 (50.698.3) 32.4 (2.852.1) 41 13 31.7
3044 56 93.2 (80.097.7) 57.9 (42.069.2) 50 14 28.0
4559 40 93.9 (81.497.8) 37.3 (24.048.0) 36 8 22.2
ART available (20082010)
1529 28 96.5 (91.498.6) 44.9 (25.259.1) 19 8 42.1
3044 38 85.8 (72.892.6) 38.7 (27.448.2) 28 15 53.6
4559 26 85.8 (59.694.4) 39.5 (28.148.9) 17 5 29.4
Of the *723 female deaths among adults aged 1559. **556 (77%) had VAs thus the difference in the number of deaths with a sero-status
and those with a corresponding VA. ARTantiretroviral therapy; CIconfidence interval; VAsverbal autopsies.
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mately 25% in 20062007 (26). Much higher levels of
knowledge of HIV status have been reported in Malawi
(95%) in 20072008 where opt-out testing and door-
to-door delivery of test results has been offered during
serological surveys. Similarly, in Masaka in Uganda,
where HIV testing is offered at the household during the
annual survey rounds, 56% of HIV-positive adults knew
their status in 2008 (11). It is most likely that the impact
of ART on mortality will be realised only when wider
coverage of VCT and ART are achieved in Kisesa.
Measuring HIV-attributable mortality is important
for the evaluation of ART delivery programmes (27).
However, it can only be properly measured with good
serological data from a representative population-based
cohort, and there are few such cohorts in most countries
affected by the HIV epidemic. Studies on HIV-positive
patients attending clinics can provide estimates of the
impact of ART on mortality (28), but do not capture the
impact of those who do not know their HIV status, or
who have not been assessed for eligibility for ART. Other
studies have shown that monitoring burial grounds can
estimate the impact of ART on HIV-related mortality,
although this does depend on the local culture surround-
ing death, and the proportion of people using public
cemeteries (29).
We compared the population HIV-attributable frac-
tions directly calculated from the sero-status of those who
died, and the HIV-attributable mortality from VA where
the cause of death had been assigned using the InterVA-4
algorithm. The comparison showed that in the pre-ART
period, InterVA tended to provide lower estimates of the
contribution of HIV to mortality, but in the period when
ART was available, InterVA overestimated the contribu-
tion of HIV to mortality. Two other studies have used
VA data, one in Kenya and the other one in Ethiopia, com-
paring the InterVA assessment with the causes of death
assigned by physicians (30, 31). In the Kenyan study, HIV-
attributable mortality was underestimated by InterVA
compared to the physician assignment, but gave similar
HIV-attributable mortality fractions when tuberculosis
and HIV/AIDS were combined (30). The Ethiopian study
on the other hand compared HIV-attributable deaths
as assigned by InterVA and those from known hospital
diagnosis and HIV status of the deceased (31). The
results from this study seem to also suggest that InterVA
performs better when HIV and TB are combined. In
Kisesa, combining TB and HIV/AIDS-related deaths from
InterVA-4 did not alter the results substantially as a
relatively small proportion of deaths were assigned to
TB (data not shown). On the other hand, a study in
Agincourt, South Africa suggests broadly similar HIV-
attributable mortality trends over time between InterVA
assessment and physician assignment of cause of death (32).
Further work may be needed to confirm the usefulness
of the InterVA algorithm in assessing HIV-attributable
mortality in sub-Saharan Africa.
There are some limitations related to this study. The
numbers of deaths used in the calculation of age-specific
HIV-attributable mortality fractions are quite small, so
the results may be due to random variation and should
therefore be interpreted with caution. We did not adjust
for potential confounders such as socio-economic status,
which may affect the relationship between availability of
ART and mortality. We also did not take into considera-
tion the selection effect that migration may bring since
those who migrate out are not followed-up to observe
their mortality. However, we have no significant reasons
to think that those who migrate both in and out of the
study area would exhibit different mortality patterns to
those of their non-moving counterparts. Participants who
tested HIV negative and either had no subsequent test, or
tested positive in the subsequent test done more than 5
years after the negative test, were assumed to be HIV
negative for up to 5 years. They were then classified as
unknown until the date of testing positive. This assump-
tion was made after observing that 95% of those testing
HIV negative in a particular round of serological survey
remained negative in the ensuing 5 years. We also did
sensitivity analysis (data not shown) assuming 2 and 10
years cut-offs for changing classifications of the HIV
negative into the unknown group. We did not observe any
significant changes in the mortality, therefore we think
that the cut-off at 5 years in not unreasonable.
In conclusion, the current study has confirmed a
decline in HIV-attributable mortality among HIV posi-
tives and all adults in the study population. The decline is
not as pronounced as has been experienced in similar
study populations in Uganda, Malawi and South Africa,
even after 3 years of availability of ART at a clinic in
Kisesa, suggesting that greater efforts are needed to
improve VCT uptake and treatment initiation for those
needing ART in this setting. Analysis of the retention
rates for those on ART should be considered in order to
confirm the duration of time that individuals starting
ART are remaining on treatment.
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O
ver the past 20 years, there have been dramatic
changes in both the levels and causes of mortality
in sub-Saharan Africa. Initial catastrophic rises
in mortality due to HIV have been partially curtailed by
antiretroviral therapy (ART) (1), and deaths due to dis-
eases conventionally associated with more affluent socie-
ties are becoming more prominent (2).
Few countries in sub-Saharan Africa have vital regis-
tration or death certification, so estimation of mortality
rates and distribution of causes of death relies on indirect
methods or on detailed studies in demographic surveil-
lance sites. In these sites, regular population updates
through repeated censuses and/or continuous registration
systems ensure almost complete registration of births and
deaths. Accurate determination of the cause of death is
much more complex. Many deaths will occur without
clinical care, and diagnostic facilities for those who do
reach care are often limited.
Demographic surveillance sites rely on verbal autopsy
to classify major causes of death (3, 4). An informant,
preferably the caregiver during the final illness, is in-
terviewed using a set of standard questions. Information
may be added from health passports if available. A di-
agnosis is made based on clinician review or through
computer algorithms such as InterVA (5). In another
paper in this series, the performance of InterVA-4 based
on responses only (not HIV status unless reported during
the verbal autopsy) was assessed against known HIV
status across six demographic surveillance sites (6). This
showed a high specificity (90%) but could not estimate
Global Health Action
Global Health Action 2014. # 2014 Judith R. Glynn et al. This is an Open Access article distributed under the terms of the Creative Commons CC-BY 4.0
License (http://creativecommons.org/licenses/by/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix,
transform, and build upon the material for any purpose, even commercially, provided the original work is properly cited and states its license.
21
Citation: Glob Health Action 2014, 7: 23621 - http://dx.doi.org/10.3402/gha.v7.23621sensitivity as HIV-positive individuals can die from
other causes.
The Karonga Prevention Study, one of those six sites,
has unusually detailed data collection and clinician review
(7). We have previously documented adult mortality rates
and causes of death up to 2009, showing a decline in all-
cause mortality following antiretroviral roll-out and re-
placement of HIV/AIDS by non-communicable disease
as the leading cause of death (2). We now update this
analysis to 2012 and assess the performance of InterVA
against the conclusions reached by the clinicians and
investigate how this varies by age group, sex, time period
(pre- and post-antiretroviral roll-out), and HIV status.
Methods
The demographic surveillance site covers a population of
about 35,000 in the southern part of Karonga District,
northern Malawi. It is predominantly rural, although half
of the population lives within 1 km of a tarmac road. The
main occupation is subsistence farming. HIV was already
present in the area in the early 1980s. The prevalence
peaked in the mid-1990s and is now around 9% in women
and 7% in men (8). The HIV is mainly subtype C (9).
Demographic surveillance started in 2002, with a base-
line house-to-house census which covered the whole
area by 2004 (10). This records detailed data on personal
identifiers, sociodemographic and economic status for
all individuals, and the physical location of all households.
Community-based key informants are responsible for up-
dating information within defined geographical areas that
cover between30 and 40 households. They reportmonthly
on births and deaths and collect migration data for annual
reports in their area. Births and deaths are followed-up
immediately by the field staff, and all events are checked
during annual re-censuses.
In 200506, a HIV sero-survey was conducted in
selected clusters of the demographic surveillance area.
Between 2007 and 2011, four annual house-to-house HIV
sero-surveys were completed in the whole demographic
surveillance area. HIV rapid tests were used, with results
availabletothe participants during thevisit (11). The sero-
surveys followed about 6 weeks after re-census in each
area (8). All adults (]15 years old) who were resident
in the demographic surveillance area at the time of the
re-census were visited at home, with up to three repeat
visits if necessary. Consent was sought separately for in-
terviewing and HIV testing. Participantswere encouraged
to know their status, but could accept testing and choose
not to know the result, in which case HIV testing was
performed at project headquarters. Interviewers asked
about previous HIV testing, including the timing and
result of the most recent test, and about ART use if the
participant reported that they were HIV positive. HIV-
positive individuals who elected to know their status were
referred for screening for eligibility for ART. HIV results
are also available from linked epidemiological studies
within the area.
Free ART was first available at the Karonga district
hospital in July 2005, in the rural hospital within the
demographic surveillance area in September 2006, and
at further clinics within the area from October 2010. By
mid-2008, ART uptake in the demographic surveillance
areawas estimated to be 58% of those eligible (12). Initial
criteria for eligibility were WHO stage 3 or 4 disease
or CD4 of B250 cells/mm
3 (after abrief period of B200).
CD4 counts were rarely available so eligibility was usually
assessed clinically. The criteria for eligibility widened to
include those with CD4 up to 350 cells/mm
3 in July 2011.
Cause of death
After a death has been reported by a key informant, a
verbal autopsy is conducted as soon as possible, after
allowing a 2-week mourning period. An interviewer with
clinical training visits the deceased’s household, and if
consent is given, fills in a semi-structured verbal autopsy
form (2). This is similar to the 2003 INDEPTH verbal
autopsy tool, which was an adaptation of the contem-
poraneous WHO questionnaire (13). Close relatives of the
deceased, preferably those who were present most of the
time or who nursed the deceased before they died, are
asked an open-ended narrative question about the death,
and then a series of closed questions about specific
symptoms. The completed questionnaire is given to two
independent clinicians (physicians or clinical officers) who
independently assign a cause of death. If the two assigned
causes of death are discordant, a third physician reviewer
assesses all the evidence, including the two previous re-
views, and assigns a cause of death. Information on HIV
status is available to the reviewers if known. Data on ART
use was asked specifically from 2009 and may have been
mentioned by relatives before that. Deaths of individuals
with tuberculosis were assigned as ‘TB’, if they had good
evidence of tuberculosis (TB) and no other symptoms of
AIDS. Otherwise, they were classified as ‘AIDS’ or ‘TB/
AIDS unspecifiable’. Different clinicians have assigned
the cause of death over the long period of study. The two
coding clinicians agreed on cause of death (comparing the
categories ‘not TB/AIDS’, ‘AIDS’, ‘TB’, ‘TB or AIDS’,
‘unspecifiable’) for 82% of deaths (Kappa 0.68). Group-
ing the TB and AIDS categories, the overall agreement
increased to 87%, Kappa 0.76.
For the InterVA analysis, the original data from thever-
bal autopsy forms were entered according to the InterVA-4
required format. Data were directly extracted from the
questionnaire for 112 of the 190 InterVA-4 input items
which are relevant for adult deaths. The remaining input
items were left as missing. Data were available for all
the key symptoms associated with HIV-related deaths
(e.g. oral candidiasis and wasting), and where possible,
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Ethical approval
Ethical approval for the study was obtained from the
National Health Sciences Research Committee of Malawi
and the Ethics Committee of the London School of
Hygiene and Tropical Medicine.
Data analysis
Data from August 2002 to the end of 2012 were included.
The study period was divided into three: pre ART (before
7 July 2005); during ART-rollout up to 2 years after
ARTavailability within the demographic surveillance area
(7 July 20056 September 2008); and more than 2 years
after the availability of ART locally (after 6 September
2008). Person-time at risk (in years) was used as the
denominator in the calculation of all mortality rates.
Analysiswas done using Stataversion 13 and the InterVA-
4 Model was run through R Studio (version 1.0) (14).
InterVA-4 requires estimates of the prevalence of HIVand
malaria among deaths in the population; these were set to
be high ( 1% of all deaths).
Analyses compared the overall mortality rates and the
proportionofdeathsattributedtoHIV/AIDSasestimated
by InterVA and by clinician review. We used the InterVA
estimations [as in Ref. (6)] but included any additional
available HIV data not already reported during the verbal
autopsy. InterVA calculates the likelihood for each cause
of death for each individual, and these are summed across
thewhole population or subgroups. We explored the effect
of including or excluding TB cases with AIDS cases in
both the InterVA and clinician estimates as the symptoms
and signs of TB and AIDS are difficult to distinguish.
Finally, we compared the most likely cause of death for
each individual as assigned by InterVAwith that assigned
by clinician review. While clinician review is far from
perfect, it is the best available diagnosis, andwas used as a
‘gold standard’ against which to estimate the sensitivity
and specificity of InterVA. The data used by the two
methods was almost the same, except that the clinicians
see the narrative which is not available to InterVA, and
InterVA was given additional data on HIV status (from
self-report and ART use data) that was not necessarily
known to the clinicians unless mentioned in the narrative.
Results
From August 2002 to December 2012, a total of 1,637
deaths of individuals aged 15 years and above were re-
gistered in 155,875 person-years at risk giving a crude
mortality rate of 10.5/1,000 person-years [95% confidence
interval (CI): 10.011.0]. Verbal autopsy questionnaire
datawere availablefor 1,618 (99%). Three had no clinician
reviewavailable, leaving 1,615 with information from both
methods.
Table 1 shows age-specific all-cause mortality rates
stratified by ART availability. All cause adult mortality
rates declined from 13.8/1,000 person-years (95% CI:
12.615.1) before ART introduction in the district to 8.5
(95%CI:7.99.2)onceARTprovisionwaswidespread,with
the reduction seen in all age groups except the over 60s.
The proportion of deaths attributable to HIV/AIDS in
different time periods according to the different methods
ofascribing cause is shown in Table2 for those aged 1559
and in Table 3 for those aged 60 and over. HIV status was
known (by test result or report) for 606 deaths, of which
Table 1. Age-speciﬁc mortality rates per 1,000 person years (all causes, both sexes) by ART availability
Before ART introduction
(before 7 July 2005)
ART introduction
(7 July 20056 September 2008)
 2 years local ART
(after 6 September 2008)
Age
group
Number
of
deaths
Number
of
person
years
Mortality rate
(95% CI)
Number
of
deaths
Number
of
person
years
Mortality rate
(95% CI)
Number
of
deaths
Number
of
person
years
Mortality rate
(95% CI)
1519 11 6,277 1.75 (0.973.16) 11 10,117 1.09 (0.601.96) 15 13,822 1.09 (0.651.80)
2024 21 5,702 3.68 (2.405.65) 17 9,212 1.85 (1.152.97) 31 10,626 2.92 (2.054.15)
2529 28 4,568 6.13 (4.238.88) 41 7,676 5.34 (3.937.25) 31 9,754 3.18 (2.244.52)
3034 50 3,373 14.82 (11.2319.56) 72 6,203 11.61 (9.2114.62) 30 8,242 3.64 (2.555.21)
3539 49 2,567 19.09 (14.4325.25) 59 4,283 13.77 (10.6717.78) 45 6,554 6.87 (5.139.20)
4044 50 2,016 24.80 (18.8032.72) 46 3,636 12.65 (9.4816.89) 43 4,650 9.25 (6.8612.47)
4549 33 1,670 19.76 (14.0527.79) 41 2,721 15.07 (11.0920.46) 41 3,903 10.50 (7.7314.27)
5054 21 1,172 17.91 (11.6827.48) 35 2,191 15.98 (11.4722.25) 30 3,013 9.96 (6.9614.24)
5559 28 1,220 22.96 (15.8533.25) 36 1,625 22.15 (15.9830.7) 31 2,359 13.14 (9.2418.68)
60 150 3,451 43.47 (37.0451.01) 239 5,861 40.78 (35.9346.29) 302 7,412 40.75 (36.4045.61)
Overall 441 32,015 13.77 (12.5515.12) 597 53,523 11.15 (10.2912.09) 599 70,334 8.52 (7.869.23)
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272 HIV-positive deaths were reported as HIV positive as
part of the verbal autopsy, and 286/334 HIV negatives
were reported as negative.
For those aged 1559, the proportion of deaths due to
HIV/AIDS decreased over time whichever method was
used, but the proportion attributed to HIV/AIDS was
higher when based on clinician review than when using
InterVA. This was partially explained by the way TB was
handled by the two methods. If TB deaths were grouped
with AIDS deaths, there was less discrepancy between the
methods. In those aged 60 and over, the proportion of
deaths attributable to HIV/AIDS was much lower, and
similar in InterVA and clinician review. In this age group,
including TB deaths greatly increased the discrepancy,
with InterVA over-diagnosing TB deaths compared to the
clinician review.
To allow a more detailed examination of the diagnoses
reached by InterVA and clinician review, the most likely
cause determined by InterVA for each individual was
compared with that from the clinician review (Table 4).
This shows the results by age group, and for those aged
1559, by sex, time period, and HIV status. Of the 320
deaths in age group 1559 attributed to HIV/AIDS by
InterVA, clinician review attributed 259 to AIDS or TB/
AIDS, 2 to TB only, 6 to other communicable disease, 40
to non-communicable disease, 1 to external causes, and
12 were indeterminate. Of the 124 attributed to TB by
InterVA, only 18 were attributed to TB alone by clinician
review with 11 attributed to TB/AIDS, 75 to AIDS, 2 to
Table 2. Percentage of deaths attributable to HIV/AIDS using different methods of interpreting the verbal autopsy data in
individuals aged 1559
Percentage of deaths attributed to HIV/AIDS
Calendar
year
Number of
deaths
InterVA (not
including TB)
InterVA
(including TB)
Clinician review (excluding deaths
attributed only to TB)
Clinician review (including
all TB deaths)
2002/2003 96 39.6 56.1 67.7 68.8
2004 135 32.9 49.6 59.3 61.5
2005 120 50.5 60.4 60.8 61.7
2006 124 45.1 56.8 50.8 55.7
2007 99 33.9 50.5 41.4 44.4
2008 95 26.6 39.1 36.8 41.1
2009 69 21.8 31.3 40.6 44.9
2010 49 27.3 33.0 38.8 38.8
2011 69 22.3 32.3 30.4 34.8
2012 80 18.1 33.3 30.0 31.3
Overall 936 33.8 46.8 48.0 50.6
Table 3. Percentage of deaths attributable to HIV/AIDS using different methods of interpreting the verbal autopsy data in
individuals aged 60 and over
Percentage of deaths attributed to HIV/AIDS
Calendar
year
Number of
deaths
InterVA (not
including TB)
InterVA
(including TB)
Clinician review (excluding deaths
attributed only to TB)
Clinician review (including
all TB deaths)
2002/2003 33 9.2 20.3 9.1 12.1
2004 70 4.5 15.2 5.7 8.6
2005 84 7.6 14.4 7.1 9.5
2006 71 7.2 11.6 8.5 8.5
2007 74 7.6 15.6 2.7 4.1
2008 76 3.9 7.9 4.0 6.6
2009 75 1.2 13.8 1.3 1.3
2010 71 0.4 9.3 1.4 2.8
2011 58 1.1 6.1 3.5 6.9
2012 67 0 10.5 1.5 6.0
Overall 679 4.2 12.2 4.3 6.3
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Clinician review
Main cause of
death assigned
by InterVA
AIDS
death
only
TB/
AIDS
death
TB
death
only
Other
communicable
Non-
communicable
Maternal/
External Indeterminate Total
Overall
(age
1559)
HIV/AIDS 251 8 2 6 40 1 12 320
TB 75 11 18 2 15 1 2 124
Other 96 2 5 84 129 105 26 447
Indeterminate 6 0 0 3 14 10 12 45
Total 428 21 25 95 198 117 52 936
Age
group
1529 HIV/AIDS 40 3 2 2 10 0 1 58
TB 7 2 2 1 3 0 0 15
Other 14 0 0 21 25 55 5 120
Indeterminate 0 0 0 0 4 2 3 9
Total 61 5 4 24 42 57 9 202
3044 HIV/AIDS 141 4 0 2 20 1 9 177
TB 47 7 9 0 6 1 2 72
Other 49 2 4 36 38 35 13 177
Indeterminate 2 0 0 1 4 5 4 16
Total 239 13 13 39 68 42 28 442
4559 HIV/AIDS 70 1 0 2 10 0 2 85
TB 21 2 7 1 6 0 0 37
Other 33 0 1 27 66 15 8 150
Indeterminate 4 0 0 2 6 3 5 20
Total 128 3 8 32 88 18 15 292
60 and over HIV/AIDS 9 0 0 6 14 0 1 30
TB 7 2 10 3 32 0 2 56
Other 9 1 4 81 365 19 66 545
Indeterminate 1 0 0 5 11 2 29 48
Total 26 3 14 95 422 21 98 679
Sex (age
1559)
Men HIV/AIDS 107 5 0 3 19 0 8 142
TB 37 5 13 1 8 0 1 65
Other 49 1 4 57 63 52 16 242
Indeterminate 4 0 0 1 11 8 11 35
Total 197 11 17 62 101 60 36 484
Women HIV/AIDS 144 3 2 3 21 1 4 178
TB 38 6 5 1 7 1 1 59
Other 47 1 1 27 66 53 10 205
Indeterminate 2 0 0 2 3 2 1 10
Total 231 10 8 33 97 57 16 452
Time
period
Before
ART
introduction
HIV/AIDS 95 4 0 2 5 0 3 109
TB 29 9 2 1 4 0 0 45
(age
1559)
Other 40 2 3 20 28 19 13 125
Indeterminate 2 0 0 0 3 5 1 11
Total 166 15 5 23 40 24 17 290
ART
introduction
HIV/AIDS 115 4 2 2 20 1 4 148
TB 30 0 10 1 4 1 1 47
Other 23 0 1 38 47 34 7 150
Indeterminate 1 0 0 1 4 3 4 13
Total 169 4 13 42 75 39 16 358
 2 years
local ART
HIV/AIDS 41 0 0 2 15 0 5 63
TB 16 2 6 0 7 0 1 32
Other 33 0 1 26 54 52 6 172
Indeterminate 3 0 0 2 7 2 7 21
Total 93 2 7 30 83 54 19 288
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disease. By contrast there was poor correlation between
InterVA and clinician diagnoses for the over 60s. Of 30
deaths attributed to HIV/AIDS by InterVA, 9 were attri-
buted to AIDS or TB/AIDS by clinician review, with 6
other communicable diseases and 14 non-communicable
diseases. And of 56 attributed to TB by InterVA, clinician
review attributed 12 to TB or TB/AIDS, 7 to AIDS, 3 to
othercommunicabledisease,and32tonon-communicable
disease.
Diagnoses reached by InterVA and clinician review
were also compared by HIV status (Table 4). Neither
method assigned HIV/AIDS as the cause if there was
a recent negative HIV test (with one exception) and
neither method automatically assigned HIV/AIDS as the
cause if there was a positive HIV test. The relative under-
reporting of HIV/AIDS deaths by InterVA was more
marked in those known to be HIV positive than HIV
unknown: among those known to be HIV positive, HIV/
AIDS deaths were diagnosed for 47% by InterVA and
80% by clinician review (53 and 84%, respectively, if
on ART). For those with unknown status, HIV/AIDS
deaths were diagnosed for 35% by InterVA and 47% by
clinician review.
The sensitivity and specificity of InterVA compared to
clinician review is shown in Table 5 (excluding those with
undetermined cause of death). Among those aged 1559,
the sensitivity of InterVA for identifying HIV/AIDS
deaths was 59% and the specificity was 88%. Sensitivity
decreasedwith age andwasonly 32% in those aged over 60.
Among those aged 1559, the sensitivity was lower in the
last period, after ART use was widely established. Speci-
ficity varied less andwas lowest during ART introduction.
Grouping HIV/AIDS and TB together greatly impro-
ved the sensitivity of InterVA in all groups, with little loss
in specificity. In the 1559 age group, the sensitivity
was 78% and the specificity 83% for the combined
definition.
Discussion
In this setting, adult mortality rates have fallen dramati-
cally since ART became widely available. This is mirrored
by the decreasing proportion of deaths attributable to
HIV/AIDS. This decrease is seen with both methods of
classifying the verbal autopsy data  InterVA or clinician
review  but there were differences between them, with the
proportion attributed to HIV/AIDS by InterVA being
lower than that attributed by clinician review in all year
Table 4 (Continued)
Clinician review
Main cause of
death assigned
by InterVA
AIDS
death
only
TB/
AIDS
death
TB
death
only
Other
communicable
Non-
communicable
Maternal/
External Indeterminate Total
Known
HIV
status
(age
1559)
HIV negative HIV/AIDS 1 0 0 2 12 0 0 15
TB 0 0 7 0 9 0 0 16
Other 0 0 0 15 46 49 5 115
Indeterminate 0 0 0 1 5 3 7 16
Total 1 0 7 18 72 52 12 162
HIV positive HIV/AIDS 104 4 1 1 8 0 3 121
TB 37 4 6 0 0 0 2 49
Other 49 1 1 12 9 6 2 80
Indeterminate 4 0 0 0 1 0 0 5
Total 194 9 8 13 18 6 7 255
HIV
unknown
HIV/AIDS 146 4 1 3 20 1 9 184
TB 38 7 5 2 6 1 0 59
Other 47 1 4 57 74 50 19 252
Indeterminate 2 0 0 2 8 7 5 24
Total 233 12 10 64 108 59 33 519
On ART HIV/AIDS 37 2 0 0 3 0 1 43
TB 11 0 2 0 0 0 1 14
Other 16 0 0 4 1 1 0 22
Indeterminate 2 0 0 0 0 0 0 2
Total 66 2 2 4 4 1 2 81
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the two methods was particularly marked in those who
were known to be HIV positive.
Part of the difference in performance in the 1559 age
group is explained by the classification of TB and TB/
AIDSdeaths.IfallTBdeathsweregroupedwiththeAIDS
deaths for both methods the results were much more
similar, although clinician review continued to attribute a
slightly higher proportion to HIV/AIDS/TB in this age
group.
In the over 60s, the proportion of deaths attributed to
HIV/AIDS without TB was low and similar in the two
methods. In this age group, the inclusion of TB deaths
greatly increased the proportion attributed to HIV/AIDS/
TB by InterVA, with much less increase in the clinician
review diagnoses. As shown in Table 4, of the 56 TB cases
diagnosed by InterVA in the over 60s, only 34% (19 cases)
wereclassifiedasTBorAIDSbyclinicianreview,and57%
(32 cases) were thought to be due to non-communicable
disease. By contrast, among those aged 1559 diagnosed
as TB deaths by InterVA, 84% (104/124) were classified as
TBorAIDS,andonly12%(15/124)asnon-communicable
disease by clinician review. In Karonga, TB case finding
and diagnosis is good, as TB has been a major focus of
studiesfor30years,soitislikelythatitistheInterVAdiag-
noses that are more often incorrect. In the over 60s,
although the overall numbers attributed to HIV/AIDS
by the two methods was similar, at an individual level
therewaspoorcorrelationsothesimilarityisprobablydue
to chance.
The estimates of sensitivity and specificity show that
the sensitivity of InterVA can be greatly improved, with
little loss of specificity, by grouping HIV/AIDS/TB as
one diagnostic category. An analysis in Nairobi com-
paring InterVA with AIDS mortality estimates from
spectrum also found under-estimation by InterVA which
was improved by including deaths classified as TB (15).
A study in Ethiopia using hospital diagnoses and HIV
testing as the comparison group found improved sensitiv-
ity without loss of specificity for InterVAwhen combining
TB and AIDS (16), and a study in Kenya found that
InterVA tended to over-diagnose TB when compared to
hospital diagnoses (17). A comparison in a demographic
surveillance site in Ethiopia found poor agreement
between InterVA and physician review for both HIV/
AIDS and TB diagnoses (18), and worse agreement in
older adults (19). A large multi-country study also found
relatively poor performance by InterVA compared to
physician review where tertiary hospital cause of death
assignments, with stringent diagnostic criteria, were used
as the gold standard (20, 21), though methodological
questions havebeen raised about some of the comparisons
in this study (22).
Obviously, clinician reviewof verbal autopsy data is not
a true gold standard. Even pre-mortem clinical diagnoses
in settings with good clinical facilities are often contra-
dicted by conventional autopsy (3, 23, 24), and reaching
a diagnosis based on a limited amount of reported infor-
mation is much more difficult. What the comparison
does test, however, is how well the computer algorithm
performs compared to two (or in cases of discrepancy,
three) clinicians working in the local environment, with
essentially the same information. The results suggest that
using the InterVA definition of HIV/AIDS alone will
underestimate AIDS death, but that it performs better for
the combined diagnosis of HIV/AIDS/TB, and this
amendment could be recommended in the 1559 age
group. Results in the over 60s appear less reliable. The
apparently lower sensitivity of InterVA for diagnosing
HIV/AIDS/TB after established ART use in the popula-
tion suggests that considerable caution will be needed in
interpreting trends in HIV-related deaths.
Table 5. Sensitivity and speciﬁcity of InterVA assignment of HIV/AIDS as the main cause of death compared with clinician
review (excluding indeterminates)
Excluding TB Including TB
Sensitivity Specificity Sensitivity Specificity
Overall (1559 years old) 58.5 88.0 78.0 83.0
Age 1529 65.2 88.4 80.0 86.3
3044 58.0 84.9 79.1 78.4
4559 55.9 91.1 74.8 85.0
60 and over 32.1 96.3 66.7 89.4
Sex (1559 years old) Male 54.9 90.0 75.6 84.7
Female 61.5 85.6 80.2 81.1
Time period (1559 years old) Before ART introduction 55.3 91.7 75.5 84.8
ART introduction 69.2 84.5 87.0 80.4
 2 years local ART 44.6 89.6 65.7 84.6
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How have ART treatment programmes changed
the patterns of excess mortality in people living
with HIV? Estimates from four countries in East and
Southern Africa
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Background: Substantial falls in the mortality of people living with HIV (PLWH) have been observed since the
introduction of antiretroviral therapy (ART) in sub-Saharan Africa. However, access and uptake of ART have
been variable in many countries. We report the excess deaths observed in PLWH before and after the introduc-
tion of ART. We use data from five longitudinal studies in Malawi, South Africa, Tanzania, and Uganda,
members of the network for Analysing Longitudinal Population-based HIV/AIDS data on Africa (ALPHA).
Methods: Individual data from five demographic surveillance sites that conduct HIV testing were used to
estimate mortality attributable to HIV, calculated as the difference between the mortality rates in PLWH and
HIV-negative people. Excess deaths in PLWH were standardized for age and sex differences and summarized
over periods before and after ART became generally available. An exponential regression model was used to
explore differences in the impact of ART over the different sites.
Results: 127,585 adults across the five sites contributed a total of 487,242 person years. Before the
introduction of ART, HIV-attributable mortality ranged from 45 to 88 deaths per 1,000 person years.
Following ART availability, this reduced to 1446 deaths per 1,000 person years. Exponential regression
modeling showed a reduction of more than 50% (HR 0.43, 95% CI: 0.320.58), compared to the period
before ART was available, in mortality at ages 1554 across all five sites.
Discussion: Excess mortality in adults living with HIV has reduced by over 50% in five communities in sub-
Saharan Africa since the advent of ART. However, mortality rates in adults living with HIV are still 10 times
higher than in HIV-negative people, indicating that substantial improvements can be made to reduce mortality
further. This analysis shows differences in the impact across the sites, and contrasts with developed countries
where mortality among PLWH on ART can be similar to that of the general population. Further research is
urgently needed to establish why the different impacts on mortality were observed and how the care and
treatment programmes in these countries can be more effective in reducing mortality further.
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P
rior to the advent of antiretroviral therapy (ART),
observed mortality rates among adults living with
HIV from population-based studies were 1015
times higher than in HIV-negative adults (14). This
indicates that 9095% of deaths in people living with HIV
(PLWH) were excess deaths due to HIV infection and
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deaths in PLWH that are due to HIV depends on the
background mortality in the population (5).
Clinic-based data have shown substantial falls in
mortality since the introduction of ART, but mortality
among PLWH is still considerably higher than among
individuals who are HIV-negative. ART programmes
have been shown to have substantial impacts on all-cause
and AIDS mortality in sub-Saharan African countries
(610) despite the poorer survival documented among
people receiving treatment in low-income countries
compared to those in high-income countries (11).
In developing countries, there are many barriers to
effective ART provision. On an individual level, PLWH
who have not received HIV testing and counselling
(HTC), or have not accessed ART clinics, do not receive
treatment (12). Within ART treatment programmes, there
may be inadequate treatment of other infections and
limited social support. Monitoring of immunological
recovery, adherence, and drug resistance is difficult in
many settings, resulting in suboptimal delivery of ART.
Factors that influence wider health, such as food security
and access to health services, also influence the uptake
and effectiveness of ART. All these factors can limit the
impact of ART on mortality (13).
Therefore, in sub-Saharan African countries, where the
relatively recent ARTrollout has been shown to havesome
impact on mortality, further reductions in HIV-positive
mortality may be possible, and this raises the question
of the number of excess deaths in PLWH, even when
treatment programmes are in place. In order to estimate
the extent of the mortality decline among PLWH since the
introduction of ART, and to estimate what further reduc-
tions may be possible, we need data on the HIV serostatus
of the general population, which is not widely available.
This article reports results from studies in Malawi (the
Karonga Prevention Study, London School of Hygiene
andTropicalMedicine),SouthAfrica(theuMkhanyakude
cohort, Africa Centre for Health and Population Studies),
Tanzania (the Kisesa cohort, National Institute for Me-
dical Research), and Uganda (the Masaka-Kyamulibwa
general population cohort, Medical Research Council/
Uganda Virus Research Institute; and the Rakai Health
Sciences Program), which form part of the network for
Analysing Longitudinal Population-based HIV/AIDS
data on Africa (ALPHA), which brings together the sites in
sub-Saharan Africa that collect longitudinal, population-
based demographic data alongside HIV serostatus. These
sites provide unique data on mortality pre- and post-
ART. Demographic data are available for a long period
(starting from 1989), and from five communities in four
countries with different HIV epidemic settings. Data on
HIV serostatus are available from different time points in
some sites; these dates are given in Table 1. These data
permit estimation of mortality rates in PLWH and HIV-
negative people and the extent of excess deaths in PLWH.
Detailed analyses of mortality in each site have been
conducted (1416).
The study sites are in predominantly rural areas. HIV
prevalence is highest in uMkhanyakude [29% among
1549 year olds in 2011 (17)], where the epidemic started
later and reached a higher level than in the other sites
and where ART is helping maintain high prevalence by
avertingdeaths among PLWH. Prevalence in the countries
with more established epidemics is stable; it is substan-
tially lower in Karonga, Kisesa, and Masaka ( 6%) and
intermediate in Rakai. ART is provided through national
treatment programmes, although Masaka delivers ART
through a study clinic rather than a government health
facility.
In this article, we compare the number of excess deaths
in PLWH in three different periods: during the 5 years
before the introduction of ART, at the time during which
eachcountry’sARTprogrammewasestablished,andthe5
years after ART became widely available in each country.
We use an exponential regression model to assess how the
death rate among PLWH has changed relative to that
among HIV-negative people during these same time
periods.
Methods
Data collection methods
This article uses data from 5 of the 10 sites that make up
the ALPHA network. The sites which contributed data
Table 1. Dates for the introduction of ART, the full rollout of ART, and the start of demographic surveillance and HIV serosurveys
Start dates for ART phases
Site
Start of demographic
data collection
Start of HIV
serosurveys
Pre-ART
phase
ART introductory
phase
Post-ART
phase
Karonga August 2002 October 2005 July 2000 July 2005 October 2006
Kisesa May 1994 August 1994 January 2000 March 2005 October 2008
Masaka November 1989 November 1989 January 1999 January 2004 January 2005
Rakai April 1999 April 1999 June 1999 June 2004 June 2006
uMkhanyakude January 2000 October 2002 January 1999 January 2005 January 2007
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(Uganda), Rakai Health Sciences Program (Uganda),
and the Africa Centre (uMkhanyakude, South Africa),
and their fieldwork methods have been described else-
where (1824). Each site runs a demographic surveillance
system (DSS) with linked HIV serostatus information
on adult residents. Four sites have demographic and
HIV status data spanning the three periods of inter-
est surrounding the introduction of ART. The fifth
(Karonga) is included for the purposes of cross-site
comparisons.
Each study site extracted, from their study databases,
information describing time spent resident in the study
area and including dates of exit from the study, due to
death or out-migration. They also extracted all informa-
tion on the HIV status of each study participant. Data
were prepared in a standard format, and data from all
sites were pooled in February 2013.
Data definitions
HIV test information was merged with the residency
episodes. The HIV status during each part of a residency
episode was derived from the test results at specific time
points. To ensure consistency between the classification
of deaths and of exposure time, person years were
classified by HIV status as shown in Table 2. All deaths
occurring in persons with a documented positive HIV test
result arising from an ante-mortem study test were
classified as HIV-related, and these composed the nu-
merator for the HIV-positive mortality rate. Deaths
amongst persons who had recently been tested in the
study and were found to be HIV-negative formed the
numerator for the negative mortality rate.
Data on the introduction of ART in each country were
used to identify three periods: before the introduction of
ART (i.e. no treatment available); a rollout phase
immediately following the introduction of ART, when
ART was assumed to be only partially available; and,
subsequently, a phase when ART was widely available
(Table 1). In these observational study sites, ART was
introduced when national treatment programmes started
to provide services. These periods therefore do not
precisely align with the demographic and serosurvey
activities in all sites, and thus data are not available for
certain periods in some sites.
Statistical methods
Each individual contributed exposure time during their
residence episodes in the DSS, which is from entry into
the DSS until exit due to migration, death, or censoring
at the time of the latest survey (or refusal to continue,
where relevant). Returning migrants, individuals who re-
entered the study following out-migration, contributed
person years only from the time they were resident in the
study site (i.e. between first entry and first exit and
between each subsequent entry and exit, as applicable).
To calculate mortality attributable to HIV, age-specific
mortality rates for HIV-negative people were applied to
the HIV-positive person years to calculate the number
of deaths expected in the HIV-positive group, had that
group experienced the mortality rates of the HIV-
negative individuals. The number of excess deaths were
classified as HIV attributable, and they were summarized
over the time periods and over sex and age groups.
The age and sex composition of the populations
differed between sites and over the ART phases. Mortal-
ity rates were standardized to allow comparison between
sites and across ART phases. The standard population
was the total number of person years contributed from all
sites in all ART phases.
A series of exponential regression models were fitted,
stratified by 5-year age group, to compare the mortality
rate among PLWH to that among HIV-negative indivi-
duals. The baseline group for comparison was HIV-
negative individuals in the later period when ART was
widely available. Mortality amongst HIV-negative indivi-
duals in the two earlier phases, and mortality among
PLWH in each ART phase, were compared by fitting an
interaction term in the model between HIV status and
ART phase. Sex and study site were included in the model
as fixed effects, and the standard errors were adjusted for
clustering by study site. By analyzing the data in this way,
the additional mortality due to HIV can be captured,
since HIV-negative individuals experienced a baseline
level of mortality. Data from Karonga were not included
Table 2. Classiﬁcation of deaths and exposure time by HIV
status
HIV-negative
HIV-
positive HIV status unknown
Between successive
negative tests
Following
any
positive
test
Never tested
Up to X years following
a negative
test with no other
subsequent test
Not yet tested (i.e. Before
first test,
whether or not that first
test was positive or
negative)
In a seroconversion
interval less
than X years duration
(negative
test followed by
positive test)
More than X years
following the last negative
test
X was based on observed incidence rates in the sites, and the
values used were 2 years in uMkhanyakude, 3 years in Rakai, and
5 years elsewhere.
HIV-attributable mortality by availability of ART
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ART phase. Those with unknown HIV status were in-
cluded in this model to account for differences over time
in the ascertainment of HIV status. These differences are
most apparent in the two sites with the most recent intro-
duction of HIV testing (Karonga and uMkhanyakude).
Results
The five study sites provided data on 244,769 adults aged
15 and older, who contributed a total of 1,149,484 person
years. This analysis is concerned with the mortality of the
127,585 adults age 15 years and above who have known
HIV status and who contributed 487,242 person years.
Table 3 shows for each site the number of subjects, person
years, the mortality rate, and the period prevalence of
HIV. The period prevalence of HIV was stable in Kisesa
and Rakai, showed a moderate increase in Masaka, and
showed a steep increase in uMkhanyakude. The propor-
tion of all deaths that were in known HIV positive
individuals declined over the three periods in all four sites
where this comparison was possible. All-cause mortality
ranged from 7 to 19 deaths per 1,000 person years.
The standardized mortality rates given in Table 4 show
the mortality rates for HIV-negative individuals and
PLWH and the excess mortality rate among PLWH, by
site, ART phase, and sex. These rates are standardized to
adjust for differences in the age composition between
sites and over ART phases. In all groups, the excess
mortality rate among PLWH was almost as high as the
total mortality rate for PLWH and much higher than the
mortality rate among HIV-negative individuals. The HIV-
positive mortality rate varied considerably between the
sites, and the excess mortality rate reflected that. With the
exception of men in Rakai, declines are apparent in both
the HIV positive overall and excess mortality, comparing
post-ARTrollout with the time before ARTwas available.
Before the advent of ART, the excess mortality rate
among PLWH was higher for men than for women. For
men and women, excess mortality was highest in Masaka
and lowest in Rakai. When ART became available, the
mortality rates fell; the extent of the decrease varied
between the site and across the sites by age group. Figure 1
shows the excess mortality rates by age, sex, and ART
phase for Kisesa, Masaka, Rakai, and uMkhanyakude.
Excess mortality rates for Karonga can only be estimated
for the post-ART phase and hence are not shown in
Fig. 1. In general, the most pronounced falls were in the
older age groups, whereas among 1519-year-old men in
Table 3. Number of subjects and person years contributed to the analysis, mortality rate and period prevalence of HIVamongst
persons with known HIV status, and the proportion of all deaths that were of individuals known to be HIV positive
ART phase
Number of
subjects Person years Deaths Mortality rate
Period
prevalence
HIV-positive
deaths (% of total)
Karonga
05 years before ART * * * * * *
ART introduction * * * * * *
ART available 18,159 46,134 316 6.8 7.4 25.9
Kisesa
05 years before ART 13,153 34,491 412 11.9 5.2 31.8
ART introduction 12,014 27,234 317 11.6 5.0 25.6
ART available 11,303 21,639 185 8.5 5.6 25.4
Masaka
05 years before ART 10,873 31,336 500 16.0 5.6 42.8
ART introduction 8,275 7,268 107 14.7 5.8 34.6
ART available 12,610 39,867 436 10.9 6.6 25.9
Rakai
05 years before ART 22,845 66,327 616 9.3 12.8 79.7
ART introduction 20,814 31,426 243 7.7 12.7 77.8
ART available 28,289 72,732 588 8.1 12.6 67.0
uMkhanyakude
05 years before ART 12,470 10,177 177 17.4 20.6 82.5
ART introduction 18,458 25,625 405 15.8 22.3 75.8
ART available 29,346 72,987 1,349 18.5 27.1 55.6
All sites pooled
05 years before ART 59,341 142,330 1,705 12.0 9.9 57.6
ART introduction 59,561 91,553 1,072 11.7 12.5 57.3
ART available 99,707 253,359 2,874 11.3 14.3 48.2
*Estimate not available.
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women in Rakai, excess mortality rates increased slightly.
The impact of ART availability is shown in Fig. 2 and
Table 5, which contain results from an age-stratified
exponential regression model comparing the mortality of
PLWH and HIV-negative individuals.
Figure 2 shows that the mortality of HIV-negative
individuals changed little between the three ART periods;
the only significant difference was that the mortality of
1519 year olds was slightly higher in the earliest period
(pre-ART). Within each age group, the mortality of
PLWH remained much higher than that of HIV-negative
people, even following the introduction of ART. Among
3034 year olds, the risk of mortality for a PLWH before
the introduction of ART was 30 times higher (95% CI:
1851) than that of an HIV-negative person. Following
the introduction of ART, the relative mortality hazard
had more than halved, but it remained 13 times higher
(95% CI: 1116) than that of HIV-negative individuals. In
the introductory phase of ART, the mortality reduction
was greatest at younger ages (those younger than 35, the
peak group for mortality). After ART was fully estab-
lished, mortality risk declined in older age groups, which
meant that the excess mortality risk among PLWH was
more uniformly distributed across the age range, with a
hazard ratio (HR) of 12 (95% CI: 916) in 1519 year
olds, 13 (95% CI: 1116) in 3034 year olds, and 5 (95%
CI: 46) among 5054 year olds.
Differences are apparent between the study sites at
different ages, reflecting the age-specific incidence pat-
tern. Masaka, Rakai, and uMkhanyakude’s mortality
was higher than Kisesa’s between the ages of 20 and 44.
Mortality in uMkhanyakude remained higher than that
of the other sites in the older age groups as well. There
were also differences between the sexes at different ages:
women’s mortality hazard was higher than men’s in the
20- to 24-year-old age group; and, from the age of 30, the
direction of this association reversed and men’s mortality
risk was higher than women’s such that by their late 40s,
women’s risk of dying was 60% that of men.
The changes between the ART phases are evident with
respect to a fixed comparison group. The models do not
show whether, between the ART phases, the mortality
changes among the PLWH are likely to be true. Separate
analysis, not shown, comparing the mortality changes
between the phases among PLWH using stratified
exponential regression confirms that the changes ob-
served are highly unlikely to be due to chance. There was
a significant difference between the mortality hazards for
each ART phase. For PLWH in their 20s and older, the
Table 4. Age-standardized mortality rates (per 1,000 person years) by site, sex, HIV status, and ART phase: rates for HIV-
negative people and PLWH, the excess mortality rate among PLWH (rate difference), and the standardized mortality ratio
(SMR)
Men Women
Site and ART phase
HIV-negative
mortality rate
HIV-positive
mortality rate Attributable SMR
HIV-negative
mortality rate
HIV-positive
mortality rate Attributable SMR
Karonga
05 years before ART    
ART introduction    
ART available 2.5 24.4 22.0 10 1.7 15.0 13.7 8.8
Kisesa
05 years before ART 3.6 55.2 51.6 15.3 4.2 52.4 48.7 12.5
ART introduction 5.2 47.1 42.2 9.1 3.2 39.8 36.9 12.4
ART available 3.2 33.8 30.8 10.6 1.8 19.6 18.3 10.9
Masaka
05 years before ART 3.9 88.0 84.8 22.6 3.2 91.5 88.3 28.6
ART introduction 2.8 77.4 75.4 27.6 3.5 60.5 58.0 17.3
ART available 3.8 43.6 39.9 11.5 2.3 30.3 28.3 13.2
Rakai
05 years before ART 2.3 42.5 40.6 17.7 1.7 45.7 43.9 25.8
ART introduction 2.2 31.1 28.9 13.1 1.0 32.8 31.8 31.8
ART available 3.2 49.4 46.2 14.4 2.5 28.3 25.8 10.3
uMkhanyakude
05 years before ART 7.6 63.4 56.2 8.3 1.8 56.7 54.9 31.5
ART introduction 8.3 47.4 39.5 5.7 2.1 38.3 36.1 18.2
ART available 5.7 43.2 37.5 7.6 1.6 22.6 21.1 14.1
HIV-attributable mortality by availability of ART
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post-ART phase. No difference in mortality was apparent
for teenagers living with HIV.
Discussion
Assessment of the mortality attributable to HIV re-
quires information on HIV serostatus and cause of death.
In countries where there is no adequate system of vital
registration, DSSs provide important estimates of levels
and trends in mortality. The members of the ALPHA
network, whose data are used here, combine the informa-
tion from demographic surveillance with information on
HIV serostatus from serological surveillance.
From these five sites, we have HIV status data on a
large proportion of five distinct populations covering
areas of very different HIV prevalence. These data can be
used to look at trends in HIV-positive mortality rates and
the excess mortality in PLWH. Excess mortality rates are
obtained from the difference between the mortality rate
of the PLWH and the mortality rate of the HIV-negative
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Fig. 1. Estimated excess mortality rate among PLWH by age, sex, and ART phase.
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ART phase and
HIV status 1519 2024 2529 3034 3539 4044 4549 5054
Pre-ART HIV  1.53
(1.142.05)
0.75
(0.441.25)
0.83
(0.691.00)
1.31
(0.483.54)
1
(0.571.74)
1.2
(0.512.82)
1.4
(0.702.84)
0.94
(0.541.62)
Pre-ART HIV 8.29
(6.2111.0)
17.38
(13.6622.1)
22.96
(18.3228.7)
30.3
(18.1750.5)
18.27
(10.0433.2)
19.2
(15.9623.1)
17.83
(11.8726.7)
11.49
(5.7323.0)
Pre-ART HIV? 2.07
(1.552.76)
4.22
(2.856.25)
7.11
(4.6310.9)
9.45
(6.5113.7)
5.85
(4.377.83)
4.97
(3.806.50)
3.66
(3.094.33)
1.9
(1.742.07)
ART intro HIV  0.97
(0.591.59)
1.39
(0.782.46)
1.3
(0.802.10)
1.26
(0.453.52)
1.18
(0.334.22)
1
(0.571.74)
1.18
(0.831.67)
1.17
(0.721.92)
ART intro HIV 3.76
(1.797.90)
12.22
(9.2716.1)
12.57
(9.3116.9)
17.38
(12.2224.7)
17.76
(15.8119.9)
15.1
(14.4915.7)
11.33
(8.7614.6)
9.45
(5.2017.1)
ART intro HIV? 2.01
(1.692.38)
3.11
(1.626.00)
6.56
(4.459.67)
8.79
(4.9215.6)
4.72
(3.157.10)
4.19
(2.826.23)
2.75
(2.043.70)
2.18
(1.772.67)
Post-ART HIV  11111111
Post-ART HIV 11.85
(8.8115.9)
8.7
(7.0210.7)
11.33
(7.9516.1)
13.09
(10.9915.5)
9.4
(7.8911.2)
8.35
(5.3313.0)
6.84
(5.149.11)
5
(4.235.91)
Post-ART HIV? 2.26
(1.343.79)
3.72
(2.276.08)
6.34
(3.4811.5)
7.93
(5.3311.8)
5.03
(4.136.13)
4.07
(2.586.42)
2.87
(2.133.87)
2.07
(1.333.23)
Sex
M e n 11111111
Women 1.02
(0.931.11)
1.32
(1.121.56)
1.06
(0.981.16)
0.9
(0.761.06)
0.75
(0.491.15)
0.59
(0.440.79)
0.57
(0.450.72)
0.53
(0.420.68)
Study site
Kisesa 1 1 1 1 1 1 1 1
Masaka 0.98
(0.881.09)
1.92
(1.662.21)
1.91
(1.752.10)
2.07
(1.852.30)
1.56
(1.421.71)
1.19
(1.061.34)
1.29
(1.181.40)
0.94
(0.920.96)
Rakai 0.94
(0.881.01)
1.35
(1.261.44)
1.74
(1.611.88)
1.87
(1.742.00)
1.62
(1.521.73)
1.12
(1.031.23)
0.99
(0.911.07)
1.18
(1.101.26)
uMkhanyakude 0.88
(0.790.99)
1.5
(1.391.62)
1.97
(1.842.11)
2.36
(2.102.64)
1.79
(1.542.08)
1.64
(1.401.92)
1.76
(1.561.99)
1.66
(1.471.87)
These results are from the same model as the estimates presented in Fig. 2.
H
I
V
-
a
t
t
r
i
b
u
t
a
b
l
e
m
o
r
t
a
l
i
t
y
b
y
a
v
a
i
l
a
b
i
l
i
t
y
o
f
A
R
T
C
i
t
a
t
i
o
n
:
G
l
o
b
H
e
a
l
t
h
A
c
t
i
o
n
2
0
1
4
,
7
:
2
2
7
8
9
-
h
t
t
p
:
/
/
d
x
.
d
o
i
.
o
r
g
/
1
0
.
3
4
0
2
/
g
h
a
.
v
7
.
2
2
7
8
9
3
5individuals. In all sites, at least 90% of the deaths among
PLWH were attributable to HIV: they were in excess of
the deaths that would be expected given background
mortality rates among the HIV-negative population.
In the Karonga district of Malawi, the fraction of
mortality in the population attributable to HIV has
decreased since the advent of ART (25). In this analysis,
Karonga is the site with the lowest overall and excess
mortality among PLWH.
The reasons for this excess are unknown. If HIV in-
fection remains undiagnosed, the individual cannot access
treatment and lower their risk of dying. Suboptimal
treatment and associated care may not be enough to
prevent death. Late presentation may make it unlikely
that treatment will succeed. Data on individual experi-
ence of HIV diagnosis, treatment, and care will help to
explain why mortality remains high. These data are diffi-
cult to collect from the general population and insuffi-
cient data were available at the point of writing, but
future analyses are planned.
Two large international trials showed that among
PLWH who achieve adequate viral suppression and
CD4
 T-cell counts of at least 500 cells/ml, the mortality
rate is the same as that experienced by the general
population (26). A European study reached a similar
conclusion, finding in a clinical cohort that the standar-
dized mortality ratio (SMR) was 4.2, but in the subset of
individuals with a CD4 count higher than 500/mm
3, the
SMR was 1.5 (27). The International Epidemiologic
Databases to Evaluate AIDS (IeDEA) consortium car-
ried out an analysis of PLWH receiving ART in Co ˆte
d’Ivoire, Malawi, South Africa, and Zimbabwe; they
found that, among people who started ART with a CD4
count over 200 and at World Health Organization
(WHO) clinical stage I or II, the mortality rate was
very similar to that of the general population (28).
However, the same study estimated an overall HIV-
attributable mortality rate of 69.5 per 1,000 person-years
among the entire group receiving treatment and an SMR
of 18.7. These estimates are higher than those reported in
this article, and one reason could be that the follow-up
ended in 2007 when ART programmes were still quite
new. Analysis of data from 13 clinical cohort studies with
follow-up between 1996 and 2006 found a crude death
rate of 12.1 per 1,000 person years among PLWH
receiving ART (29). Another analysis of nine cohorts
found crude mortality rates among PLWH on ART that
ranged from 2.9 to 22.9 per 1,000 person years, with a
pooled crude rate of 9.5 per 1,000 (30).
However, the people identified as living with HIV in
the ALPHA studies are from population-based cohorts,
which include those who are on ART, those who have not
yet started ART, and those who are undiagnosed. Unlike
the clinical cohort studies, participants in the observa-
tional ALPHA cohorts may remain undiagnosed or
untreated at an advanced stage of infection, even once
ART is available. This might explain the higher mortality
rate among PLWH in the ALPHA sites compared to the
rates estimated from studies in Europe and North
America. The HIV-positive mortality rates from some
of the ALPHA sites lie within the range from the clinical
cohorts, even though ART coverage does not reach 100%
in any site. This may be because the ALPHA sites
regularly test all individuals who participate in the
studies, and many of those subsequently identified as
living with HIV will be at the early stages of HIV
infection and initially experience little excess mortality.
Individuals like this are likely to be underrepresented
in a clinical cohort. This may also explain why the
ALPHA estimates are lower than those from the IeDEA
study (28).
A strength of these results is that the estimation of
background mortality is directly measured  available
from the same population and at the same time  whereas
most previous studies have relied on national estimates.
The validity of these findings depends on the assumption
that the ascertainment of HIV status is essentially
complete, with the HIV status and stage of infection
among those who have not been tested assumed to be the
same as among those whose status is known. If this is not
the case, then the true difference in mortality between
PLWH and HIV-negative individuals may be different
from that estimated. The proportion of individuals (aged
15) in the DSS for whom HIV status had never been
measured, by the end of the last phase of follow-up,
ranged from 16% in Masaka (the longest running study)
to 60% in uMkhanyakude (the site with the shortest
history of HIV testing).
In this article, we have not used data on cause of death
to distinguish AIDS mortality from other causes of death
among PLWH, which is another way of estimating
mortality attributable to HIV. Population-based cause-
of-death information is not routinely available in these
countries. A variable proportion of recorded deaths in
ALPHA sites have had a verbal autopsy (VA) done. VA
data can be used to assign a probable cause of death for
people dying outside hospital settings either by physician
review or through the use of software. We have not used
VA data in this article because the differences in VA
coverage between the sites, and over time, are sufficient to
undermine our ability to make comparisons between sites
and over time.
VA data have been used to show that HIV-associated
deaths are a major contributor to adult mortality in
different sub-Saharan African populations (25, 31). VA
data have also been used to show the share of AIDS
deaths in the population as a whole, which depends on
the prevalence of HIV in the population as well as the
background mortality in HIV-negative individuals.
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cause-specific mortality estimates by modeling data from
a variety of sources. They estimated that the proportion
of all deaths attributable to HIV/AIDS was highest in
South Africa (41.1%) and lower in Malawi (23.6%),
Tanzania (21.2%), and Uganda (17.2%). In each of these
countries, they estimated that HIV/AIDS is the leading
cause of disease burden (32). When ART was available in
the Malawi and Tanzanian sites, and one of the Ugandan
sites, we estimate that 25% of deaths occurred in people
known to be living with HIV. In the other Ugandan site,
Rakai, the estimate was much higher (67%). Historically,
HIV incidence and prevalence have been higher in Rakai
than Masaka. Since 2005, ARTand circumcision services
have been available in Rakai, and HIV incidence has
fallen. Mortality in Rakai among PLWH and HIV-
negative people has been lower than in Masaka, and
this difference was especially pronounced before ART
was available. This may have been due to research
activities in Rakai which included active follow-up for
participants who tested HIV-positive, a system of com-
munity counselors, mobile clinics which provided sexually
transmitted infection treatment and referrals to the static
clinics, and nevirapine for pregnant and breastfeeding
women with HIV. These activities may have lowered
mortality among known PLWH prior to ART treatment
being widely available.
Mortality declines have been seen following the intro-
duction of ART. Once treatment programmes were widely
available, PLWH mortality fell to about half of the level
it was before the introduction of ART. However, PLWH
retain a high level of excess mortality with almost 10
deaths to every 1 that would be expected.
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Background: The Spectrum computer package is used to generate national AIDS mortality estimates in settings
wherevital registration systems are lacking. Similarly, InterVA-4 (the latestversion ofthe InterVAprogramme) is
used to estimate cause-of-mortality data in countries where cause-specific mortality data are not available.
Objective: This study aims to compare trends in adult AIDS-related mortality estimated by Spectrum with
trends from the InterVA-4 programme applied to data from a Health and Demographic Surveillance System
(HDSS) in Nairobi, Kenya.
Design: A Spectrum modelwasgenerated for the cityof Nairobi based on HIV prevalence data for Nairobi and
national antiretroviral therapy coverage, underlying mortality, and migration assumptions. We thenused data,
generated through verbal autopsies, on 1,799 deaths that occurred in the HDSS area from 2003 to
2010 among adults aged 1559. These data were then entered into InterVA-4 to estimate causes of death
using probabilistic modelling. Estimates of AIDS-related mortality rates and all-cause mortality rates from
Spectrum and InterVA-4 were compared and presented as annualised trends.
Results: Spectrum estimated that HIV prevalence in Nairobi was 7%, while the HDSS site measured 12% in
2010. Despite this difference, Spectrum estimated higher levels of AIDS-related mortality. Between 2003 and
2010, the proportion of AIDS-related mortality in Nairobi decreased from 63 to 40% according to Spectrum
and from 25 to 16% according to InterVA. The net AIDS-related mortality in Spectrum was closer to the
combined mortality rates when AIDS and tuberculosis (TB) deaths were included for InterVA-4.
Conclusion: Overall trends in AIDS-related deaths from both methods were similar, although the values
were closer whenTB deathswere included inInterVA.InterVA-4might not accuratelydifferentiatebetweenTB
and AIDS deaths.
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I
t appears that the global fight against AIDS is bear-
ing positive results in most countries burdened by the
epidemic (1). New infections and AIDS deaths have
declined significantly over the last decade (1). In Kenya,
the annual number of adult new infections dropped from
102,000 in 2000 to 91,000 in 2011, and the number of
adult AIDS deaths has reduced significantly within the
same period (2).
However, in the face of persistent global economic
uncertainty, there are doubts as to whether the continued
global investments in the HIV response can be sustained
(35). As of 2011, there were over 1.4 million adults living
with HIV in Kenya. About 592,000 adults were eligible
for antiretroviral therapy (ART), and about 83% of those
received ART (6).
To ensure continued funding, countries need to gen-
erate empirical evidence that demonstrates their progress
in the HIV response. Population-level impact data will be
particularly useful as many HIV programmes have been
in existence for several years. However, many of the most
affected countries lack the complete vital registration-
type data needed to generate direct population-level
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estimates (79). Consequently, statistical modelling and
estimation account for much of what is known about the
reduction in population-level impact of HIV, particularly
with regard to mortality (1012).
The Spectrum computer package is at the forefront of
HIV statistical modelling and estimation (13). Over 100
countries use Spectrum to estimate the impact of HIV
on their populations. The results from Spectrum are used
by the Joint United Nations Programme on HIV and
AIDS (UNAIDS) to produce global estimates of the HIV
epidemic which are published regularly in the ‘Global
report on the HIV/AIDS epidemic’ (1). In addition,
countries use Spectrum results for short-term planning
purposes, advocacy, and for estimating the impact of HIV
programmes. Spectrum has not been widely validated
against empirical data. Stover et al. compared Spectrum
mortality results against six studies in 2004 (14). Upda-
ted comparisons are needed because major revisions in
Spectrum software have updated the calculations of
AIDS mortality and given changes in mortality patterns
with the roll-out of ART. Specifically, it would be use-
ful to validate the output from Spectrum with other
population-level AIDS mortality data.
In the absence of complete vital registration systems,
empirical data on causes of death can be obtained from a
Health and Demographic Surveillance System (HDSS).
An HDSS typically monitors health and demographic
indicators in a population within a defined geographic
area (15). Additionally, an HDSS commonly uses verbal
autopsy (VA) to generate cause-of-death data. VA entails
interviewing the primary caregivers of recently deceased
persons to collect information about the circumstances
surrounding a death (16). This process depends on the
ability of the primary caregiver  often a family member 
to recognise, recall, and volunteer symptoms experienced
by the deceased that can be interpreted and analysed to
derive the most likely cause(s) of death (17). The InterVA
programme is a computer-based probabilistic programme
that has been developed to interpret VA data and assign
possible causes of death. This computer programme is
based on Bayes’ probability theorem and is freely avail-
able in the public domain (18).
Often, urban estimates of mortality and other health
indicators in general do not make a distinction between
slum and non-slum urban areas. This tends to mask any
disparities between these often distinct groups. On the
one hand, globally applied models such as those pro-
duced by Spectrum tend to represent urban (and rural)
data estimates in the broad sense. On the other hand,
locally applied programmes such as InterVA are typically
used to produce site-specific (e.g. slum) estimates. Con-
sidering the projected increases in the size and spread of
slum populations across urban centres in developing
countries such as Kenya (1921), it would be useful to
establish how AIDS mortality estimates representing an
urban setting in the broad sense compare with estimates
from a purely urban-slum setting.
The primary objective of this article is to compare
annualised trends in AIDS-related deaths as estimated
by Spectrum with similar data generated by InterVA.
However, to provide context to the findings of this
comparison, we will first present general trends in
mortality and survival as estimated by Spectrum versus
routine demographic surveillance data from the areas
under study.
Methods
Nairobi Urban Health and Demographic
Surveillance System
We use cause-of-death data on 1,799 deaths for which VA
was done (i.e. 85% of all deaths) that occurred in the
Nairobi Urban Health and Demographic Surveillance
System (NUHDSS) between 1 January 2003 and 31
December 2010 among adults aged between 15 and 59.
We were unable to include the remaining 15% of deaths
for which VAs were not done since no symptom-level data
were available for these deaths. Symptom-level data are
needed for input into the InterVA-4 computer pro-
gramme (discussed further in this article). The NUHDSS
has been operational since 2002 under the coordination
of the African Population and Health Research Center
(APHRC), a regional research institution headquartered
in Nairobi, Kenya. The NUHDSS covers the two slums
of Korogocho and Viwandani, which are both located
less than 10 km from Nairobi (22). Korogocho and
Viwandani occupy an area less than about half a square
kilometre each.
According to the NUHDSS database, as of 1 January
2003, there were 55,266 residents living in 22,537 house-
holds in both slums. Like most slums in Nairobi,
Korogocho and Viwandani have high levels of poverty,
crime, and unemployment. Access to basic amenities and
services, including healthcare services, is also limited.
Additionally, slum residents generally have poorer health
outcomes in comparison with rural and non-slum urban
residents (2325).
Verbal autopsy in the NUHDSS
The routine data on demographic events such as births,
deaths, and migration are collected at the NUHDSS in a
4 monthly cycle. Causes of deaths in the NUHDSS are
determined using VA; the details of VA in these circum-
stances have been published elsewhere (26, 27). In brief,
trained interviewers visit each household where a death is
reported to have occurred and administer a structured,
paper-based questionnaire to a consenting (informed)
respondent. The completed questionnaires are captured
into an SQL database, and a VA data set is prepared for
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prepared data file is imported into InterVA in order to
interpret and assign the probable cause of death to each
case.
InterVA-4
InterVA processes a range of ‘indicators’ relating to
a particular death by fitting them in a mathematical
programme based on Bayes’ probabilistic theorem (18).
‘Indicators’ is a general term used by InterVA to describe
the range of items of information about the circum-
stances of a death, including basic background charac-
teristics, signs and symptoms of illness, and past medical
history, to mention a few. These indicators are derived
from the VA symptom-level data set and entered into the
InterVA programme which then produces likely cause(s)
of death as its output. In this article, we use the latest
version of the programme  InterVA-4. The causes of
death produced by InterVA-4 follow the new VA cause-
of-death categories as defined in the World Health
Organization (WHO) 2012 Verbal Autopsy Instrument,
together with WHO cause-of-death codes and corre-
sponding International Classification of Diseases (ICD-
10) categories. In our analysis, we use only the most likely
cause of death produced by InterVA-4. Those cases in
which InterVA is unable to generate any most likely cause
of death are classified as ‘indeterminate’. Complete
details of the InterVA modelling approach are available
in a range of peer-reviewed publications (2838) and on
the InterVA website, www.interva.net.
Spectrum modelling
The Spectrum computer package, developed by the
Futures Institute (www.futuresinstitute.org), is a suite
of models that allow users to calculate the impact of
different public health interventions. The AIDS Impact
Module (AIM) within Spectrum was used for this
analysis (version 4.50). The software is described in detail
elsewhere (39). Here, we provide a brief description of
how the software works and how it was adjusted to create
a Nairobi-specific model.
The Spectrum package is based on the demographic
inputs provided by the UN Population Division 2010
projections of population size, fertility, and mortality. To
estimate the impact of HIV, the AIM module uses HIV
prevalence data from antenatal clinic (ANC) surveillance
and from household surveys to produce an incidence
curve over time. The incidence curve is applied to a sex
and age distribution. Age and sex determine the pro-
gression of HIV-infected people through different CD4
levels which are modified by ART and determine future
survival. Deaths due to AIDS and non-AIDS deaths are
available by 5-year age groups over time. Spectrum
estimates AIDS-related deaths, or the net increase in
deaths during an HIV epidemic, whether the deaths are a
result of AIDS or other causes that are exacerbated by
HIV.
To create a Nairobi-specific Spectrum model, the
population before the introduction of HIV is required
to start the projection. The first case of HIV was detected
in 1984 (40). The age and sex distributions of Nairobi
were determined from the 1969 and 2009 censuses. The
total fertility rate from the 2003 and 2008 Demographic
and Health Surveys (DHS) for Nairobi was used in the
model for the appropriate years, and linear interpola-
tion was used to determine the values for years without
surveys (41, 42). Mortality rates were assumed to be the
same as the national level and not adjusted. Migration
was estimated based on the change in population between
1970 and 2009 using a stable in-migration among men
and an increasing in-migration among women. The
specific values for the key assumptions are included in
Table 1.
The AIM module requires HIV prevalence data and
ART coverage data to determine HIV incidence over
time. Data from five ANC sites were used to describe
trends in HIV prevalence in Nairobi. These sites included
four University of Nairobi sites and one Jericho ANC
clinic. HIV prevalence data from the DHS for 2003 and
2008 were available for the city of Nairobi. These data
provided a calibration for the magnitude of HIV pre-
valence to correct for the bias introduced through the
ANC data due to the lack of men in the sample and the
variations in prevalence among pregnant women versus
all women (43).
To estimate an incidence curve from prevalence, Spec-
trum uses information on the number of people on ART
to acknowledge its increasing prevalence as people stay
alive longer. The percentage of those eligible for ART
(those with CD4 counts lower than 350) who are receiving
therapy was estimated to be 72% in 2010 for Kenya. The
same level and trend in coverage were assumed for
Nairobi (3% in 2003, 26% in 2005, and 50% in 2007) (44).
Data analysis
General trends in mortality and survival
We calculated age-specific mortality rates for 5-year age
groups for ages 1559 years by gender, slum of residence,
and 4-year periods (20032006 and 20072010, corre-
sponding to the estimated periods before and after the
massive roll-out of ART in Nairobi). In addition, we
calculated the probability of a 15-year-old surviving to
60 years (45Q15) by gender and slum. Furthermore, all-
cause adult mortality was calculated by year. Finally,
the parameters discussed here were estimated using the
Nairobi Spectrum file and presented alongside the
NUHDSS longitudinal data output.
InterVA versus Spectrum
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The InterVA cause-of-death outputs are used to calculate
the number of AIDS-related deaths versus all-cause
deaths among those aged 1559 by gender and slum of
residence. The same parameters were also generated using
the Nairobi Spectrum file. The results are presented as
annualised trends for the period 20032010.
Results
HIV prevalence
An HIV seroprevalence study conducted in the NUHDSS
from 2007 to 2008 determined the prevalence of HIV
among adults aged 1549 to be 11.25% [95% confidence
interval (CI) 10.3412.14] overall (9.89%, 95% CI
8.5411.28 in men; and 12.1%, 95% CI 10.9313.29
in women). Spectrum estimates HIV prevalence among
adults aged 1549 in Nairobi in 2008 to be 7.4%
(uncertainty bounds 5.89.1) overall, 6.2% in men and
8.6% in women (see Fig. 1).
All-cause mortality by age (Spectrum vs. NUHDSS
mortality data)
The trends in age-specific mortality rates (ASMRs) for
all-cause mortality, as determined by Spectrum and
InterVA, are similar to the extent that both show
increasing mortality rates with age (see Fig. 2). However,
the Spectrum rates show a distinct ‘hump’ in the age
bracket between 35 and 49 years which is not evident in
the NUHDSS rates. The bump reflects typical mortality
in countries with high HIV prevalence and low ART
coverage (45). The peak mortality rate is 20 deaths per
1,000 for the age group 3539 years and declines to close
to 15 among persons over age of 50. In contrast, the
highest mortality rate for the InterVA programme is
19 for persons aged 5559. When disaggregated bygender
(see Fig. 3), the overall pattern remains the same with
two observable differences. First, the NUHDSS mortality
rates are consistently higher among women than men
across all age groups. Second, Spectrum mortality rates
peak at earlier age groups for women than men.
In Fig. 4, we consider the potential effect of ART roll-
out in Nairobi and analyse the ASMRs for the periods
before its mass roll-out (20032006) and after the roll-out
(20072010). Spectrum shows a decline in the ASMRs for
all age groups except the 15 to 19-year age group. Among
persons aged 3539, the ASMR drops from 26.9 in the
period 20032006 to 13.5 in the period 20072010. The
NUHDSS data show a less dramatic decline in ASMRs,
with a decline from 10.5 to 8.3 for the same age group.
AIDS-attributable mortality over time
(Spectrum vs. InterVA-4)
Spectrum estimates that 63% of mortality, among persons
aged 1559, was AIDS related in 2003 and that this value
decreased to 40% by 2010. The InterVA programme esti-
mates that the proportion of mortality due to AIDS in
the same age group decreased from 25 to 16%. Although
the overall downward trend between 2003 and 2010 is
similar between Spectrum and InterVA, the proportion
of deaths attributed to AIDS according to Spectrum
appears significantlyand consistently higher than InterVA
estimates (Figs. 5 and 6). If deaths attributed to AIDS
according to InterVA are expanded to include deaths
Table 1. Demographic data used in Spectrum ﬁle
1970 1980 1990 2000 2005 2006 2007 2008 2009 2010
Total fertility rate based on survey data for Nairobi
8.06 6.44 4.81 3.19 2.74 2.76 2.78 2.8 2.79 2.77
Life expectancy at birth based on national estimates
Male 49.9 55.3 58.4 59.3 58.9 59 59.2 59.3 59.5 59.7
Female 54.1 59.1 62.2 63.1 62.7 62.9 63.1 63.3 63.5 63.8
In-migration (net change in the number of persons migrating to Nairobi per year)
Male 11,800 11,800 11,800 11,800 11,800 11,800 11,800 11,800 11,800 11,800
Female 4,750 6,361 7,972 9,583 10,389 10,550 10,711 10,872 11,033 11,194
Adult ART coverage based on national coverage
0% 0% 0% 0% 26% 40% 50% 63% 68% 70%
Median HIV prevalence from 4 antenatal clinics in Nairobi
10.30 14.90 9.60 10.10 na na 8.30 8.00
HIV prevalence from household survey for Nairobi
9.9 (2003) 7.00
nanot available.
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InterVA match those of Spectrum more closely, and
InterVA shows a decline in the proportion of mortality
related to AIDS and TB from 59 to 46%. When disag-
gregated by sex, the trends in AIDS-attributable deaths
(including TB deaths in the InterVA estimates) over time
are quite similar between InterVA and Spectrum among
men only. Among women, however, InterVA estimates
that the proportion of mortality due to AIDS and TB
remains stable at around 60% throughout the period,
while Spectrum shows a smooth downward trend in the
proportion of AIDS-related mortality from 68% in 2003
to 46% in 2010.
Discussion
We set out to determine how comparable InterVA and
Spectrum were in terms of estimating AIDS-related mor-
tality patterns in Nairobi’s informal settlements. How-
ever, prior to this comparison, we demonstrated that
there was an overall decline in adult mortality both as
estimated by Spectrum and as calculated using demo-
graphic data from the NUHDSS. Against this backdrop,
we found reductions in the proportion of adult mortal-
ity that is due to AIDS as determined by both InterVA
and Spectrum over the same period. The decline in
Fig. 1. HIV prevalence ages 1549, by sex, Nairobi, 19902010,
Spectrum model estimates.
Fig. 2. Adult age-speciﬁc mortality rates, all causes, both
sexes, 20032010.
Fig. 3. Adult age-speciﬁc mortality rates, all causes, by sex,
20032010.
Fig. 4. Adult age-speciﬁc mortality rates, all causes, both
sexes, before and after roll-out of ART.
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increase in the roll-out of ART services from less than
5% coverage in 2003 to 70% coverage in 2010.
As regards the mortality rates, we found that unlike the
Spectrum results, the NUHDSS data do not show the
typical age-specific mortality patterns expected from an
area with high HIV prevalence (seen through increasing
mortality rates in ages 3049). The reasons for this
could be an aggressive roll-out of ART, under-reporting
of AIDS deaths in the NUHDSS, or out-migrating just
before death.
The proportion of mortality that was AIDS relatedwas
two times higher according to Spectrum than according
to InterVA, even though HIV prevalence was lower in
Nairobi than the prevalence estimated for the slum
population in the same year (7% vs. 12%, respectively).
However, if AIDS-related deaths according to InterVA
are expanded to include deaths due to TB, then the
proportion of AIDS-related deaths among all deaths
and trends from InterVA matches closely with that from
Spectrum.
We observed that HIV prevalence in the slum popula-
tion was higher than in Nairobi. This is not unexpected
as slum settlements are typically characterized by poor
living conditions, which in turn has a major impact on
health and access to healthcare for the population
(4652). However, despite higher HIV prevalence in the
slum population, the proportion of deaths that were
AIDS related was higher in Nairobi than in the slum
according to Spectrum and InterVA, respectively. The
proportions of AIDS-related mortality from Spectrum
and InterVA are similar when the InterVA-4 results
include both AIDS and TB deaths.
The ICD-10 classification of deaths includes all TB
deaths to persons living with HIVas AIDS-related deaths.
WHO estimates that in Kenya, 39% of TB patients are
living with HIV (53). A model recently developed by
the Futures Institute to estimate TB-related deaths (2)
suggests that of 13,000 TB deaths in Kenya in 2010, 7,700
of those deaths were among persons living with HIV,
and the remaining 5,300 would be HIV negative and thus
TB deaths. Thus, many of the deaths in this age group
among persons with TB are likely to be AIDS deaths
(5456). Given the levels of TB incidence in Kenya, we
would expect fewer TB deaths than AIDS deaths. The
InterVA results suggest that TB mortality is about two-
thirds higher than HIV mortality (see Fig. 5) in the slum
populations.
The InterVA method has likely misclassified the HIV-
related deaths as TB. Symptoms of terminal TB and
terminal AIDS are similar, which makes it challenging for
InterVA to discern between the two. Additional dif-
ficulties for InterVA in identifying an HIV death occur
when:
1) Persons living with TB did not know their HIV
status.
2) Persons living with HIV and TB know their HIV
status but did not disclose their status to the care-
giver or family.
3) Persons living with HIV and TB who knew their
HIV status disclosed their status to the caregiver
or family, yet the NUHDSS respondent did not
mention HIV status during the survey.
Fig. 5. Percentage of AIDS-related deaths from Spectrum
and AIDS- and TB-attributed deaths from InterVA, aged
1559, Nairobi.
Fig. 6. Percentage of AIDS-related deaths from Spectrum
and deaths attributed to AIDS and TB from InterVA, by
year and sex, aged 1559, Nairobi.
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tion of AIDS deaths as attributed by Spectrum and
InterVA could be that we chose to utilise only the most
likely cause of death determined by InterVA-4 in cal-
culating the cause-specific mortality fraction attributable
to AIDS. The developers of InterVA-4 recommend that
all causes identified by InterVA be considered propor-
tionate to their likelihood values in the mortality rate
calculations. They also recommend that if the likelihood
cause-of-death values for a particular death did not add
up to 1, the difference between the sum of the likelihood
values for probable causes of death and 1 was allocated
to the ‘indeterminate’ cause (18). We did go to this extent
because Spectrum does not produce multiple likelihoods
for causes of death, unlike InterVA-4.
Our study is primarily limited by the fact that we are
comparing different geographic areas: Nairobi versus
NUHDSS sites (informal settlements). Assumptions on
underlying mortality, migration, and ART coverage are
critical for creating a Spectrum file. These data were not
available for Nairobi or the two settlements, so assump-
tions were made that might not be accurate. Finally,
there are no perfect data against which to compare either
Spectrum or InterVA-4 to determine which is more
accurate. However, a recent study found that InterVA-4
achieved a specificity of 90% in identifying typical AIDS
deaths. This study analysed InterVA-4 interpretations of
routine VA data from six population surveillance sites in
Africa against known serostatus (57).
In conclusion, it is encouraging that despite the limi-
tations, InterVA and Spectrum show results that are
generally comparable in estimating AIDS-related mor-
tality patterns. The comparability improves when TB
deaths are included in AIDS deaths determined by
InterVA. This is not surprising as TB is an AIDS-defining
disease among people living with HIV, and there are
significant overlaps between the symptoms associated
with non-TB AIDS, TB deaths among people living with
HIV, and TB deaths among HIV-negative persons.
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Does the Spectrum model accurately predict trends in
adult mortality? Evaluation of model estimates using
empirical data from a rural HIV community cohort
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Introduction: Spectrum epidemiological models are used by UNAIDS to provide global, regional and national
HIV estimates and projections, which are then used for evidence-based health planning for HIV services.
However, there are no validations of the Spectrum model against empirical serological and mortality data
from populations in sub-Saharan Africa.
Methods: Serologic, demographic and verbal autopsy data have been regularly collected among over 30,000
residents in north-western Tanzania since 1994. Five-year age-specific mortality rates (ASMRs) per 1,000
person years and the probability of dying between 15 and 60 years of age (45Q15,) were calculated and
compared with the Spectrum model outputs. Mortality trends by HIV status are shown for periods before the
introduction of antiretroviral therapy (19941999, 20002005) and the first 5 years afterwards (20052009).
Results: Among 3034 year olds of both sexes, observed ASMRs per 1,000 person years were 13.33 (95% CI:
10.7516.52) in the period 19941999, 11.03 (95% CI: 8.8413.77) in 20002004, and 6.22 (95% CI; 4.75
8.15) in 20052009. Among the same age group, the ASMRs estimated by the Spectrum model were 10.55,
11.13 and 8.15 for the periods 19941999, 20002004 and 20052009, respectively. The cohort data, for both
sexes combined, showed that the 45Q15 declined from 39% (95% CI: 2755%) in 1994 to 22% (95% CI: 17
29%) in 2009, whereas the Spectrum model predicted a decline from 43% in 1994 to 37% in 2009.
Conclusion: From 1994 to 2009, the observed decrease in ASMRs was steeper in younger age groups than
that predicted by the Spectrum model, perhaps because the Spectrum model under-estimated the ASMRs in
3034 year olds in 199499. However, the Spectrum model predicted a greater decrease in 45Q15 mortality
than observed in the cohort, although the reasons for this over-estimate are unclear.
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T
anzania, like many other sub-Saharan African
countries, has experienced high adult mortality
due to HIV/AIDS. The adult mortality rate is the
probability of dying between age 15 and 60 years and is
known to demographers as 45Q15. In Tanzania 45Q15 was
estimated as 45% in 1995, 45% in 2000, and 40% in 2005
(1), but in a study in northern Tanzania in 1999, the 45Q15
was estimated as 49% for men and 46% for women (2).
There is strong evidence that all-cause, adult mortality
rates elsewhere in East Africa have declined over the past
Global Health Action
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mortality declined by 25% following the roll-out of
anti-retroviral therapy (ART) (3). Other sites in Africa
compare all-cause adult mortality 26 years following
ART roll-out with pre-ART period and show a decrease
of 42% in Karonga, Malawi; 21% in Kisesa, Tanzania;
and 21% in UMkhanyakude, South Africa (4), although
the overall pattern in South Africa may not show much
decrease in all-cause adult mortality (5). However, HIV is
still a leading cause of adult death in many countries in
East and Southern Africa (6).
In Tanzania in 1996, in a population aged 1554 years
with a 4% prevalence of HIV, 35% of all deaths occurred
in HIV positives (7). In Zambia in 1999 in two townships
with a 15% prevalence of HIV among adults, 53% of all
deaths were attributable to HIV (8) while in Zimbabwe, in
2006, 61% of all adult deaths were attributable to HIV
(9). However, HIV-attributable mortality has declined in
Tanzania since 2004 (C. Kanjala et al., unpublished
data), and the most obvious reason for the decline in
all-cause and HIV-attributable mortality is the availabil-
ity of ART (10).
Duetotheweaknessesinvitalregistrationandhealthin-
formation systems in developing countries, little informa-
tion is available for planning of health services. National
and regional health planners depend on estimates and
projections from demographic and epidemiological mod-
els. Even if there were reliable demographic data in these
countries, good, validated models would be needed to
study the potential impact of health interventions. The
Spectrum model, developed by the Futures Institute, uses
information from national or sentinels, population-based
surveys, in order to estimate key parameters of the HIV
epidemic (11, 12). Estimating HIV incidence from pre-
valence relies on an accurate progression and survival
model for HIV, which has thus far beenvalidated against a
limited number of data sets. Problems with data quality
and model specification can lead to incorrect projections.
Demographic surveillance sites that also collect HIV data
can be used to verify the model specification, and validate
theout-parametersoftheSpectrummodel,thusimproving
the model fit, and the understanding of the HIVepidemic
curves applied to the data.
This paper describes trends and patterns in age-specific
mortality rates (ASMRs) and in the index of adult
mortality (45Q15) in Kisesa HIV cohort study in north-
western Tanzania from 1999 to 2009. The paper then
compares these observed mortality rates and 45Q15 with
estimates from the Spectrum model.
Methods
Population data
The Kisesa HIV cohort study is based on the population
of seven villages located approximately 20 km east of
Mwanza City in north-western Tanzania. The seven
villages range from urbanised, roadside settlements near
the ward’s trading centre to remote rural settlements,
with 95% of the population belonging to the Sukuma
tribe, the largest ethnic group in Tanzania. The main
economic activities are small-scale farming and petty
trade of both agricultural and livestock products, while a
minority of residents are fishermen. The demographic
surveillance system (DSS) conducts a household count
every 36 months to record new residents through births
and in-migration, as well as those lost to the cohort
through death and out-migration. The DSS began in
1994, with a population of 19,350, and by 2011 the
population had increased to 34,000 (13). Over the same
period (19942011), six serological surveys have been
conducted, 23 years apart, to monitor trends in the HIV
epidemic in adults aged 15 years and over in the
population (14, 15). Dry blood spots are collected and
two independent enzyme-linked immunosorbent assays
are used, according to Tanzanian guidelines to determine
those who are HIV positive.
Data management and statistical analysis
All data from community cohort were entered using
Census and Surveys Processing (CSPro) software (U.S.
Bureau of the Census & ORC Macro’s MEASURE DHS
project, 2000), and transferred to STATAVersion12 (Stata
Corp., College Station, Texas) for analysis. ASMRs were
calculated by dividing the number of deaths observed by the
person years of follow-up, for each sex and 5-year age group
in the resident population. Adult mortality was summarized
as 45Q15, which is obtained by multiplying the survival
derived from the ASMRs. The 45Q15 measure was obtained
separately for males and females in the cohort, and based
on the serological HIV status of those who had been tested,
the 45Q15 measure was obtained for HIV-positive, HIV-
negative and HIV-unknown groups. Parameters, ASME
and 45Q15, estimated from the cohort data are shown with
95% confidence intervals (95% CI) derived from the Poisson
distribution for deaths in this cohort.
The Spectrum model
The Spectrum model analyses existing country-specific
data to estimate the current and future population
structure and health of the people in the country. It
comprises of different, integrated policy modules such as
the Demographical Projection (DemProj), AIDS Impact
(AIM), Family Planning (FamPlan), Child Survival
(LIST) among others. Each module relies on program-
matic input data and demographical information ob-
tained from DemProj (which in turns bases its projection
on data from the UN Population Division) to produce
indicators for a given public health area.
AIM is at the root of the Spectrum estimates for HIV-
attributable mortality. It consists of three independent
sub-models: mother-to-child transmission, child HIVand
Evaluation of the Spectrum model
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incidence trends, including the number of people living
with HIV, number of new infections, number of pregnant
women infected with HIV, and mortality due to AIDS.
It is widely used to forecast near-term treatment and
prevention of mother-to-child transmission (PMTCT)
needs. In addition to the role AIM plays in HIV program
planning, it is also used to estimate the impact of HIV
prevention programs, such as the impact of expanding
PMTCT and ART programs.
The Spectrum model used the general patterns of the
HIV epidemic in Tanzania, with changes to specifically
model the age and sex structure in Kisesa. The specific
input parameters to the Spectrum model were obtained
from a workshop in 2012 with members of the network
for Analysis of Longitudinal Population-based HIV data
in Africa (ALPHA). Details of data analysis work by
the ALPHA network are given by Maher et al. (16).
The structure of the Spectrum modelling and the general
parameters are described elsewhere (17).
Ethical issues
Individual informed consent was obtained from sero
survey study participants. Research activities in the
Kisesa cohort study were granted ethics approval by the
TanzanianNationalResearchEthicsReviewSub-commit-
tee (NatREC) and the London School of Hygiene and
Tropical Medicine (LSHTM) ethics committee.
Results
Adult ASMRs
Figure 1 shows the ASMRs for three periods (19941999,
20002004, 20052009). ASMRs per 1,000 person years
amongthoseaged3034were13.33(95%CI:10.7516.52)
in the period 19941999, 11.03 (95% CI: 8.8413.77) in
20002004, and 6.22 (95% CI: 4.758.15) in 20052009.
Overall all-cause mortality rates in Kisesa are lower in the
period 20052009 than in previous periods for all age
groups, although the 95% confidence intervals are wide
and the differences for any age group may not be signifi-
cant. In all periods, all-cause mortality increasedwith age,
with ASMRs for three periods (19941999, 20002004
and 20052009) shown separately for men and women
(Table 1). The Spectrum model showed that ASMRs for
adults aged 3049 years increased between the 19941999
period and the 20002004 period. For all ages the ASMRs
decreased between 20002004 and 20052009.
45Q15 mortality trends
Table 2 shows time trends of the index of the proportion
of adult deaths between 15 and 60 years of age (45Q15)b y
sex from the Kisesa DSS data, and the Spectrum model
estimates. The probability of dying in the age group
1560 has declined from the year 2000 for both sexes. The
chance of dying in the 1560 age group for both sexes
combined was 39% (95% CI: 2755%) in 1994 and 22%
(95% CI: 1531%) in 2009. Men were found to have a
higher 45Q15 than women across all time periods, though
the 95% confidence intervals overlap in each of the years.
With ART introduction in 2005, there is a consistent
decline in the 45Q15 measure over the next 5 years.
The Spectrum model showed an increase in the 45Q15
measure of mortality for both sexes from 43% in 1994 to
48% in 2000 and a subsequent decline to 37% in 2009.
A similar pattern was shown for women and men
separately, with men having a higher probability of dying
than women across all periods of time. Figure 1 illustrates
trends in the index of adult mortality (45Q15) by sex. The
45Q15 was generally higher in men compared to women
except in a few years. The difference in 45Q15 measure of
Fig. 1. Adult age-speciﬁc mortality rates per 1,000 person years (all-cause, both sexes) estimated in Kisesa DSS, 19942009.
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50 Citation: Glob Health Action 2014, 7: 21783 - http://dx.doi.org/10.3402/gha.v7.21783Table 1. Adult age-speciﬁc mortality rates per 1,000 person years (all-cause, men and women) from Kisesa cohort data and Spectrum model estimates
19941999 20002004 20052009
Empirical data
Spectrum
estimate Empirical data
Spectrum
estimate Empirical data
Spectrum
estimate
Age
group
Number
of deaths
Number of
person
years
Mortality rate
(95% CI)
Mortality
rate
Number
of deaths
Number of
person
years
Mortality rate
(95% CI)
Mortality
rate
Number
of deaths
Number of
person
years
Mortality rate
(95% CI)
Mortality
rate
Men
1519 19 6,064 3.13 (24.91) 3.06 19 6,275 3.03 (1.934.75) 2.69 15 7,654 1.96 (1.183.25) 2.31
2024 19 4,716 4.03 (2.576.32) 4.86 17 5,029 3.38 (2.15.44) 4.23 20 5,229 3.82 (2.475.93) 3.58
2529 25 3,615 6.91 (4.6710.23) 7.51 24 4,089 5.87 (3.938.76) 6.81 31 4,165 7.44 (5.2310.58) 5.60
3034 49 3,312 14.80 (11.1819.58) 10.24 32 3,344 9.57 (6.7713.53) 10.09 28 4,096 6.84 (4.729.90) 8.07
3539 45 2,654 16.96 (12.6622.71) 13.95 33 2,922 11.30 (8.0315.89) 14.60 37 3,249 11.39 (8.2515.72) 11.85
4044 21 1,903 11.04 (7.216.93) 15.02 49 2,425 20.21 (15.276.74) 16.14 31 2,744 11.30 (7.9416.06) 13.10
4549 31 1,609 19.26 (13.5527.39) 15.38 31 1,688 18.36 (12.9126.11) 16.09 25 2,254 11.09 (7.4916.41) 13.55
5054 25 1,333 18.76 (12.6827.76) 15.29 25 1,290 19.39 (13.128.69) 14.90 31 1,563 19.83 (13.9428.19) 12.73
5559 23 1,005 22.89 (15.2134.44) 25.15 24 1,093 21.95 (14.7132.75) 23.61 21 1,147 18.31 (11.9428.08) 19.97
60 126 2,387 52.79 (40.3369.79) 62.28 138 2,500 55.20 (42.3571.80) 59.95 135 2,801 48.20 (36.3463.88) 56.86
Women
1519 10 5,265 1.90 (1.023.53) 2.59 19 5,774 3.29 (2.15.16) 2.23 17 6,881 2.47 (1.543.97) 1.80
2024 35 4,983 7.02 (5.049.78) 4.81 28 4,954 5.65 (3.98.19) 4.23 10 5,310 1.88 (1.013.5) 3.43
2529 35 4,164 8.40 (6.0311.71) 8.97 36 4,572 7.87 (5.6810.92) 8.71 29 4,767 6.08 (4.238.75) 6.82
3034 46 3,598 12.78 (9.5817.07) 10.85 46 3,728 12.34 (9.2416.47) 12.17 25 4,423 5.65 (3.828.37) 9.44
3539 25 2,619 9.55 (6.4514.13) 12.15 40 3,164 12.64 (9.2717.24) 14.16 28 3,402 8.23 (5.6811.92) 11.87
4044 22 2,059 10.69 (7.0416.23) 11.48 30 2,436 12.31 (8.6117.61) 13.04 25 2,995 8.35 (5.6412.35) 10.94
4549 18 1,566 11.50 (7.2418.25) 14.00 21 1,884 11.15 (7.2717.1) 14.80 23 2,379 9.67 (6.4214.55) 12.35
5054 19 1,368 13.89 (8.8621.78) 14.30 20 1,406 14.22 (9.1822.04) 13.74 19 1,733 10.97 (6.9917.19) 11.30
5559 19 1,079 17.62 (11.2427.62) 13.84 20 1,186 16.87 (10.8826.14) 12.63 18 1,363 13.21 (8.3220.97) 10.71
60 151 2,866 52.69 (40.2169.00) 55.60 132 3,113 42.40 (36.3148.81) 53.60 139 3,612 38.48 (33.454497) 51.03
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1mortality between empirical data and the modelled
estimate ranged from 0.03 to 0.16 among men and 0.01
to 0.17 among women. Figure 3 illustrates how the two
data sources, which are empirical versus modelled data
for index of adult mortality (45Q15) by sex and calendar
year, compare to each other.
Adult mortality (45Q15) trends by HIV status
Figure 2 illustrates trends in 45Q15 by HIV status sep-
arately for men and women. The highest 45Q15 for men
was reported in 1999 (58%, 95%CI: 4670%) whilst the
highest 45Q15 for women was in 2000 (42%, 95%CI: 34
51%). 45Q15 for HIV-positive adults was consistently
higher than HIV-negative adults across all time periods.
Adults with unknown sero status had higher 45Q15 than
HIV-negatives but lower than HIV-positive adults. The
trend was the same for both men and women. Although
not conclusive, there was a downward trend of 45Q15
when both sexes were combined regardless of the sero
status. This downtrend was more pronounced among
the HIV-positive females than among the HIV-positive
males.
Discussion
Adult ASMRs in Kisesa peaked during the mid-1990s
and declined during the periods from 2000 onwards. As
expected ASMRs increased with increasing age, and the
observed pattern of ASMRs corresponds to the expected
mortality patterns in HIV infected adults (18). ART
became available in Tanzania in 2005 through the care
and treatment clinics (CTC) and the first members of the
Kisesa cohort were referred to CTC in 2005. Uptake of
ART in this cohort among those estimated to be in need
of treatment has been estimated at less than 3% (19), but
substantial declines in ASMRs have been seen, especially
among adults aged 3049 years. This is similar to the de-
clines in ASMRs seen in other countries in sub-Saharan
Africa following the introduction of ART (3).
The probability of dying between 15 and 60 years of
age (45Q15) also showed a peak in the mid-1990s with
a subsequent decrease of around 25% through to 2009.
The agreement of the empirical data with the Spectrum
model estimates for 45Q15 show the expected epidemic
curve for HIV peaking in the mid-1990s, and the larger
declines from 2005 due to the introduction of ART in the
community. This analysis shows good agreement between
theoutputsfromtheSpectrummodelandtheASMRsand
45Q15 estimated from the empirical data using HIV ser-
ology. The model-based results for these measures of adult
mortality in some population segments aresmoothed, and
the empirical results show variation from year toyear, due
to the relatively small numbers of deaths observed in this
rural community cohort. Further work is needed to
evaluate the model with community-based mortality
data from other serological and verbal autopsy studies.
For the estimates of 45Q15 in this rural cohort, the
agreement between the serological estimates and those
Table 2. Index of adult mortality (45Q15) by sex and calendar year from Kisesa cohort data and Spectrum model estimates
Men Women Both sexes
Year
Empirical 45Q15
a
(95% CI)
Spectrum
estimates Difference
g
Empirical 45Q15
a
(95% CI)
b
Spectrum
estimates Difference
g
Empirical 45Q15
a
(95% CI)
Spectrum
estimates Difference
g
1994 0.43 (0.260.63) 0.47 0.04 0.35 (0.180.61) 0.40 0.05 0.39 (0.270.55) 0.43 0.04
1995 0.30 (0.210.40) 0.48 0.18 0.43 (0.320.55) 0.41 0.02 0.36 (0.290.45) 0.45 0.09
1996 0.42 (0.320.53) 0.49 0.07 0.42 (0.310.54) 0.43 0.01 0.41 (0.340.49) 0.46 0.05
1997 0.53 (0.420.64) 0.50 0.03 0.36 (0.270.48) 0.44 0.08 0.45 (0.380.54) 0.47 0.02
1998 0.37 (0.270.50) 0.50 0.13 0.34 (0.230.48) 0.45 0.11 0.35 (0.280.44) 0.48 0.13
1999 0.58 (0.460.70) 0.50 0.08 0.34 (0.260.45) 0.46 0.12 0.47 (0.390.55) 0.48 0.01
2000 0.46 (0.350.57) 0.50 0.04 0.42 (0.340.51) 0.46 0.04 0.44 (0.370.51) 0.48 0.04
2001 0.42 (0.320.53) 0.49 0.07 0.39 (0.300.50) 0.46 0.07 0.41 (0.340.49) 0.48 0.07
2002 0.33 (0.240.44) 0.49 0.16 0.35 (0.270.45) 0.46 0.11 0.34 (0.280.41) 0.47 0.13
2003 0.45 (0.350.56) 0.48 0.03 0.35 (0.270.46) 0.46 0.11 0.40 (0.330.48) 0.47 0.07
2004 0.43 (0.340.54) 0.47 0.04 0.32 (0.240.43) 0.45 0.13 0.38 (0.320.45) 0.46 0.08
2005 0.40 (0.310.50) 0.46 0.06 0.36 (0.280.46) 0.44 0.12 0.38 (0.320.45) 0.45 0.07
2006 0.35 (0.260.47) 0.45 0.10 0.22 (0.140.32) 0.43 0.11 0.29 (0.220.36) 0.44 0.15
2007 0.46 (0.350.59) 0.43 0.03 0.31 (0.220.41) 0.40 0.09 0.38 (0.310.46) 0.41 0.03
2008 0.30 (0.210.41) 0.40 0.10 0.25 (0.160.36) 0.37 0.12 0.27 (0.200.34) 0.38 0.11
2009 0.26 (0.180.38) 0.38 0.12 0.18 (0.130.26) 0.35 0.17 0.22 (0.170.29) 0.37 0.15
a45q15 denotes probability of dying between 1560 years of age.
bCI denotes the 95% confidence intervals.
gDifferenceSpectrum 45Q15 minus Empirical 45Q15.
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ware were less convincing. Whereas the serological data
showed a marked drop in the proportion dying in 2005,
after the introduction of ART, the verbal autopsy results
showed little change after 2005 (C. Kanjala et al.,
unpublished data). In this supplement, Oti validates the
Spectrum model against verbal autopsy data interpreted
through Inter-VA4 in Nairobi and concludes that both
HIV and TB deaths from the model need to be included
to give an agreement with the Spectrum results (20). This
may also be the reason for poor correlation between the
empirical and Spectrum-modelled results in Kisesa.
In 2004, Stover et al. validated the Spectrum model
estimates against empirical estimates of mortality from
six population-based studies and concluded that the
model performed well (21). However, there are few
reports of validation of the Spectrum model against
empirical serological data from populations in sub-
Saharan Africa. A previous report noted that model-
based approaches may over-estimate mortality due to
HIV and may therefore over-estimate the decline in
mortality with the introduction of ART (22).
In this analysis, estimated ASMRs in adults from the
empirical data agreed well with the estimates from the
Spectrum model. In particular, the decline in mortality
seen in adults aged 3049 years from 2005 onwards
provides some evidence of the impact of ART in this
population. A pooled analysis of population-based data
in four selected sites in East and Southern Africa de-
picted a similar trend in adult mortality, which is greatly
influenced by the introduction of ART in these areas
(3, 19, 23). These results suggest that mortality trends and
patterns may have been adequately modelled and pre-
dicted by the Spectrum model.
Fig. 2. Index of adult mortality by HIV status and calendar year with 95% conﬁdence intervals.
Fig. 3. Index of adult mortality (45Q15) by sex and calendar year from Kisesa cohort data and Spectrum model estimates.
Evaluation of the Spectrum model
Citation: Glob Health Action 2014, 7: 21783 - http://dx.doi.org/10.3402/gha.v7.21783 53The observed data on the probability of dying between
15 and 60 years of age in this analysis were similar to the
estimates from a population-based study in Uganda. In
Uganda, the 45Q15 before 2004 was estimated as 51% for
men (95% CI: 4557%) and 44% for women (95% CI: 39
49%), decreasing from 2005 onwards, to 38% (95% CI:
3344%) for men and 32% (95% CI: 2837%) for women
(3). Although there was a slightly higher overall estimate
of 45Q15 in Uganda compared to these results, there is
a consistent trend in a decreasing 45Q15 following the
introduction of ART.
A comparison of the 45Q15 estimates for those known
to be HIV positive reinforces the conclusion that mor-
tality has decreased, and that a greater decrease has been
observed in women than men. From 2005, empirical data
show that the 45Q15 in women has been declining, in-
dicating that survival in those that are HIV positive has
improved. It is not surprising that women have shown
greater improvements in survival, as it has been shown
that women are more likely to access ART relative to
estimated need for treatment and that they access ART
with higher CD4 counts and better immunological status
(24).
The data for this paper have been taken from demo-
graphic surveillance of vital events in 30,000 people since
1994. With less than 100 deaths per annum between the
ages of 15 and 60 years, there is considerable variation in
the annual adult mortality. Previous studies have shown
that epidemiological models may over-estimate mortality
due to HIV/AIDS, although some deaths may have been
missed from this study due to out-migration. We have
presented the data on ASMRs and 45Q15 in this paper,
and have not shown age adjusted mortality rates, as the
population structure in Kisesa has not changed much
over the 19 years of follow-up, and the age adjusted adult
mortality rate is very similar to the 45Q15 that we present.
Although the size of the decline in all-cause mortality
may differ between the model and the observed data, the
decline from pre-ART to post-ART periods is clear from
both the data and the model outputs.
Conclusion
Most resource-limited countries lack vital registration
data, in order to estimate mortality rates and other
demographic population parameters. This article presents
a fair comparison of mortality estimates generated by the
Spectrum model against empirical data from a long-
standing population-based cohort. From 1994 to 2009,
the observed decrease in ASMRs was steeper in younger
age groups than that predicted by the Spectrum model
perhaps because the Spectrum model under-estimated the
ASMRs in 3034 year olds in 199499. However, the
Spectrum model predicted a greater decrease in 45Q15
mortality than observed in the cohort, although the
reasons for this over-estimate are unclear. These findings
have evidently shown a technical gap to be filled to
improve the Spectrum model such that it can exactly
predict population parameters in setting where empirical
data are scarce but they are needed for health planning.
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Mortality and its predictors among antiretroviral
therapy naı ¨ve HIV-infected individuals with CD4
cell count ]350 cells/mm
3 compared to the
general population: data from a population-based
prospective HIV cohort in Uganda
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Background: Evidence exists that even at high CD4 counts, mortality among HIV-infected antiretroviral
therapy (ART) naı ¨ve individuals is higher than that in the general population. However, many developing
countries still initiate ART at CD4 5350 cells/mm
3.
Objective: To compare mortality among HIV-infected ART naı ¨ve individuals with CD4 counts ]350 cells/
mm
3 with mortality in the general Ugandan population and to investigate risk factors for death.
Design: Population-based prospective HIV cohort.
Methods: The study population consisted of HIV-infected people in rural southwest Uganda. Patients were
reviewed at the study clinic every 3 months. CD4 cell count was measured every 6 months. Rate ratios were
estimated using Poisson regression. Indirect methods were used to calculate standardised mortality ratios (SMRs).
Results: A total of 374 participants with CD4 ]350 cells/mm
3 were followed for 1,328 person-years (PY) over
which 27 deaths occurred. Mortality rates (MRs) (per 1,000 PY) were 20.34 (95% CI: 13.95 29.66) among
all participants and 16.43 (10.48 25.75) among participants aged 15 49 years. Mortality was higher in periods
during which participants had CD4 350 499 cells/mm
3 than during periods of CD4 ]500 cells/mm
3 although
the difference was not statistically significant [adjusted rate ratio (aRR) 1.52; 95% CI: 0.71 3.25]. Compared to
the general Ugandan population aged 15 49 years, MRs were 123% higher among participants with CD4 ]500
cells/mm
3 (SMR: 223%, 95% CI: 127 393%) and 146% higher among participants with CD4 350 499 cells/mm
3
(246%, 117% 516). After adjusting for current age, mortality was associated with increasing WHO clinical stage
(aRR comparing stage 3 or 4 and stage 1: 10.18, 95% CI: 3.82 27.15) and decreasing body mass index (BMI)
(aRR comparing categories 517.4 Kg/m
2 and ]18.5 Kg/m
2: 6.11, 2.30 16.20).
Conclusion: HIV-infected ART naı ¨ve individuals with CD4 count ]350 cells/mm
3 had a higher mortality than the
general population. After adjusting for age, the main predictors of mortality were WHO clinical stage and BMI.
Keywords: mortality; HIV-infected; antiretroviral therapy naı ¨ve; general population; CD4 cell count ]350 cells per mm
3;
rural Uganda
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M
ortality among HIV-infected individuals is
much higher than in the general population
(1 3) with the risk of death increasing as the
CD4 cell count declines (4). Antiretroviral therapy (ART)
is currently the most effective intervention for reducing
mortality among HIV-infected individuals. The impact
of ART in reducing mortality among HIV-infected
people has been reported in developed countries (5) and
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countries, ART is still initiated when there is evidence of
a significantly high risk of death, usually evidenced by
clinical deterioration or low CD4 cell count. Currently,
CD4 cell count is the most commonly used marker of
immunological deterioration and HIV disease progres-
sion (7). In 2010, the World Health Organization (WHO)
advised that HIV-infected people should be initiated on
ART when their CD4 cell count is 5350 cells/mm
3 (8).
As a result Uganda responded by issuing new national
ART treatment guidelines shifting the threshold for
initiating ART from 5250 (9) to 5350 cells/mm
3 (10).
Over the last decade, ART has become more readily
available with some countries even achieving universal
ART access (11). There is a debate among experts
concerning whether HIV-infected people are initiated
on ART too late (12). Evidence shows that delayed
ART initiation is associated with poorer outcomes such
as morbidity (13), and that starting ART at higher CD4
cell count reduces the riskof death (14). Besides the effect
of ART on reducing mortality and morbidity, early
initiation of ART has been reported to reduce HIV
transmission by up to 56% (15).
By providing ART only to HIV-infected people with a
low CD4 cell count, it indirectly implies that mortality
among HIV-infected individuals whose immune status is
still competent, as evidenced by higher CD4 count, is low
and similar to that observed in the general population.
However, a large observational study in Europe and
North America of over 40,000 patients reported higher
death rates among HIV-infected ART naive individuals
with CD4 cell counts ]350 cells/mm
3 than among the
general population (16).
Several studies have reported predictors of mortality
among HIV-infected people but mainly among those with
advanced immunosuppression and on ART. A retro-
spective ART cohort study in Ethiopia reported weight
loss ]10%, bedridden functional status at baseline,
advanced WHO clinical stage and CD4 cell count
5200 cells/mm
3 as independent predictors of death
(17). Another hospital-based ART follow-up study in
Thailand reported anaemia and severe immunosuppres-
sion at baseline as predictors of early mortality, whereas
CD4 increase from a baseline CD4 of B50 cells/mm
3,
persistent anaemia and virological response at 6 months
were identified as predictors of long-term mortality (18).
On the other hand, a longitudinal pre-ART study in
Zimbabwe reported haemoglobin and HIV clinical sta-
ging (CDC classification) as strong independent predic-
tors of mortality, but this study did not assess predictors
of mortality stratified by CD4 cell count (19).
Although most HIV-associated deaths occur in sub-
Saharan Africa, information on mortality and its pre-
dictors among ART naı ¨ve individuals with high CD4 cell
counts is still scarce, yet this information is useful in
informing policy on the most appropriate time to start
ART. Data on mortality patterns among HIV-infected
persons with high CD4 cell counts are essential before
expanding access to ART among this group.
We conducted the current study among HIV-infected
ART naı ¨ve individuals with CD4 cell count ]350 cells/
mm
3. We estimated overall mortality, compared mortality
in the CD4 cell count category 350 499 cells/mm
3 with
that in the ]500 cells/mm
3 category, and compared
mortality among study participants with mortality in the
general population in Uganda. We also investigated risk
factors for death among HIV-infected ART naı ¨ve persons
with CD4 cell count ]350 cells/mm
3.
Methods
Setting and study population
The Rural Clinical Cohort (RCC) is an open HIV cohort
that followed a total of 696 HIV-positive participants
between 1992 and 2011. It is located in rural southwest
Uganda and was established to study the natural history
of HIV infection. The study setting has a stable, homo-
geneous population with most people belonging to the
Baganda tribe. The majority of people are Christians and
half the population is below 15 years of age (20). The
RCC is nested within a large general population cohort
(GPC) that conducts annual serosurveys and census on
20,000 residents of 25 study villages (21 23). In 1990, the
RCC recruited one third of the HIV prevalent cases
identified in the 1989 baseline GPC serosurvey; there-
after, HIV incident cases identified in subsequent annual
GPC serosurveys were recruited (24). Following ART
availability in Uganda in 2004, HIV-positive cases that
remained in the GPC were invited to be screened and
were enrolled into RCC if they qualified to start ART.
Study participants’ recruitment and follow-up
Trained field workers visited individuals eligible for
enrolment, explained the nature of the study and invited
them to the study clinic where theygave informed consent
before enrolment. After enrolment, study participants
attended scheduled visits every 3 months at the study
clinic. Data collected included medical, demographic,
sexual and behavioural history and WHO clinical stage.
HIV infection was staged according to WHO clinical
staging (25). The WHO clinical staging system was
developed in 1990 to guide physicians, in resource-limited
settings, to make decisions related to management of
HIV/AIDS patients. According to the WHO clinical
staging system, HIV disease progression is grouped into
four stages, i.e. stages 1, 2, 3 and 4. Study participants
attended interim visits whenever ill and they received free
investigations and treatment according to national guide-
lines (26) or were referred to a nearby health facility
about 20 km away, for in-patient management. In 2004,
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duals according to the existing National ART guide-
lines at the time (27). These guidelines described ART
eligibility then as: CD4 count of 200 cells/mm
3 or below,
or WHO clinical stage 4, or advanced stage 3 with
persistent or recurrent oral thrush and invasive bacterial
infections regardless of CD4 count, or CD4 count of 250
cells/mm
3 or below in pregnancy. Although the National
Cotrimoxazole prophylaxis guidelines were released in
2005 (28), cotrimoxazole prophylaxis among HIV-
infected individuals had been introduced in the cohort
in 2004. To minimize loss to follow-up, study participants
were transported to the study clinic (or given transport
refund) for their scheduled visits, and those who missed
their scheduled visits were visited at home within 3 days.
Field workers who received information about a study
participant’s death by the deceased’s next of kin, relative,
friend or community-based recorders in the GPC notified
study clinicians of deaths.
Laboratory assessment
CD4 cell counts were measured every 6 months among
HIV-infected study participants not yet on ART, using
FACS Count Machine (Becton Dickinson, San Jose,
California, USA). HIV viral load measurement was
done at enrolment and annually thereafter, using two
methods during the study. Up to September 2007, we
used the VERSANT RNA 3.0 (Bayer, Bayer HealthCare,
NY, USA) assay (lower detection limit 50 copies/ml).
However, due to problems with lack of reagents and lack
of service support, we used the COBAS Amplicor
MONITOR 1.5 (Roche, Roche Molecular Systems, NJ,
USA) assay (lower detection limit 400 copies/ml) from
October 2007 onwards. Other laboratory tests done at
scheduled visits included thick blood malaria smears,
stool analysis, urine examination and full blood counts.
Outcome
The outcome of interest was death, with mortality rates
(MRs) estimated from deaths per 1,000 person-years
(PY), and age- and sex- standardised MRs.
Exposures
The primary exposure variable was current CD4 count
350 499 and ]500 cells/mm
3 among ART naı ¨ve HIV-
infected individuals. The following secondary exposure
variables were measured at enrolment: age, sex, tobacco
consumption (measured as years of tobacco consumption
and number of times tobacco is consumed each day),
alcohol consumption (measured as number of units
consumed and number of consumption days each
week), level of education (none, primary and secondary
or above) and height (in centimetres). The following
secondary exposure variables were measured at enrol-
ment and every 3 months: marital status (married, with
steady sexual partner, single, divorced or widowed),
diarrhoea (three or more loose motions each day) for
more than 1 month, WHO clinical stage (measured as
stage 1, 2, 3 or 4), malaria (diagnosed from blood smear),
height, weight (in kilograms) and viral load.
Statistical analysis
Data were double-entered, cleaned and validated using a
MS Access database and analysed using STATA version
11.0 (StataCorp, College Station, Texas, USA). Mortality
data from the general Ugandan population were ex-
tracted from the 2011 Uganda Demographic and Health
Survey (DHS) (29). At the time of the DHS, there were a
total of 80 districts from which a representative sample of
9,854 households was selected using multistage sampling.
Age-specific MRs, for women and men aged 15 49 years,
were calculated for the 7 years before the survey was
carried out (mid-2004 to mid-2011).
Because our primary objective was to estimate mor-
tality among HIV-positive persons who were not yet
eligible for ART, person-time at risk started at the first
CD4 cell count ]350 cells/mm
3 and was censored at the
earliest of death, CD4 cell count B350 cells/mm
3, start of
ART or date last seen. Multiple episodes of observation
and gaps were allowed if an individual’s CD4 count fell
below 350 and then later increased to ]350 cells/mm
3
without ART initiation. Loss to follow-up was defined as
a participant who was not known to be dead but had not
been seen at the study clinic for at least 1 year. If a
participant missed a CD4 cell count at a scheduled visit,
the value from the previous visit was carried forward,
if within the last 6 months. CD4 cell counts were con-
sidered to be unknown during periods when there was
 6 months since the last CD4 cell count and this period
was excluded from the analysis. Similarly, viral load data
were carried forward if the previous measurement was
less than 12 months ago. Viral load measurements were
considered to be unknown in the periods when there was
 12 months since the last measurement.
Baseline characteristics (defined as the point when the
participant first entered the analysis) were calculated and
tabulated by CD4 count category. Calendar time was
divided into two periods before ARTwas available (1992 
1999 and 2000 2003) and two periods after ART was
available (2004 2007 and 2008 2011). MRs were calcu-
lated using standard person-year methods. Crude and
adjusted rate ratios (RR) were calculated using Poisson
regression and associations assessed using likelihood
ratio tests (LRT). Adjusted RRs (aRR) for CD4 count
category, adjusted for the effect of current age, sex and
calendar period as a priori confounders, were calculated.
Effect modification of CD4 cell count category by age,
sex and calendar period was also assessed.
To identify independent risk factors for mortality, a
multivariate Poisson model was constructed. Current age
was considered to be a priori confounder and included in
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analysedastime-updatedexposures.Riskfactorsthatwere
associated with mortality at PB0.20 in the univariate
analysis were assessed for inclusion in the multivariate
model. A forwardstepwisemethodwas used, starting with
the factor that had the strongest association and adding
other factors to the model one by one; those that were
associated at PB0.05 were retained. In the final model,
effect modification between CD4 count category and each
of the other covariateswas assessed. Survival probabilities
were evaluated using Kaplan-Meier curves stratified by
CD4 count categories. Standardised mortality ratios
(SMRs) for age and sex were calculated using the indirect
method and the analysis was restricted to 15 49 years of
agetomatchwiththeUgandaDHSdata.Withtheindirect
method of standardisation, the age- and sex-specific MRs
in the Ugandan population are multiplied by the person-
years in each sex and age group in our study cohort to
obtain the expected number of deaths in our cohort if the
two populations had the same mortality.
Ethical considerations
The RCC from which this data was extracted received
ethicalapprovalfromtheUgandaVirusResearchInstitute
Science and Ethics committee and the Uganda National
Council for Science and Technology. All informed consent
and confidentiality procedures were adhered to.
Results
Characteristics of participants
Between June 1992 and March 2011, 374 participants
had a CD4 cell count ]350 cells/mm
3 on at least one
occasion during follow-up (Table 1). Overall median
age among study participants was 31 years (IQR: 25 
41), and 55% (n 204) were females. At baseline, defined
as entry to the analysis, 71% (n 264) of participants had
a CD4 cell count ]500 cells/mm
3, and 29% had a CD4
cell count of 350 499 cells/mm
3. The majority (n 243,
65%) of participants were married or had a steady sexual
partner, and had some primary education (66%). Most
participants (65%) reported not using tobacco and not
consuming alcohol (69%). Sixteen percent of participants
had a body mass index (BMI) B18.5 Kg/m
2, 8% had
haemoglobin level of B11 g/dL, and 3.2% were in WHO
clinical stage 3 or 4. There were no significant differences
in the distribution of the baseline characteristics by CD4
cell count category.
Missing data
At baseline, only a small proportion of participants
(B10%) had missing data for most covariates, except
for haemoglobin that was missing for 23% participants
(Table 1). During follow-up, CD4 counts were missing
in 15% of the total observation time, and viral load
measurements were missing during 31% of observation
time. Other covariates were missing for B2% of observa-
tion time, except for haemoglobin which was missing for
9% of observation time.
Follow-up time and survival among participants
with CD4 ]350 cells per mm
3
Thirteen (3.5%) participants were censored due to loss to
follow-up, of whom 11 (85%) had a CD4 cell count ]500
cells/mm
3 and two (15%) had a CD4 cell count 350 499
cells/mm
3. Overall, the 374 participants in the periods
with CD4 cell count ]350 cells/mm
3 contributed 1,328
PY at risk. There were 2,921 visits made by 295 par-
ticipants during periods of CD4 count 350 499 cells/
mm
3; 60% (n 1,766) of visits were scheduled follow-
up visits and the remainder were interim (unscheduled)
visits. At 43 scheduled visits (2.4%), participants reported
having been hospitalised since their last visit; overall,
34 participants (11.5%) were hospitalised at least once
during a period when their CD4 count was 350 499 cells/
mm
3. There were 5,521 visits made by 309 participants
during periods of CD4 counts ]500 cells/mm
3; 64%
(n 3,551) of visits were scheduled follow-up visits.
Participants reported having been hospitalised at 66
scheduled visits (1.9%); overall, 48 participants (15.5%)
were hospitalised at least once when their CD4 count was
]500 cells/mm
3.
There were 27 deaths among the study participants
(overall MR 20.34/1,000 PY; 95% CI: 13.95 29.66).
Twelve deaths occurred among individuals with CD4 cell
count 350 499 (MR 27.10/1,000 PY; 95% CI: 15.37 
47.66) and 15 deaths among individuals with CD4 count
]500 (MR 17.00/1,000 PY; 95% CI: 10.23 28.14)
(Table 4). Twelve deaths (MR 17.20/1,000 PY; 95%
CI: 9.77 30.29) occurred in the pre-ART period (1990 
2003) and 15 deaths (MR 23.80/1,000 PY; 95% CI:
14.35 39.48) occurred in the ART period (2004 2011)
(Data not shown).
Although not statistically significant, the unadjusted
MR in participants with CD4 cell count 350 499 cells/
mm
3 was 1.6 times higher than in those with CD4 cell
count ]500 cells/mm
3 (Table 2 and Fig. 1). After
adjusting for age, sex and calendar period, the risk of
death among those with CD4 cell count 350 499 cells/
mm
3 remained higher than among those with CD4 cell
count ]500 cells/mm
3, but the difference was still not
statistically significant (aRR:1.44; 95% CI: 0.71 3.25)
(Table 2). There was some evidence that the effect of
CD4 cell count category varied by calendar period. Par-
ticipants with CD4 cell count category 350 499 cells/
mm
3 had a higher MR than those with CD4 cell count
]500 cells/mm
3 in the period before 2004, however,
after 2004, the MR in participants with CD4 cell count
350 499 cells/mm
3 was lower than that that in partici-
pants with CD4 cell counts ]500 cells/mm
3 (P-value for
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CD4 cell count (cells/mm
3) N 374
Characteristic 350 499 n 110 (column %) ]500 n 264 (column %) Total (column %)
Age (years) P0.49
14 19 9 (8.2) 22 (8.3) 31 (8.3)
20 29 33 (30.0) 103 (39.0) 136 (36.4)
30 39 33 (30.0) 70 (26.5) 103 (27.5)
40 49 22 (20.0) 39 (14.8) 61 (16.3)
]50 13 (11.8) 30 (11.4) 43 (11.5)
Overall median age (IQR) 32 (25 43) 30 (24 40) 31 (25 41)
Sex P0.11
Female 53 (48.2) 151 (57.2) 204 (54.5)
Male 57 (51.8) 113 (42.8) 170 (45.5)
Tribe P0.12
Baganda 57 (51.8) 162 (61.4) 219 (58.6)
Banyarwanda 28 (25.5) 59 (22.3) 87 (23.3)
Other 17 (15.5) 36 (13.6) 53 (14.2)
Missing 8 (7.3) 7 (2.7) 15 (4.0)
Religion P0.07
Catholic 61 (55.5) 170 (64.4) 231 (61.8)
Church of Uganda 24 (21.8) 37 (14.0) 61 (16.3)
Other 18 (16.4) 50 (18.9) 68 (18.2)
Missing 7 (6.4) 7 (2.7) 14 (3.7)
Marital status P0.88
Married /Steady sexual partner 73 (66.4) 170 (64.4) 243 (65.0)
Single 9 (8.2) 25 (9.5) 34 (9.1)
Divorced/widowed 27 (24.5) 64 (24.2) 91 (24.3)
Missing 1 (0.9) 5 (1.9) 6 (1.6)
Education level P0.47
None 14 (12.7) 43 (16.3) 57 (15.2)
Primary 72 (65.5) 175 (66.3) 247 (66.0)
Secondary and above 18 (16.4) 39 (14.8) 57 (15.2)
Missing 6 (5.5) 7 (2.7) 13 (3.5)
Alcohol consumption (times/week) P0.14
Don’t use 69 (62.7) 190 (72.0) 259 (69.3)
1 3 30 (27.3) 59 (22.4) 89 (23.8)
]4 10 (9.1) 15 (5.7) 25 (6.7)
Missing 1 (0.9) 0 1 (0.3)
Years of tobacco use P0.79
Don’t use 70 (63.6) 172 (65.2) 242 (64.7)
55 10 (9.1) 31 (11.7) 41 (11.0)
6 10 7 (6.4) 14 (5.3) 21 (5.6)
11 19 12 (10.9) 21 (8.0) 33 (8.8)
]20 4 (3.6) 14 (5.3) 18 (4.8)
Missing 7 (6.4) 12 (4.5) 19 (5.1)
Body mass index (Kg/m
2) P0.46
]25.0 5 (4.5) 21 (8.0) 26 (7.0)
18.5 B25 83 (75.5) 201 (76.1) 284 (75.9)
B18.5 20 (18.2) 40 (15.2) 60 (16.0)
Missing 2 (1.8) 2 (0.8) 4 (1.1)
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fication by age (P 0.38) or sex (P 0.97).
Mortality in participants with CD4 ]350 cells per
mm
3 compared with the general population
Among individuals aged 15 49 years, the MR in the
Ugandan population was 5.66/1,000 PY (95% CI: 5.46 
5.87), compared with 16.43/1000 PY (95% CI: 10.48 
25.75) among study participants with CD4 count ]350
cells/mm
3. Mortality was 146% higher among study
participants with CD4 counts of 350 499 cells/mm
3
(SMR 246%; 95% CI: 117 516%) and 123% higher
among study participants with CD4 counts of ]500
cells/mm
3 (SMR: 223%; 95% CI: 127 393%). Mortality
in male participants with CD4 ]350 cells/mm
3 was more
than double that in males in the general Ugandan
population (SMR: 313%; 95% CI: 173 565%). Mortality
in female participants with CD4 ]350 cells/mm
3 was
over 100% higher than that in females in the general
Ugandan population (SMR: 245%; 95% CI: 123 490%;
Table 3).
Risk factors for mortality among participants
with CD4 ]350 cells/mm
3
In the univariate analysis, mortality was strongly asso-
ciated with increasing current age (RR 2.8; 95% CI:
1.1 7.5 comparing those aged ]50 years with those
30 39 years; P 0.001) and decreasing BMI (RR 17.1;
95% CI: 7.0 41.8, comparing BMI B17.5 Kg/m
2 with
BMI ]18.5 Kg/m
2; PB0.001). Mortality was also
strongly associated with a haemoglobin level B11 g/dL
(RR 3.8; 95% CI 1.6 8.8; P 0.005) and increasing
WHO clinical stage (17.9; 95% CI: 7.4 43.3, comparing
WHO stage 3 or 4 and WHO stage 1; PB0.001). There
was also an association between mortality and increasing
viral load (RR 4.4; 95% CI: 1.1 18.5, comparing viral
load categories ]250,000 copies/ml and B25,000 copies/
ml; P 0.003).
In the multivariate analysis, after adjusting for current
age, independent factors associated with mortality were
decreasing BMI (aRR 6.1; 95% CI: 2.3 16.2, compar-
ing BMI B17.5 kg/m
2 to BMI ]18.5 kg/m
2; PB0.001)
and increasing WHO clinical stage (aRR 10.2, 95% CI:
3.8 27.2 comparing WHO stage 3 or 4 to WHO stage 1;
PB0.001) (Table 4). After adjusting for current age, BMI
and WHO stage, although mortality was slightly higher
in those with CD4 cell count 350 499, there was no
evidence of an association with CD4 count category
(aRR 1.2, 95% CI; 0.6 2.7; P 0.63). There was no
evidence of effect modification of CD4 count category by
any of the covariates in the final model (P-value for
interaction with age 0.42, with BMI 0.77 and with
WHO stage 0.36).
Table 1 (Continued)
CD4 cell count (cells/mm
3) N 374
Characteristic 350 499 n 110 (column %) ]500 n 264 (column %) Total (column %)
Haemoglobin (g/dL) P0.70
B11.0 9 (8.2) 21 (8.0) 30 (8.0)
] 11.0 76 (69.1) 172 (65.2) 248 (66.3)
Missing 25 (22.7) 71 (26.9) 96 (25.7)
WHO stage P0.64
1 91 (82.7) 215 (81.4) 306 (81.8)
2 13 (11.8) 29 (11.0) 42 (11.2)
3 and 4 4 (3.6) 8 (3.0) 12 (3.2)
Missing 2 (1.8) 12 (4.5) 14 (3.7)
P-value from Chi-squared test for comparison of proportions.
Table 2. Crude rate ratios and rate ratios adjusted for current age, sex and time period, by CD4 cell count category
CD4 category
(cells/mm
3)
Deaths
(person-years)
Mortality rate/1,000
person-years (95% CI)
Crude rate
ratio (95% CI)
Adjusted rate
ratio (95% CI)
P 0.23
$ P 0.29
$
]500 15 (884) 17.00 (10.23 28.14) 1.00 1.00
350 499 12 (443) 27.07 (15.37 47.66) 1.60 (0.75 3.41) 1.52 (0.71 3.25)
95% CI 95% confidence interval.
$P-value from likelihood ratio test.
Mortality among HIV-infected ART naı¨ve individuals with CD4 counts ]350 cells/mm
3
Citation: Glob Health Action 2014, 7: 21843 - http://dx.doi.org/10.3402/gha.v7.21843 61Discussion
In this study, we found that mortality among individuals
with CD4 cell count 350 499 cells/mm
3 was higher than
that among people with CD4 ]500 cells/mm
3, although
this was not statistically significant. Individuals with CD4
cell count 350 499 cells/mm
3 and ]500 cells/mm
3 had
146% and 123% higher risk of death compared with the
general population of Uganda. After adjusting for age,
increasing WHO clinical stage and decreasing BMI were
independent predictors of death.
Among the strengths of this study was the prospective
study design, which allowed measurement of the main
exposure of interest (CD4 cell count), and other time-
varying exposures. There was active tracing of partici-
pants who missed their scheduled visits which ensured
good compliance, minimized loss to follow-up and re-
duced number of missed deaths. Participant recruitment
was done from a general population source which min-
imized selection bias and made study findings more
representative of the population. The long study duration
Fig. 1. Kaplan-Meier survival function for cohort, by CD4 cell count category.
a
aP-value for log-rank test for equality of survival function 0.14.
Table 3. Standardised mortality ratios (SMRs), by sex, among individuals 549 years and CD4 cell count ]350 cells/mm
3
Observed
cohort deaths
Observed follow-
up (person-years)
Mortality rate in standard
population (per 1,000 person-years)
Expected
deaths SMR (95% CI)
Age (]500 cells/mm
3)
15 29 years 1 325 3.5 1.14
30 39 years 4 300 8.2 2.46
40 49 years 7 150 11.9 1.79
Overall 12 775 5.7 5.39 223% (127 393%)
Age (350 499 cells/mm
3)
15 29 years 1 119 3.5 0.42
30 39 years 4 178 8.2 1.46
40 49 years 2 81 11.9 0.96
Overall 7 378 5.7 2.84 246% (117 516%)
Males
]500 cells/mm
3 6 353 2.29
350 499 cells/mm
3 5 188 1.22
Overall 11 541 6.5 3.51 313% (173 565)
Females
]500 cells/mm
3 6 422 2.24
350 499 cells/mm
3 2 194 1.03
Overall 8 616 3.27 245% (123 490%)
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Variable
Deaths
(person-years)
Mortality rate
(per 1,000 person-years)
Crude rate ratio
(95% CI)
Adjusted rate ratio
%
(95% CI)
Current age (years) P0.001
$ P0.16
$
14 29 2 (446) 4.5 0.27 (0.06 1.27) 0.41 (0.09 1.96)
30 39 8 (480) 16.7 1.00 1.00
40 49 9 (231) 39.0 2.34 (0.90 6.05) 1.81 (0.69 4.72)
]50 8 (171) 46.8 2.81 (1.05 7.48) 1.61 (0.58 4.50)
Sex P0.23
$ P0.85
$
Female 11 (693) 15.9 1.00 1.00
Male 16 (635) 25.2 1.59 (0.74 3.42) 1.08 (0.48 2.45)
Marital status* P0.10
$ P0.09
$
Married 13 (885) 14.7 1.00 1.00
Single 2 (120) 16.7 1.14 (0.26 5.04) 1.18 (0.26 5.49)
Widowed/Divorced 11 (307) 35.8 2.44 (1.09 5.44) 3.21 (0.64 16.16)
Alcohol consumption P0.37
$ P0.11
$
Yes 18 (986) 18.3 1.00 1.00
No 9 (340) 26.4 1.45 (0.65 3.22) 2.07 (0.87 4.96)
Tobacco use* P0.08
$ P0.90
$
No 11 (884) 12.4 1.00 1.00
Yes 11 (417) 26.4 2.12 (0.92 4.89) 0.94 (0.37 2.40)
Body mass index (Kg/m
2)* PB0.001
$ PB0.001
$
]18.5 8 (1,101) 7.3 1.00 1.00
17.5 B18.5 6 (121) 49.8 6.85 (2.38 19.73) 4.52 (1.54 13.32)
B17.5 12 (97) 124.3 17.10 (6.99 41.84) 6.11 (2.30 16.20)
Haemoglobin (g/dL)* P0.005
$ P0.09
$
]11.0 17 (1,100) 15.8 1.00 1.00
B11 8 (134) 59.7 3.78 (1.63 8.76) 0.43 (0.17 1.07)
CD4 category P0.23
$ P0.65
$
]500 cells/mm
3 15 (884) 17.0 1.00 1.00
350 499 cells/mm
3 12 (443) 27.1 1.60 (0.75 3.41) 1.22 (0.56 2.67)
WHO stage PB0.001
$ PB0.001
$
1 8 (987) 8.1 1.00 1.00
2 6 (241) 24.9 3.07 (1.07 8.85) 2.36 (0.77 7.19)
3 and 4 13 (89) 145.5 17.94 (7.44 43.29) 10.18 (3.82 27.15)
Malaria during follow-up* P0.44
$ P0.81
$
No 23 (1,151) 20.0 1.00 1.00
Yes 2 (169) 11.8 0.59 (0.14 2.51) 0.84 (0.20 3.61)
Diarrhoea 1 month P0.18
$ P0.48
$
No 26 (1,319) 19.7 1.00 1.00
Yes 1 (9) 112.1 5.69 (0.77 41.90) 2.26 (0.29 17.41)
Viral load (copies/ml)* P0.03
$ P0.45
$
B25,000 5 (467) 10.7 1.00 1.00
25,000 B100,000 4 (268) 14.9 1.39 (0.37 5.20) 0.92 (0.24 3.47)
100,000 B250,000 6 (114) 52.5 4.90 (1.49 16.05) 2.37 (0.69 8.17)
]250,000 3 (64) 47.2 4.41 (1.05 18.45) 1.67 (0.35 7.00)
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of observation.
However, the study limitations included the small
numbers of deaths which makes mortality estimates from
our study subject to substantial reduction in statistical
power. The study lacked information on the duration of
HIV infection for participants who had been recruited as
prevalent cases. Since disease duration is a key factor
known to influence mortality among HIV-infected indivi-
duals, survival bias could not be excluded. The analysis
did not take into account of the confounding effect of
tuberculosis which is prevalent in the study area and a
major cause of death. Some of the time-varying variables
such as smoking and education were not recorded during
follow-up.Thebigproportionofobservationtimeinwhich
some exposure variables such as CD4 cell count (the main
exposure of interest) and viral load were missing had an
impact statistical power. Lastly, there was no adjustment
madeforcotrimoxazoleprophylaxisontheindividuallevel
since these datawere not available; however, we did adjust
for calendar period which would have captured some
of this effect, since cotrimoxazole was prescribed for all
patients after 2004.
Although not significant due to small numbers, the
higher mortality among individuals with CD4 cell count
350 499 cells/mm
3 compared with CD4 cell count ]500
cells/mm
3isanindicationoftheincreasedriskofmortality
associated with deteriorating immune status which has
been reported in previous studies (30, 31). Our reported
MRs in the CD4 categories of 350 499 and ]500 cells/
mm
3 (17.0 and 27.1 per 1,000 PY, respectively) are similar
to what has been reported in a pre-ART follow-up study
done in Ivory Coast (32). However, our observed MRs
are lower than what was reported in a pre-ART study in
West Africa (33). The latter was a bigger study based on
data from five longitudinal cohorts. However, that study
didnothavedatafromareferencepopulationtoenablethe
calculation of SMRs to compare observed mortality with
background population mortality.
Individuals who are on ART and have achieved high
CD4 cell count have been reported to have a similar
mortalityexperiencetothatofthegeneralpopulation(34).
Therefore,onewouldexpectasimilar mortalityexperience
among HIV-infected ART naı ¨ve individuals with compar-
able immune status. However, our results indicate that
people with CD4 cell count ]350 cells/mm
3 have a higher
risk of death than that in the general population of
Uganda. A study in France also reported a higher overall
mortality among individuals on combinational ART than
in the general population. However, among individuals
who had attained CD4 cell counts ]500 cells/mm
3, the
mortality which was higher than that in the general
population up to 3 years on ART reached the level in the
general population after the sixth year on ART (35). In
reality, not offering ART to people with CD4 cell count
]350 cells/mm
3 is mainly due to cost implications and
concerns about long-term potential side effects, but it may
also indirectly imply that the risk of death among this
group of individuals is low. In our cohort, where partici-
pants were regularly reviewed by study clinicians and
received free medical care, one would expect mortality to
be similar to that seen in the general population of
Uganda. There is evidence that participants in cohorts
with free access to investigations and treatment are less
likely to die (32) and therefore mortality estimates from
our cohort are likely to underestimate mortality of HIV-
positive individuals in Uganda in general.
Our results raise three important questions for physi-
cians and policy makers in the developing countries
where the threshold for starting ART is 5350 cells per
mm
3: 1) Are we still waiting too long to start HIV-
infected individuals on ART? 2) Are we actually treating
all individuals who need ART? 3) Is it still necessary to
start people on ART basing on CD4 cell count cut-offs?
Table 4 (Continued)
Variable
Deaths
(person-years)
Mortality rate
(per 1,000 person-years)
Crude rate ratio
(95% CI)
Adjusted rate ratio
%
(95% CI)
Calendar period P0.67
$ P0.27
$
1992 1999 5 (381) 13.1 1.00 1.00
2000 2003 7 (315) 12.2 1.69 (0.54 5.33) 1.60 (0.50 5.11)
2004 2007 8 (350) 22.8 1.74 (0.57 5.32) 1.82 (0.57 5.78)
2008 2011 7 (281) 24.9 1.90 (0.60 6.00) 3.22 (0.99 10.39)
*Variables with some missing data. For all variables except haemoglobin and viral load, data are missing for B2% of total observation
time. Haemoglobin missing for 8.8% of observation time (117 PY) and viral load missing for 31.3% (415 PY).
$P-value from likelihood ratio test.
%Adjusted for age (a priori) and all independent predictors of mortality (variables in bold): age, BMI and WHO stage. The final model was
based on 1,308 PY of observation time and 26 deaths.
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of available evidence and the economical implications of
starting ART at higher CD4 cell counts in the developing
world.
Although this study is based on small numbers, it
supplements the existing evidence that mortality among
HIV-infected people with high CD4 cell count is higher
than that in the general population. More light will be
shed from results of an ongoing multi-site randomized
START Trial that is assessing whether immediate initia-
tion of ART at CD4 cell counts above 500 cells/mm
3 is
superior to deferral of ARTuntil CD4 cell count declines
below 350 cells/mm
3 (36). Nevertheless, long-term bene-
fits of ART, especially in reducing HIV-associated
mortality and morbidity and reducing HIV transmission,
clearly outweigh the cost implications which are often
cited in sub-Saharan Africa.
Increasing WHO clinical stage and decreasing BMI
were identified as predictors of death among individuals
with CD4 cell count above ]350 cells/mm
3. WHO
clinical stage and BMI could both reflect underlying
morbidity such as tuberculosis which is common among
HIV-infected persons in sub-Saharan Africa and is a
major cause of death. Low BMI can also reflect other
conditions like malnutrition and HIV wasting syndrome
which are associated with HIV infection and are well
known to lead to poor survival. These findings further
confirm the importance of WHO clinical stage assess-
ment in HIV care, especially in this era when CD4 cell
count is increasingly becoming available to clinicians.
Conclusion
This study provides additional evidence that mortality
among HIV-infected ART naı ¨ve individuals with CD4
cell count ]350 cells per mm
3 is higher than that in the
general population. To avert these preventable deaths,
ART guidelines in developing countries should aim to
initiate ART at higher CD4 cell counts than the current
threshold, as is done in developed countries. Conse-
quently, there is a need to allocate more resources for the
expected increase in patients initiating ART at the higher
CD4 threshold. After adjusting for current age, WHO
clinical stage and BMI were the main predictors of
mortality, and they should be considered during the
clinical assessment for ART eligibility.
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Coming home to die? The association between
migration and mortality in rural Tanzania before and
after ART scale-up
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Background: Prior to the scale-up of antiretroviral therapy (ART), demographic surveillance cohort studies
showed higher mortality among migrants than residents in many rural areas.
Objectives: This study quantifies the overall and AIDS-specific mortality between migrants and residents
prior to ART, during ART scale-up, and after widespread availability of ART in Rufiji district in Tanzania.
Design: In Health and Demographic Surveillance System (HDSS), the follow-up of individuals aged 1559
years was categorized into three periods: before ART (19982003), during ART scale-up (20042007),
and after widespread availability of ART (20082011). Residents were those who never migrated within and
beyond HDSS, internal migrants were those who moved within the HDSS, and external migrants were those
who moved into the HDSS from outside. Mortality rates were estimated from deaths and person-years of
observations calculated in each time period. Hazard ratios were estimated to compare mortality between
migrants and residents. AIDS deaths were identified from verbal autopsy, and the odds ratio of dying from
AIDS between migrants and residents was estimated using the multivariate logistic regression model.
Results: Internal and external migrants experienced higher overall mortality than residents before the
introduction of ART. After widespread availability of ART overall mortality were similar for internal and
external migrants. These overall mortality experiences observed were similar for males and females. In the
multivariate logistic regression model, adjusting for age, sex, education, and social economic status, internal
migrants had similar likelihood of dying from AIDS as residents (adjusted odds ratio [AOR]1.14, 95%
confidenceinterval[CI]:0.701.87)whileexternalmigrantswere70%morelikelytodiefromAIDScomparedto
residents prior to the introduction of ART (AOR1.70, 95% CI: 1.062.73). After widespread availability of
ARTwith the same adjustment factors, the odds of dying from AIDS were similar for internal migrants and re-
sidents(AOR1.56,95%CI:0.803.04)andexternalmigrantsandresidents(AOR1.42,95%CI:0.762.66).
Conclusions: Availability of ART has reduced the number of HIV-infected migrants who would otherwise re-
turnhometodie.Thishasreducedtheburdenonruralcommunitieswhohadcaredforthereturnexternalmigrants.
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R
ural-urban migration pattern is the dominant
form of mobility in developing countries char-
acterized by youth migrating to urban cities in
search for work, better life, and advanced education (1).
The reverse pattern is commonly characterized by people
returning home after retirement (24). A substantial pro-
portion of research on migrations and health has focused
much on the growing population of urban migrants,
where emphasis has been on increased vulnerability to
poor health and acquisition of diseases relative to urban
residents. However, upon their return to rural areas, little
is known about their health status and survival relative
to rural residents. Public health research on migration
patterns provides insights on factors that drive mobility
and their influence on health-seeking behavior, disease
transition, and mortality.
In the process of integrating with urban residents,
rural-urban migrants are more likely to be exposed to
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their urban counterpart (57). In developing countries,
there is a growing evidence of higher HIV prevalence for
return rural migrants compared to rural residents (810).
In South Africa, Welaga described the mortality differ-
entials between migrants and nonmigrants in a rural
community in South Africa (11). After adjusting for age,
sex, and social economic status, this study showed higher
overall mortality and elevated odds of dying from AIDS
for external migrants compared to residents. Another rural
cohort study in a similar setting in South Africa reported
higher mortality for external migrants than residents in
communities with circular labor migrants (12).
Before the introduction of free antiretroviral therapy
(ART), the majority of infected migrants could not afford
treatment cost in urban centers approximated at US$35/
month, and often returned to their rural home villages
to seek care from traditional healers, and to be looked
after by their families in anticipation of death (1317).
In Thailand, Knodel reported consistent patterns of adults
with AIDS migrating home to seek care from their
parents at final stages of illness (17).
Overall ART coverage in Tanzania was estimated at
42% among adults and 18% among children by 2010,
following the introduction of free ART services (1821).
Several studies have investigated the differentials in treat-
ment access and reported higher loss to follow-up in the
continuum of care, less good adherence to care, and
treatment by migrants than residents (2225). We antici-
pate and hypothesize that the scaling-up of free ART
program may possibly contribute to a reduction in return
migrants seeking terminal care in rural areas (2630).
However, there are few reports on mortality among rural
migrants in Africa, and how this has been affected by
HIV and the availability of ART.
Evaluating differentials in mortality among migrants
and residents in rural requires continuous follow-up and
documentation of death events of both migrants and
residence. In addition, evaluation of AIDS-related mor-
tality requires further follow-up that documents cause of
death for both migrants and residence. This study focuses
on the longitudinal follow-up of residents and migrants
from 1998 to 2011 in a rural setting in Rufiji district in
Tanzania. The district is located 170 km from Dar-es-
Salaam, the largest and closest city with approximately
4.36 million inhabitants. Majority of migrants from Rufiji
relocate to Dar-es-salaam while maintaining links with
theirparentsandfamilies.Thisstudyquantifiesdifferences
in overall and AIDS-specific mortality between migrants
and residents and investigates changes in the mortality
risks and likelihood of dying from AIDS before ART
was introduced, during ART scale-up, and after wide-
spread availability of ART in the rural district of Rufiji in
Tanzania.
Methods
Study area
This study used data collected from Rufiji Health and
Demographic Surveillance System (HDSS) in Tanzania.
The HDSS covers 38 villages, with approximately 95,000
individuals in about 19,000 households and it covers
approximately 50% of district population. Rufiji HDSS is
a member of the INDEPTH Network (31) and of the
Analysing Longitudinal Population-based HIV data in
Africa (ALPHA) network (32).
The surveillance is designed as an open cohort of
individuals who enter through initial census enumeration,
birth, and in-migration and exit through out-migration,
lost to follow-up, and death. An initial census was
conducted between October 1998 and January 1999 by
enumerating all individuals in the selected study area.
Basic demographic events of birth, deaths, in- and out-
migration were regularly documented during household
visits that are normally conducted once in every 4
months. Baseline socioeconomic (education and occupa-
tion) and environmental (source of drinking water and
type of toilet facilities) factors were collected during the
initial census and in follow-up rounds.
Residency status definition
Individuals migrating into the surveillance area are
registered if they have been in the surveillance for at
least 4 months and are expecting to stay in the study area
for a longer period of time, or if they are married to a
resident. Information on reasons for migration and where
the migrant came from is also collected. Annually about
6,000 individuals aged 1559 years migrate within or into
the study area. Patterns of migration for males and
females between 2000 and 2011 are shown in Fig. 1.
Residents were defined as all individuals who were pre-
sent during initial census, or were born into the cohort,
or who had resided in the same household for 2.5 years.
Individualswho migrated into the study area from outside
Fig. 1. Trends in in-migration for males and females (2000
2011).
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from the date of migration until 2.5 years after migration.
Those who changed location within the study area were
considered as internal migrants from the date of migration
until 2.5 years after migration. After 2.5 years, both
external and internal migrants were considered residents.
ART period definition
All individuals aged 15 to 59 years in the study area from
2000 to 2011 were included in the analysis. The total
person-years of observation (PYO) were calculated from
1 January 2000, or the date the individual entered the
cohort, at the age of 15 years, or through migration until
the date the person died, left the HDSS, was lost to
follow-up, attained the age of 60 years, or at the end of
analysis period (31 December 2011). The observation
time was divided into three periods for this analysis:
period prior to availability of ART (20002003), period
when ART was scaled-up (20042007), and period of
widespread availability of ART (20082011). Within each
period, all deaths and person-years of follow-up were
recorded, and the overall mortality rates were calculated
for residents and migrants separately.
Cause of death
The cause of death information of all registered deaths
was derived from verbal autopsy (33). The process in-
volves interviewing close relatives of the deceased through
a structured questionnaire that details an account of the
sequence of events and symptoms leading to death. Two
sets of questionnaire were implemented between 1999
and 2011, but the basic questions necessary to detect
AIDS deaths did not differ between the two question-
naires. Structured questionnaires were then reviewed by
two independent physicians and the cause of death was
assigned using International Classification of Diseases,
tenth revision (ICD10) (34). A third physician was in-
volved in cases of disagreement between the two. Where
we have all three discordant, the cause was registered as
‘undetermined’. Validated studies have shown that the
verbal autopsy procedure is among reliable tools for
identifying AIDS deaths in the absence of reliable
medical death certificate (3537).
Statistical analysis
Descriptive analysis described all cause and AIDS-related
mortality for migrants and residents stratified by sex
and ART period. Predictive analysis used statistical
models to compare residents and migrants adjusted for
sex, age, level of education, and social economic status.
Age categories were generated by splitting residency
episodes at age 15, 25, 40, and 60 years. Education
level was collected during regular updates of household
and individual level variables. Social economic status
variable was generated from principal component analysis
ofhouseholdownershipofselecteditemsincludingbicycle,
car, motor cycle, radio, fridge, TV, watch, land, sofa set,
bed, video, mattress, water pump, animals such as cow,
tailoring machine, satellite dish, iron, fan, concrete floor,
water sources, and type of energy used for cooking (38).
Multivariate survival model
Since Rufiji HDSS does not collect data on HIV status of
participants, all cause mortality rates were estimated for
residents and external and internal migrants with mor-
tality rate ratios (RRs) and 95% confidence intervals
(95% CI) comparing migrants to residents. In each ART
period, we compared all cause mortality for residents and
migrants using multivariate Poisson regression obtaining
hazard rate ratios (HRR) and 95% CIs, adjusting for
possible confounders.
Logistic regression for AIDS deaths
We evaluated AIDS mortality from the verbal autopsy
cause of death, defining a binary response variable of
AIDS death or not AIDS death. In each ART period,
we used a multivariate logistic regression to assess the
adjusted odds ratio (AOR) of dying from AIDS for
external migrants and internal migrants compared to
residents, adjusting for age, sex, education, and socio-
economic status. Stata software version 12 (StataCorp,
College Station, TX) was used to perform all statistical
analysis.
Results
Overall mortality in 4 years
Table 1 shows results of longitudinal follow-up of adults
aged 1559 years with a total of 428,010 person-years,
and 2,653 deaths recorded from 2000 through 2011.
Crude mortality rates were stratified by gender and ART
periods, and were higher for external migrants than
residents before and during ART scale-up (RR1.38,
95% CI: 1.161.63 and RR1.40, 95% CI: 1.131.64,
respectively). After widespread availability of ART, mor-
tality was comparable for residents and external migrants
(RR1.14, 95% CI: 0.921.40). Similar patterns of
overall mortality were observed for males and females.
Internal migrants were observed with higher mortality
than residents before ART (RR1.22, 95% CI: 1.04
1.43), while lower mortality rates comparable to residents
were observed during scale-up and after widespread
availability (RR1.14, 95% CI: 0.961.35 and RR
0.91, 95% CI: 0.741.13), respectively. Sex-specific mor-
tality rates for residents and internal migrants were
comparable over all ART periods, except during ART
scale-up when female internal migrants were observed
with higher mortality than residents.
Estimates from the multivariate survival model in
Table 2 indicate that internal and external migrants had
a higher mortality rate than residents after adjusting for
Migration, mortality and ART
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residents, higher mortality rates were observed among
external migrants [adjusted hazard ratio (AHR)1.54,
95% CI: 1.301.84] and internal migrants (AHR1.24,
95% CI: 1.051.46) before ART was available. During
ART scale-up, external migrants continued to show
persistently higher mortality rates than residents (AHR
1.43, 95% CI: 1.171.73), while internal migrant’s mor-
tality was higher compared residents but not statistically
significant (AHR1.13, 95% CI: 0.951.35). Internal
and external migrants had comparable mortality rates to
residents after widespread availability of ART.
Logistic regression model for AIDS deaths
Table 3 shows the number of deaths assessed using verbal
autopsy and the proportion that was identified as AIDS
deaths. In the crude analysis, there were no significant
associations between AIDS death and residency status
within males and females separately and over all ART
periods. In a multivariate logistic regression of all deaths
(Table 4), adjusting for sex, age, education, and social
economic status, external migrants were 70% more likely
to die from AIDS compared to residents before the
introduction of ART (AOR1.70, 95% CI: 1.062.73).
During ART scale-up and after widespread availability of
ART, there were no significant differences in the odds of
AIDS mortality between residents, internal migrants, and
external migrants.
Reasons for migration
The dominant reason for migration among deceased
individuals varied depending on the ART period as
shown in Table 5. Prior to the introduction of ART,
about 50% of diseased external migrants were reported to
follow their parents as their main reason for migration
into the study area. Among external migrants, 8% moved
to the study area to seek for treatment compared to
2.4% of internal migrants. After widespread availability
of ART, patterns of reasons for migration changed for
external migrants, where the proportion of external
migrants reported following parents decreased from 50
to 34%. The proportion of external migrants returning to
seek for treatment decreased from 8% prior ART to 5%
during ART scale-up and 1.8% after widespread avail-
ability of ART.
Discussion
This study shows higher overall mortality among external
migrants compared to residents before ART became
widely available in the district. Internal migrants also
had higher mortality than residents before the introduc-
tion of ART. Decreasing trends in mortality rates were
noted for both migrants and residents between 2000 and
2011. Sex-specific crude mortality rate for external
migrants was higher for males than females. Although
the overall mortality rates for females were slightly higher
than those of males, there was no statistical difference
Table 1. Adult (aged 15 to 59 years of age) deaths, person-years of observation (PYO), overall mortality and mortality RRover
ART periods stratiﬁed by gender
Before ART ART scale-up Widespread of ART
Deaths PYO Rate RR Deaths PYO Rate RR Deaths PYO Rate RR
Overall
Residents 629 94.9 6.6 1 577 98.9 5.8 1 558 108.9 5.1 1
Internal 194 24.0 8.1 1.2
a 177 26.6 6.7 1.1
b 103 22.0 4.7 0.9
b
External 167 18.3 9.1 1.4
a 135 17.0 7.9 1.4
a 113 19.3 5.9 1.1
b
Overall 990 137.3 7.2 889 142.5 6.2 774 150.2 5.2
Male
Residents 306 46.6 6.6 1 285 49.5 5.8 1 267 55.1 4.8 1
Internal 73 9.1 8.0 1.2
b 55 10.2 5.4 0.9
b 40 8.3 4.8 1.0
b
External 76 8.0 9.5 1.4
a 63 7.0 9.1 1.6
a 47 8.0 5.9 1.2
b
Males 455 63.7 7.1 403 66.7 6.0 354 71.4 5.0
Females
Residents 323 48.3 6.7 1 292 49.4 5.9 1 291 53.8 5.4 1
Internal 121 14.9 8.1 1.2
b 122 16.4 7.5 1.3
a 63 13.7 4.6 0.8
b
External 91 10.3 8.8 1.3
a 72 10.1 7.2 1.2
b 66 11.3 5.8 1.0
b
Females 535 73.6 7.3 486 75.8 6.4 420 78.8 5.3
RR- Mortality rate ratio of external and internal migrants over residents estimated using Mantel-Haenszel method.
aMortality rates are different (pB0.05).
bMortality rates are comparable (p 0.05).
PYO in thousands.
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Before ART ART scale-up Widespread of ART
Migration status
Residents 1 1 1
Internal 1.24 (1.051.46) 1.13 (0.951.35) 0.98 (0.791.22)
External 1.54 (1.301.84) 1.43 (1.171.73) 1.20 (0.971.48)
Sex
Male 1 1 1
Female 0.99 (0.871.13) 0.99 (0.871.14) 0.95 (0.821.10)
Education
Tertiary 1 1 1
Primary 1.12 (0.851.48) 1.28 (0.921.77) 1.36 (0.902.05)
Secondary 0.66 (0.411.07) 0.81 (0.501.32) 0.55 (0.310.97)
No education 0.95 (0.711.26) 1.16 (0.831.63) 1.43 (0.942.17)
Age
1525 1 1 1
2540 2.66 (2.223.18) 3.13 (2.543.86) 2.36 (1.892.96)
4059 3.66 (3.044.42) 4.92 (3.976.08) 4.26 (3.425.30)
Economic status
5th Least poor 1 1 1
1st Poorest 1.01 (0.821.24) 1.03 (0.831.28) 0.99 (0.791.25)
2nd quintile 0.77 (0.620.96) 0.72 (0.570.91) 0.88 (0.691.11)
3rd quintile 0.79 (0.640.97) 0.81 (0.651.01) 0.66 (0.520.84)
4th quintile 0.83 (0.681.02) 0.93 (0.751.14) 0.85 (0.681.07)
Missing 1.78 (1.432.21) 2.03 (1.572.63) 1.07 (0.811.42)
Adjusted mortality risk ratio of migrants over residents estimated using parametric regression model with exponential distribution
adjusted for sex, education, age and social economic status.
Confidence interval estimated at 95% significant level.
Table 3. Characteristics of participants included in the AIDS mortality model
Before ART ART scale-up Widespread of ART
Variable Deaths AIDS deaths (%) Deaths AIDS deaths (%) Deaths AIDS deaths (%)
Overall
Residents 620 72 (11.6) 527 71 (13.5) 461 76 (16.5)
Internal 191 27 (14.1) 163 30 (18.4) 74 16 (21.6)
External 164 32 (19.5) 127 23 (18.1) 89 18 (20.2)
Overall 975 131 (13.4) 817 124 (15.2) 624 110 (17.6)
Male
Residents 304 36 (11.8) 263 27 (10.3) 218 24 (11.0)
Internal 73 3 (4.1) 46 4 (8.7) 32 6 (18.8)
External 75 15 (20.0) 59 9 (15.3) 36 3 (8.3)
All males 452 54 (11.9) 368 40 (10.9) 286 33 (11.5)
Female
Residents 316 36 (11.4) 264 44 (16.7) 243 52 (21.4)
Internal 118 24 (20.3) 117 26 (22.2) 42 10 (23.8)
External 89 17 (19.1) 68 14 (20.6) 53 15 (28.3)
All females 523 77 (14.7) 449 84 (18.7) 338 77 (22.8)
These were the overall (both males and females).
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mortality rates in any of ART periods. Prior to ART
introduction, the odds of an AIDS death was significantly
higher among deaths in external migrants than in resi-
dents (AOR1.70, 95% CI: 1.062.73). After widespread
availability of ART, there remained higher odds of
AIDS deaths among deaths in external migrants than in
residents, but this was no longer significant (AOR1.42,
95% CI: 0.762.66). Females were more likely to die from
AIDS than males during all ART periods.
Both the crude mortality analysis and subanalysis of
those who died affirm our hypothesis that scaling-up of
free ART programs may possibly have contributed to the
reduction of return migrants seeking care in rural areas
as a result of improved health status and survival among
those on ART treatment. Elevated odds of dying from
Table 4. Adjusted odds ratio for multivariate logistic regression model for factors associated with AIDS deaths by migration
status and ART period
Before ART ART scale-up Widespread of ART
Migration status
Residents 1 1 1
Internal migrants 1.14 (0.701.87) 1.26 (0.762.09) 1.56 (0.803.04)
External migrants 1.70 (1.062.73) 1.37 (0.802.33) 1.42 (0.762.66)
Sex
Male 1 1 1
Female 1.31 (0.881.96) 1.78 (1.162.73) 2.37 (1.503.76)
Education
Primary 1 1 1
Secondary 1.20 (0.512.82) 1.95 (0.576.72) 1.11 (0.304.07)
Tertiary 1.16 (0.265.08) 2.69 (0.5612.90) 0.76 (0.134.64)
No education 0.95 (0.392.30) 1.55 (0.445.40) 0.67 (0.182.54)
Age
1525 1 1 1
2540 2.97 (1.525.80) 2.10 (1.064.20) 2.66 (1.265.61)
4059 1.84 (0.913.74) 1.86 (0.913.78) 1.63 (0.763.48)
Economic status
1st Poorest 1 1 1
2nd quintile 0.85 (0.441.63) 0.80 (0.391.62) 0.75 (0.361.56)
3rd quintile 0.92 (0.471.81) 1.08 (0.542.17) 1.06 (0.512.17)
4th quintile 1.19 (0.652.19) 1.65 (0.893.06) 1.46 (0.732.95)
5th Least poor 0.92 (0.491.74) 1.21 (0.662.24) 1.40 (0.742.65)
Missing 1.42 (0.772.61) 1.07 (0.512.28) 0.49 (0.171.37)
Table 5. Reasons for migration for deceased adults’ Pre-ART, ART scale up and Post ART
Before ART ART scale-up Widespread of ART
Reasons Internal migrants External migrants Internal migrants External migrants Internal migrants External migrants
Follow-parents 24.7 49.7 32.2 52.6 34 30.1
Following spouse 11.9 10.8 8.5 8.9 6.8 9.7
Change residency 33 14.4 25.4 12.6 28.2 25.7
Follow family 1.5 1.2 7.9 5.9 6.8 7.1
Married 0 0.6 4.5 3 8.7 7.1
Agriculture 2.6 2.4 7.3 7.4 5.8 7.1
Divorced 4.1 1.2 1.7 0.7 2.9 3.5
Seek treatment 2.1 7.8 1.7 5.2 1.9 1.8
Others 20.1 12 10.7 3.7 4.9 8
Total 194 167 177 135 103 113
These were the overall (both males and females).
Francis Levira et al.
72 Citation: Glob Health Action 2014, 7: 22956 - http://dx.doi.org/10.3402/gha.v7.22956AIDS for external migrants compared to residents
observed in this study were comparable with findings
from other cohort studies in Rural South Africa before
the introduction of ART (11, 12).
The introduction of free ARV in 2004, in Tanzania,
may have influenced HIV-infected migrants to stay in
urban areas, who would otherwise return home for
palliative care while waiting to die in the absence of
treatment. This is reflected in the reduced risk of death
and odds of AIDS deaths for migrants after widespread
availability of ART. Treatment and care for HIV patients
were made available and accessible for free to majority of
health centers and hospital hence reduced migration of
AIDS-infected individual to rural areas previously in-
duced by AIDS-related illness and morbidity. High AIDS
mortality rate for males external migrants compared to
females could be attributed by lower ARV coverage
among males as reported in routine health system in
Tanzania (10, 22) and other parts of the world (24). This
is due to the fact that more females than males are
accessing ART services through provider-initiated pro-
grams, where all females attending antenatal clinic are
counseled, tested for HIV, and those with the disease are
enrolled on care or treatment (19).
Analysis of reasons for migration could be used to
factor out the ‘coming home to die’ concept from other
possible factors pulling individuals to rural areas. Before
ART was available, more than half of the deceased
external migrants reported to follow parents as their
main reason for migration. However, following parents
could possibly feature ‘follow parent for care or possibly
die’ because the majority who reported this reason were
in the age of independence (2559 years) from their
parents. This means that they may possibly return home
not to stay with their parents but seek for care or
treatment from their parents or relative. In many devel-
oping countries affected by the HIV epidemic, mothers
are highly involved in the care of their infected sons and
daughters to the point of death as well as the care of
orphans left behind by their children. Majority of
infected return migrants did not report return home for
care or treatment as their main reason for migration in an
attempt to hide their HIV. This was mainly contributed
by high stigma behaviour in the study area toward HIV
positive individuals and ARV users (39, 40). Men’s
superiority behavior observed elsewhere may also influ-
ence some of the male respondents not to report return
home for care or treatment in an effort to maintain their
status quo (3941). Following widespread availability of
ART, diseased individuals reporting ‘follow parents’
decreased from 50 to 34%. External migrants group was
also reported to have the highest percentage of those
reported returning home to seek treatment compared to
internal migrants. Other reasons for migration, such as
retirement, contribute little to reasons of return migrants
because majority (approximately 80%) of internal and
external migrants were in the age range between 25 and
59 years, while retirement age in Tanzania is 60 years and
above. Since the quality of health care in urban areas is
often superior to rural, then seeking care in rural could
mean consulting traditional healers or waiting to die
from incurable diseases such as AIDS.
This study has several limitations that need to be
considered when interpreting the findings and make
general conclusions to other settings. The analysis of
this HDSS data mainly depended on mortality events
rather than HIV prevalent cases. If HIV sero-surveys
were available in the study area, we could provide more
concrete analysis on return migrants and residents by
HIV status. The subset analysis of those who died in the
study area could be more precise in settings where the
HIV status of migrants and residents was available. This
analysis is restricted to individuals aged 1559 years;
therefore, care should be taken in extrapolating results
to individual aged below 15 years and above 60 years.
Comparability of cause of deaths over time and mis-
classification HIV/AIDS-related deaths should be taken
into consideration. Although verbal autopsy has been
successful in detecting HIV/AIDS deaths (3537), com-
parability of results generated by physicians may not be
consistent due to their changes in general perception of
local AIDS epidemic. While some physician may perceive
AIDS mortality decreasing in the population and tend to
assign less frequent AIDS deaths during cause of death
assignment, others may regard AIDS mortality a growing
public health concern and assign AIDS death more
frequent. Over the last 10 years there have been changes
in physicians who assign cause of death. This could
possibly result in changes in number of deaths assigned as
HIV/AIDS death due to differences in implementing
ICD10 procedures among physicians. TB and HIV
misclassification is another limitation in this study. Co-
infection of the diseases and existence of similarity in
signs and symptoms may lead to misclassification (42,
43). In this study, we have taken the definition of AIDS
death alone, though some other studies have grouped
together the two diseases (44).
The findings in this study support the widespread
evidence of benefits of ART on premature mortality and
population mobility among HIV-positive migrants.
Conclusions
This work has provided evidence that ART’s universal
accesspolicyinTanzaniahasavertedasubstantialnumber
of deaths connected with AIDS in rural areas among
internal and external migrants. Prior to ART scale-up,
criticallyillAIDSpatients preferredtomigratetoruralfor
care and possibly die because of the absence of affordable
treatment and care. The return rural-urban migrants who
are critically ill contributed in burdening the already
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spread availability of ART has reduced the burden of
care to families and health-care system in rural areas.
ReductionofAIDSpatientsseekingcareinruralmayhave
resulted in savings for families, increased time foreconom-
ic activities, especially in agriculture and improving other
sectors of health such maternal and newborn health.
Projection studies show 50% of African inhabitants
will be living in urban area by 2,025 implying increased
rural-urban migrants in the future (3). The fact that
rural-urban migrants are more likely to engaging in risky
sexual behaviors, health-care planners need long-term
plans and investments in strengthening HIV/AIDS edu-
cation both to rural and urban inhabitants. Reducing the
gap in access to ARV among the poor should be the
key factor in designing intervention programs aimed at
optimizing the effect of ARV’s to both migrants and
residents. This is due to the fact that majority of rural-
urban migrants are poor and their access to ARV may be
compromised compared to those who are economically
well in urban.
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